date,datetime,title,summary,url,source,search_query,query_group,collection_timestamp,drug_specific,company_specific,fda_regulatory,financial,competitive,overall_relevance,sentiment_score,sentiment_confidence,sentiment_positive,sentiment_negative,sentiment_neutral,revenue_mentioned,profit_mentioned,loss_mentioned,percentage_change,currency_amount,milestone_pre_clinical,milestone_ind_application,milestone_phase_1_trials,milestone_phase_2_trials,milestone_phase_3_trials,milestone_bla_submission,milestone_fda_review,milestone_fda_inspection,milestone_fda_approval,milestone_product_launch,milestone_market_penetration,milestone_regulatory_issues,primary_fda_milestone,fda_milestone_confidence,priority_score
2021-07-29,2021-07-29 07:00:00,Biocon Biologics interchangeable insulin Semglee gets US FDA approval - The Economic Times,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics interchangeable insulin Semglee gets US FDA approval</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Economic Times</font>",https://news.google.com/rss/articles/CBMi9gFBVV95cUxNcEFTdFZtZlNDd2ZYdFlzQ2lXcXd4ZlBjcGVYdUE4Rm9Sa0UweXRXakIwcTJsbll0UWVpNDdxbzhBVU11TE9JdzBnd1g4ZkRScVdqSHNXQ0ZkSWFpYWFjdUpMenRhNXBleThCejd6ZnlLbFFQRHBLeGcxTnhQV3EwUnM4cG9vTk5ERWRFb3J2bkU4MGptVEpLREROeWQ0NXJHdG9QdFdLaGxmYXpvLTdDbGtWS1BJdUhGOFhOV0tWMTY2YzQ1RGxRRndRYTRhQ1k4S09hWFc4M1hvUFNtVm1JT0dCc0d4NFk4dm55TVRPMF9BVDVGQnfSAfsBQVVfeXFMTWx6NnAtal9OcTBCS2Z4QVBXNTNVMkFxdGxJOGhTX29Cejg0cDR2dk5UamZYN3JCWlh1WG9KOWZSaXN6enppRU91eEp1dlluNzhHSmJKY01qa1VQcEhvYnp2VzVseTh3QTNKTVRWU1Z1UlNlNk94UWdkRnlaam5CbDJSb19wSXhwMEF4Sm9VQTJ0TnViZGlzMXVNMGFpdFdITUhSRjVtVnFrZmV3WlhPRHc3c3hXMmI0VEhMckdoZjlIcnhfVVNHMDh6TWZCd0hOdEY2eHVWOXhmbDdXYzVnV3dxdlg1VjZMTlRCNU5YV3pxaGsyOEJJZGhuVkE?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413593,0.4,0.5,0.4,0.0,0.0,0.32,0.3125302559565188,0.5953021370357937,0.3125302559565188,0.0,0.6874697440434812,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,7.5,0.0,0.0,0.0,fda_approval,7.5,41.63759076786956
2021-07-29,2021-07-29 07:00:00,Semglee Receives FDA Approval as First Interchangeable Biosimilar Insulin - Beyond Type 1,"<a href=""https://news.google.com/rss/articles/CBMibkFVX3lxTE9lUDVIWEFPd0ZxQ214RDM4VU8wY3U5NmFrU0QzWXI3X3NIdllFZEtVRVd5N214ZmI3bnRkeHM5QS0taU85M21YSENrQnFRR1NCMDhKWmUxdXBJTTRfZ3l5Slh1VUFJNUlNUjY0aTRR?oc=5"" target=""_blank"">Semglee Receives FDA Approval as First Interchangeable Biosimilar Insulin</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Beyond Type 1</font>",https://news.google.com/rss/articles/CBMibkFVX3lxTE9lUDVIWEFPd0ZxQ214RDM4VU8wY3U5NmFrU0QzWXI3X3NIdllFZEtVRVd5N214ZmI3bnRkeHM5QS0taU85M21YSENrQnFRR1NCMDhKWmUxdXBJTTRfZ3l5Slh1VUFJNUlNUjY0aTRR?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.412871,0.2,0.0,0.6,0.0,0.0,0.21000000000000002,0.6190875751499073,0.5014886289490593,0.6190875751499073,0.0,0.3809124248500927,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,7.5,0.0,0.0,0.0,fda_approval,7.5,41.45726272544972
2021-07-29,2021-07-29 07:00:00,FDA clears interchangeable insulin biosimilar Semglee - Drug Store News,"<a href=""https://news.google.com/rss/articles/CBMihgFBVV95cUxOYWJBQlBmalc2M3FaNVEyRU1tSmNHLVFIaUJxREdLaWRPcmd5S2JmV21feDB3YkhIU2Vxc1p3V1RIWWh3ajNUN29ydk1CNDRvMG42OWhyQXFxLTh3WXU5TjdGWVlUX0hQV0FLdjM4U0ZhRk1zdWpidUEyT3JiZzZWVWRmNlNxUQ?oc=5"" target=""_blank"">FDA clears interchangeable insulin biosimilar Semglee</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Drug Store News</font>",https://news.google.com/rss/articles/CBMihgFBVV95cUxOYWJBQlBmalc2M3FaNVEyRU1tSmNHLVFIaUJxREdLaWRPcmd5S2JmV21feDB3YkhIU2Vxc1p3V1RIWWh3ajNUN29ydk1CNDRvMG42OWhyQXFxLTh3WXU5TjdGWVlUX0hQV0FLdjM4U0ZhRk1zdWpidUEyT3JiZzZWVWRmNlNxUQ?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413519,0.6,0.0,0.4,0.0,0.0,0.27999999999999997,0.021676567200290004,0.36044468024571735,0.021676567200290004,0.0,0.97832343279971,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,35.36502970160087
2021-11-17,2021-11-17 08:00:00,Biocon Biologics and Viatris announce launch of interchangeable SEMGLEE (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection - Healthcare Radius,"<a href=""https://news.google.com/rss/articles/CBMi5AFBVV95cUxNcVo4UXpmWDVBNkZ3Rk9zQkhMNG9IN1MwaG5TQm9RTjVKLWJkcU9Gd0p1STRNNkozYlBDb09UZWFXYkZjUWdVVkpOaWdiaFM3akJTOWM1UktZMEM4bkw2YURvY0dhSjhrV3NUeGc2TXZRbEFRbDJ2QU91dDFqSU9BcEcyVjlhQWxHdnhMb2Jxb2NERW9GOEZzNkZKWVBrRTFhSjJEWUdCNk5zWlVtY3Zza0xURzlWWEZJMlQ5WVBZek5QdHRPQVNQVVgzNzdKTnhTOFEyMzVzSEx6OTViSEJXbUVfTnI?oc=5"" target=""_blank"">Biocon Biologics and Viatris announce launch of interchangeable SEMGLEE (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Healthcare Radius</font>",https://news.google.com/rss/articles/CBMi5AFBVV95cUxNcVo4UXpmWDVBNkZ3Rk9zQkhMNG9IN1MwaG5TQm9RTjVKLWJkcU9Gd0p1STRNNkozYlBDb09UZWFXYkZjUWdVVkpOaWdiaFM3akJTOWM1UktZMEM4bkw2YURvY0dhSjhrV3NUeGc2TXZRbEFRbDJ2QU91dDFqSU9BcEcyVjlhQWxHdnhMb2Jxb2NERW9GOEZzNkZKWVBrRTFhSjJEWUdCNk5zWlVtY3Zza0xURzlWWEZJMlQ5WVBZek5QdHRPQVNQVVgzNzdKTnhTOFEyMzVzSEx6OTViSEJXbUVfTnI?oc=5,Google News,Semglee interchangeable insulin,drug_fda,2025-06-27T05:41:09.803213,0.6,0.5,0.0,0.0,0.0,0.27999999999999997,0.0,0.30705275138219196,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,35.3
2021-11-16,2021-11-16 08:00:00,Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMitwJBVV95cUxPeFdZZElGeWNuVDhIc19nNG1ld1FRei1mSm5wYVozSmJhNE5CbWNBcE56czVrMk5oTEdmV205TDBMS3ZLbFQxaWVXcVlYd0VZWkZaeUtsSktQcjF0UkRXVFdsb3RKUlZ5ZzFPNG9aaTJrRkd3LWctbmx2Sld0VlpWQjlLQk02NU5IV1JLZUEyODFTbkQ3ZHY5cGVQLTI1WFplaUlISjk2Y182NUtUSVY5SGo3YWpiTmhrVkUyZTN3d3BRa2pfUENIcWVGTVBEYzVjOXctbTdQMHFmaGlYRnlxYWNXV2szY29BUFF5NjZjYjc2V2JmVl9mWWxkR28zd0o1amJBUVA4MDRYLVFKNk9qQjZaZTNCNTM3TXdGZERZbDBBNFVPNHlaMUQtbFFubWhORTZ1UVVhQQ?oc=5"" target=""_blank"">Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMitwJBVV95cUxPeFdZZElGeWNuVDhIc19nNG1ld1FRei1mSm5wYVozSmJhNE5CbWNBcE56czVrMk5oTEdmV205TDBMS3ZLbFQxaWVXcVlYd0VZWkZaeUtsSktQcjF0UkRXVFdsb3RKUlZ5ZzFPNG9aaTJrRkd3LWctbmx2Sld0VlpWQjlLQk02NU5IV1JLZUEyODFTbkQ3ZHY5cGVQLTI1WFplaUlISjk2Y182NUtUSVY5SGo3YWpiTmhrVkUyZTN3d3BRa2pfUENIcWVGTVBEYzVjOXctbTdQMHFmaGlYRnlxYWNXV2szY29BUFF5NjZjYjc2V2JmVl9mWWxkR28zd0o1amJBUVA4MDRYLVFKNk9qQjZaZTNCNTM3TXdGZERZbDBBNFVPNHlaMUQtbFFubWhORTZ1UVVhQQ?oc=5,Google News,Semglee interchangeable insulin,drug_fda,2025-06-27T05:41:09.801959,0.6,0.5,0.0,0.0,0.0,0.27999999999999997,0.0,0.30673567454020184,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,35.3
2025-04-10,2025-04-10 07:00:00,"Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio - PR Newswire","<a href=""https://news.google.com/rss/articles/CBMi-gFBVV95cUxQcG5TMThQVFo3VWx4b2R4aWtKYVFYLWV4REk5SFc1M01TdTJ1SzZiU1AyUlEzNVBNNzUxYVduVUFoeDFUMm5TRUoxWU1LXzl3bm90UkZuLUtuTm5IRXpranhkc0RDckRBbkIxREVRNmNlejRpdlVuaXFGeTAweTRzQktueE5SS3RVc3ItTG52UHhnVkZ3V1lpV2xIQ0otVEU5Vko4T1FSVlhTdElPRFdTdUttSGhxOXpIYUo4MEoxWWtaWXpvNDJ0clNhQnV6VC1sWjJPMHlIZVBrd1JjVGhOWDl0ZXBXYzNmSFJjdTdleWxHdVExUXVtX3Nn?oc=5"" target=""_blank"">Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi-gFBVV95cUxQcG5TMThQVFo3VWx4b2R4aWtKYVFYLWV4REk5SFc1M01TdTJ1SzZiU1AyUlEzNVBNNzUxYVduVUFoeDFUMm5TRUoxWU1LXzl3bm90UkZuLUtuTm5IRXpranhkc0RDckRBbkIxREVRNmNlejRpdlVuaXFGeTAweTRzQktueE5SS3RVc3ItTG52UHhnVkZ3V1lpV2xIQ0otVEU5Vko4T1FSVlhTdElPRFdTdUttSGhxOXpIYUo4MEoxWWtaWXpvNDJ0clNhQnV6VC1sWjJPMHlIZVBrd1JjVGhOWDl0ZXBXYzNmSFJjdTdleWxHdVExUXVtX3Nn?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.632955,0.0,0.5,0.6,0.0,0.0,0.25,0.8057409291705081,0.5336077706336976,0.8057409291705081,0.0,0.1942590708294919,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,20.417222787511523
2025-04-11,2025-04-11 07:00:00,Biocon Share Price Rises 5.5% After USFDA Approval For JOBEVNE Biosimilar - Samco,"<a href=""https://news.google.com/rss/articles/CBMiwgFBVV95cUxOT2tPSFdjb2k4bFdmQ1ozeG95NkpOcG5DcGFxZDRUazJEVExuaUluYTkwc1NyLUlySHVIR2tWWUJEaUZfZV9jbS05Vk9HTUhJM1BQVUpkTVF4b253SlY1NWwyYU5XSHhSSDloZTZUNGJLSEhrbXMtOEduX25kTUV6ZE9QdFNSM3J5YjdRWjJuSEhqWDdDZDZWUGd4WWIxU0pTVU5jMXJQMTRfNDVGd2xIamRLdVdIT3FOT2VYMVNheERwdw?oc=5"" target=""_blank"">Biocon Share Price Rises 5.5% After USFDA Approval For JOBEVNE Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Samco</font>",https://news.google.com/rss/articles/CBMiwgFBVV95cUxOT2tPSFdjb2k4bFdmQ1ozeG95NkpOcG5DcGFxZDRUazJEVExuaUluYTkwc1NyLUlySHVIR2tWWUJEaUZfZV9jbS05Vk9HTUhJM1BQVUpkTVF4b253SlY1NWwyYU5XSHhSSDloZTZUNGJLSEhrbXMtOEduX25kTUV6ZE9QdFNSM3J5YjdRWjJuSEhqWDdDZDZWUGd4WWIxU0pTVU5jMXJQMTRfNDVGd2xIamRLdVdIT3FOT2VYMVNheERwdw?oc=5,Google News,Biocon stock price reaction,financial,2025-06-27T05:41:44.924472,0.0,0.25,0.6,0.16666666666666666,0.0,0.225,0.8862244085661948,0.5904138644536336,0.8862244085661948,0.0,0.11377559143380522,0,0,0,5.5,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,20.408673225698585
2025-04-11,2025-04-11 07:00:00,Biocon Biologics secures FDA approval for Avastin biosimilar Jobevne - World Pharmaceutical Frontiers,"<a href=""https://news.google.com/rss/articles/CBMipAFBVV95cUxQeEgyZ2lqMlh1YUNDMUZ6ZlJKdTBLdGliRXZIT3RyRHRpYTdXLU5EUXNURTl1WThRM3B1Q3EyZ2paU2NIeFl6Y1FZWDB5SXlxaS14a0V4eEdTZjBfU0dfUHpKbjAzZEZEVkhYQVBrbWpNOW1ZclNKMkk0OTB1S1VrbUVKMkJ0N056MWJrY0dsM0Nmd0FDQ2kwcTFrUGszUkVULTEzbA?oc=5"" target=""_blank"">Biocon Biologics secures FDA approval for Avastin biosimilar Jobevne</a>&nbsp;&nbsp;<font color=""#6f6f6f"">World Pharmaceutical Frontiers</font>",https://news.google.com/rss/articles/CBMipAFBVV95cUxQeEgyZ2lqMlh1YUNDMUZ6ZlJKdTBLdGliRXZIT3RyRHRpYTdXLU5EUXNURTl1WThRM3B1Q3EyZ2paU2NIeFl6Y1FZWDB5SXlxaS14a0V4eEdTZjBfU0dfUHpKbjAzZEZEVkhYQVBrbWpNOW1ZclNKMkk0OTB1S1VrbUVKMkJ0N056MWJrY0dsM0Nmd0FDQ2kwcTFrUGszUkVULTEzbA?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.381712,0.0,0.5,0.6,0.0,0.0,0.25,0.4596595811671988,0.5474973516146342,0.4596595811671988,0.0,0.5403404188328012,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,19.378978743501598
2025-04-11,2025-04-11 07:00:00,"Biocon Shares in Focus, Strengthens US Oncology Footprint with Biosimilar Approval - Groww","<a href=""https://news.google.com/rss/articles/CBMingFBVV95cUxOR195WnVUMnhKeVg3Sk16NmFQbkY3cDU1QlE1eEUzV1dmdmtmRkRuNFAwRWptdFJuNG4xdFJrYU5JWWZTSm9vTzZfZHhkdWhIcjhSU1FDOWVwa0JXWnBPMGNNenlkWEhYaW1zZ1d4c0VkUUJkaUwyc3FFZnBzVjZBMGtsLWRydGw5ZkhMbFdFTFJleHVKTnFCdlViZXcxdw?oc=5"" target=""_blank"">Biocon Shares in Focus, Strengthens US Oncology Footprint with Biosimilar Approval</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Groww</font>",https://news.google.com/rss/articles/CBMingFBVV95cUxOR195WnVUMnhKeVg3Sk16NmFQbkY3cDU1QlE1eEUzV1dmdmtmRkRuNFAwRWptdFJuNG4xdFJrYU5JWWZTSm9vTzZfZHhkdWhIcjhSU1FDOWVwa0JXWnBPMGNNenlkWEhYaW1zZ1d4c0VkUUJkaUwyc3FFZnBzVjZBMGtsLWRydGw5ZkhMbFdFTFJleHVKTnFCdlViZXcxdw?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634549,0.0,0.25,0.4,0.0,0.0,0.15,0.7923882466125246,0.4910819925626119,0.7923882466125246,0.0,0.2076117533874754,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,19.377164739837575
2025-04-10,2025-04-10 07:00:00,"Biocon Biologics secures US FDA approval for Biosimilar Bevacizumab, JOBEVNE - Express Pharma","<a href=""https://news.google.com/rss/articles/CBMiqAFBVV95cUxOczFIemVhMFg4bFNuUVZVb2pFb1FpZ1U2N0xzOE90bXhhOWdIYzFpZDNhUWVrZ2p2QU9WdUJ2czRxTjhpTFJDUGcxWmtRS3pTdVgzbzNWSzE0azc0OW9EejUwRWtFWURMTjU0elhKek1iX1hCX3ZzVHotd0pUV2FXckh4TGpTY2MwamxsMTRFYzdWaGwwMzc3WFdPXy1oVjJxSW9FNHAzSkvSAa4BQVVfeXFMUEhYYklLRFBhRW9sMmNrdDhQVnJkc0Jnc01SQ0VfRWMtR01aZENKOUJ0UkZyXzJOcEo4MkswVHZsdEQzMmljTlZJQkVSVFkwMWtvVm5vUmpTMUdrUFR3a21SVEZBZU9GdTVQcGZMZFJIU0NuSEREdVItc0NlM3lNU2NWY2s2MTdJYW9lUlB3LWJCY1ZRLVg0bk9feUdCMkhUdmcxVmQ0Q0licGM3UTJn?oc=5"" target=""_blank"">Biocon Biologics secures US FDA approval for Biosimilar Bevacizumab, JOBEVNE</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Express Pharma</font>",https://news.google.com/rss/articles/CBMiqAFBVV95cUxOczFIemVhMFg4bFNuUVZVb2pFb1FpZ1U2N0xzOE90bXhhOWdIYzFpZDNhUWVrZ2p2QU9WdUJ2czRxTjhpTFJDUGcxWmtRS3pTdVgzbzNWSzE0azc0OW9EejUwRWtFWURMTjU0elhKek1iX1hCX3ZzVHotd0pUV2FXckh4TGpTY2MwamxsMTRFYzdWaGwwMzc3WFdPXy1oVjJxSW9FNHAzSkvSAa4BQVVfeXFMUEhYYklLRFBhRW9sMmNrdDhQVnJkc0Jnc01SQ0VfRWMtR01aZENKOUJ0UkZyXzJOcEo4MkswVHZsdEQzMmljTlZJQkVSVFkwMWtvVm5vUmpTMUdrUFR3a21SVEZBZU9GdTVQcGZMZFJIU0NuSEREdVItc0NlM3lNU2NWY2s2MTdJYW9lUlB3LWJCY1ZRLVg0bk9feUdCMkhUdmcxVmQ0Q0licGM3UTJn?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634386,0.0,0.5,0.6,0.0,0.0,0.25,0.4553593501761923,0.5526676969210307,0.4553593501761923,0.0,0.5446406498238077,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,19.36607805052858
2025-04-10,2025-04-10 07:00:00,"Biocon Biologics gets US FDA approval for Biosimilar Bevacizumab, expanding oncology portfolio - BioSpectrum India","<a href=""https://news.google.com/rss/articles/CBMi3gFBVV95cUxPZnU3V2lYbjU3eFNfTjBiWllrcHozUmNpekV5SkNCdmQtNEVqRHcxUmc0NnNCTl9UUllSejdrVjlBU25fLVliQ3dOX2RDbm9Td3dMcFMyTmNYMnRiRk4waEZDZFJGek9PZWRRZXR6NjRydWVWSTlYNjFOM3ZnZzgwVGJnQWN5MmppS2FtYWtBMThkZ3BjazljMDN4Tkk1WFFJZWIzc3BDSF9fcm9oa0ZaQmJhNjlRcy1sOXB1WlNzbGpoQ1RJZTB0QWkzYk9sRmh0aXhxZ0Y4Z3VJb05od0E?oc=5"" target=""_blank"">Biocon Biologics gets US FDA approval for Biosimilar Bevacizumab, expanding oncology portfolio</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BioSpectrum India</font>",https://news.google.com/rss/articles/CBMi3gFBVV95cUxPZnU3V2lYbjU3eFNfTjBiWllrcHozUmNpekV5SkNCdmQtNEVqRHcxUmc0NnNCTl9UUllSejdrVjlBU25fLVliQ3dOX2RDbm9Td3dMcFMyTmNYMnRiRk4waEZDZFJGek9PZWRRZXR6NjRydWVWSTlYNjFOM3ZnZzgwVGJnQWN5MmppS2FtYWtBMThkZ3BjazljMDN4Tkk1WFFJZWIzc3BDSF9fcm9oa0ZaQmJhNjlRcy1sOXB1WlNzbGpoQ1RJZTB0QWkzYk9sRmh0aXhxZ0Y4Z3VJb05od0E?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633871,0.0,0.5,0.6,0.0,0.0,0.25,0.3986818053681076,0.4517989055633545,0.3986818053681076,0.0,0.6013181946318924,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,19.196045416104322
2025-04-10,2025-04-10 07:00:00,Biocon Biologics receives USFDA approval for Jobevne (Biosimilar Bevacizumab) - Business Standard,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics receives USFDA approval for Jobevne (Biosimilar Bevacizumab)</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633744,0.0,0.5,0.6,0.0,0.0,0.25,0.3631701501578842,0.4959768947283427,0.3631701501578842,0.0,0.6368298498421159,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,19.089510450473654
2025-05-02,2025-05-02 07:00:00,Interchangeable Status Rapidly Boosted Scripts for Insulin Biosimilar - MedPage Today,"<a href=""https://news.google.com/rss/articles/CBMicEFVX3lxTE16VFBnbWd1S0QzRXFKbWRrSjJaT2w3cGZ0RXN6RnJMTWFOTWZscjhrR0h3bG9uM1JJVXpnVE4wUlB5YU5IZ3ZRazFiU05tYjJtMDJwRTNORGxGRXZ2THJaeFJubWsxOWVhd0ZUazU4UkI?oc=5"" target=""_blank"">Interchangeable Status Rapidly Boosted Scripts for Insulin Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">MedPage Today</font>",https://news.google.com/rss/articles/CBMicEFVX3lxTE16VFBnbWd1S0QzRXFKbWRrSjJaT2w3cGZ0RXN6RnJMTWFOTWZscjhrR0h3bG9uM1JJVXpnVE4wUlB5YU5IZ3ZRazFiU05tYjJtMDJwRTNORGxGRXZ2THJaeFJubWsxOWVhd0ZUazU4UkI?oc=5,Google News,Semglee interchangeable insulin,drug_fda,2025-06-27T05:41:09.801323,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.761204236375008,0.4929285661061605,0.761204236375008,0.0,0.238795763624992,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,18.883612709125025
2025-04-10,2025-04-10 07:00:00,Biocon Biologics receives U.S. FDA approval for Jobevne - The Hindu,"<a href=""https://news.google.com/rss/articles/CBMiqwFBVV95cUxORjl6cTVKTVZmdHR0MG5YTDRBNTZPYnpaTk5BYUJsME1KdXdLU2prRkFoc2l1MldXMVQ4cVdNb0ctQ2FFYzVLNzE1TXh4SnhPTnNVc1VsSjZMZDludVNEVTFxeklzOTk3aWUteTJyZnJrOUFZVTlyWHZGUXRPYzJCb04wVXJYOVg1VW54VUFiNjhxX1k4NHRWcVVFQ0k5YzNscy1Ca21uRWh3eW_SAbIBQVVfeXFMUFpRUllrdXUzVnJmYnVFUkhJdkY2U054LTRLVHd6V3cyTjBvQ2ZfMm9IRzZueEhjOUhqaWM1NnBoclI3SU5RYjV6UXl1YlljOXVlQVpIMGhfZHNYd0lvQmFKRjlJNjFnQURBX3FMOS1BYjBrQXhITGowSmhqZHJjaFZ4T1htdUZIbGdERllUWEdjX2tWSS1qSkxkVUdwUk4ybUh2UUI5c05maXFWWkFRM04yUQ?oc=5"" target=""_blank"">Biocon Biologics receives U.S. FDA approval for Jobevne</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Hindu</font>",https://news.google.com/rss/articles/CBMiqwFBVV95cUxORjl6cTVKTVZmdHR0MG5YTDRBNTZPYnpaTk5BYUJsME1KdXdLU2prRkFoc2l1MldXMVQ4cVdNb0ctQ2FFYzVLNzE1TXh4SnhPTnNVc1VsSjZMZDludVNEVTFxeklzOTk3aWUteTJyZnJrOUFZVTlyWHZGUXRPYzJCb04wVXJYOVg1VW54VUFiNjhxX1k4NHRWcVVFQ0k5YzNscy1Ca21uRWh3eW_SAbIBQVVfeXFMUFpRUllrdXUzVnJmYnVFUkhJdkY2U054LTRLVHd6V3cyTjBvQ2ZfMm9IRzZueEhjOUhqaWM1NnBoclI3SU5RYjV6UXl1YlljOXVlQVpIMGhfZHNYd0lvQmFKRjlJNjFnQURBX3FMOS1BYjBrQXhITGowSmhqZHJjaFZ4T1htdUZIbGdERllUWEdjX2tWSS1qSkxkVUdwUk4ybUh2UUI5c05maXFWWkFRM04yUQ?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633073,0.0,0.5,0.4,0.0,0.0,0.2,0.3303470633099229,0.54525686267217,0.3303470633099229,0.0,0.6696529366900771,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,18.491041189929767
2025-04-10,2025-04-10 07:00:00,Biocon Subsidiary Secures USFDA Approval - Equitypandit,"<a href=""https://news.google.com/rss/articles/CBMifEFVX3lxTE1qRm9JTEVkcm4tQkxoWGdhSTIwY2JhQmZqZFU1NEhFeUdXSjQ3NGhTQ0JzeEM4cG5zTnE0aEVpTjFnRjV5eTJFSHlsTFhqNnVoZV9ORlA4VVVyUU11cWtSeEZqZjJ4dTNqUUtPT2swTkZvOTVZbXRYcnZtLXI?oc=5"" target=""_blank"">Biocon Subsidiary Secures USFDA Approval</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Equitypandit</font>",https://news.google.com/rss/articles/CBMifEFVX3lxTE1qRm9JTEVkcm4tQkxoWGdhSTIwY2JhQmZqZFU1NEhFeUdXSjQ3NGhTQ0JzeEM4cG5zTnE0aEVpTjFnRjV5eTJFSHlsTFhqNnVoZV9ORlA4VVVyUU11cWtSeEZqZjJ4dTNqUUtPT2swTkZvOTVZbXRYcnZtLXI?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.635103,0.0,0.25,0.4,0.0,0.0,0.15,0.41850391665319836,0.6013382272402445,0.41850391665319836,0.0,0.5814960833468017,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,18.255511749959595
2025-04-10,2025-04-10 07:00:00,Pharma stock in focus: Biocon arm announces USFDA approval for Jobevne - Business Today,"<a href=""https://news.google.com/rss/articles/CBMi0wFBVV95cUxQNFI4S2hLZTEtTHdLd0Q2U0p3Njhlc01iLU9FOVNLNUh1THBiUURXYWZqdHNOc25iZnVRYUdmQm9nc2FUTXZucm9QSzlFeDNFa000di0zLXBMUGNGMlNpWjZpclhNWHM4NzFhU1c4dUUzbkJ4Z1QzVVBORU1ZNGp4VWZ3QkplZ0tzQmZ6bUJkcEFYNWgwSGRGRkRMRVBveFU5Wk9nVzVwWk9RWjVfTjlmUTRYVVpSd1FtZDBPWDhtdGJyWDlHVFViUEV1WGtEWDNISlBz0gHYAUFVX3lxTE13TWNNLU9GMlY2V18zRW9mTGo0QnF1T0UwUDltUVFXMEJFNE8tYWppTGEyUEwwdmRDdVNFSjlCME5JN21rakQwSDhFV1lCTzVHYzlsQ0RoMDVLeW9GMWdzaTdOQU9FeTBvSjU0SDFENThSQ0V5TU5yNE00eHQwRzlEWERnODdpT0RQam9SQVA4bnA2NnNoaWRNdFA0SFk5T3p3dG1DNVU4SV9jUUZkSlhSSUhXWWl1VWVaUlpwMGNlMGs0OHVRZ3VNTVgzNmtfZW9zYUpSZUItZA?oc=5"" target=""_blank"">Pharma stock in focus: Biocon arm announces USFDA approval for Jobevne</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Today</font>",https://news.google.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?oc=5,Google News,Biocon stock price reaction,financial,2025-06-27T05:41:44.924956,0.0,0.25,0.4,0.16666666666666666,0.0,0.175,0.3306079845586615,0.5448265370051066,0.3306079845586615,0.0,0.6693920154413384,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,18.241823953675983
2025-04-10,2025-04-10 07:00:00,Biocon arm announces U.S. FDA approval for Jobevne - Moneycontrol,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon arm announces U.S. FDA approval for Jobevne</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Moneycontrol</font>",https://news.google.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?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634124,0.0,0.25,0.4,0.0,0.0,0.15,0.3315847938995046,0.5432215428670247,0.3315847938995046,0.0,0.6684152061004953,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,17.994754381698513
2025-04-15,2025-04-15 07:00:00,"Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. - PR Newswire","<a href=""https://news.google.com/rss/articles/CBMi8gFBVV95cUxOdUVLNnNlRnpvLTN5OVN5Z0k3dVp3R0V5QVFGcUNGanNvT3FZYmc5R1RoS1kzTnJjcVpacmJkbzkzeDM3bjV4cmtRblR5a0FoUGNmdUdOSHdaNGtfYm1LcWVXQThuZGpCN0xjcmstNTA1WEFibXlVRVJQRENqUEVYNkFuUGVQcUFib1lseGsyRE84MzFEM04zY2ViZXk4UElUTGU2bG5mODctRlYyNVVZU2hZaGU2eTM4N08yQm9RemJLTjZ0b2EyMXZzRS1JSXRHT1QxcTVmbE83eGdNWXBoeWF0b1VnNHZ4UENlMTdFQ0h0dw?oc=5"" target=""_blank"">Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi8gFBVV95cUxOdUVLNnNlRnpvLTN5OVN5Z0k3dVp3R0V5QVFGcUNGanNvT3FZYmc5R1RoS1kzTnJjcVpacmJkbzkzeDM3bjV4cmtRblR5a0FoUGNmdUdOSHdaNGtfYm1LcWVXQThuZGpCN0xjcmstNTA1WEFibXlVRVJQRENqUEVYNkFuUGVQcUFib1lseGsyRE84MzFEM04zY2ViZXk4UElUTGU2bG5mODctRlYyNVVZU2hZaGU2eTM4N08yQm9RemJLTjZ0b2EyMXZzRS1JSXRHT1QxcTVmbE83eGdNWXBoeWF0b1VnNHZ4UENlMTdFQ0h0dw?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633473,0.0,0.5,0.2,0.0,0.0,0.15,0.20932684567795726,0.49475221233367916,0.20932684567795726,0.0,0.7906731543220428,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,17.62798053703387
2025-04-10,2025-04-10 03:59:43,Biocon Biologics bags US FDA approval for Jobevne to treat cancer - IndiaMedToday,"<a href=""https://news.google.com/rss/articles/CBMilwFBVV95cUxOVHA3WFp6THIzMHYwOVd6SGtZZ0ItbEJSeDZraE9IVDJFWElCeWI5SEE5RW4yV3RrOVZwWE1YV1RRMkhTSVJTNDNyeTJSYWxSWXNNNmdacm1BOFlJZ2RKLXEtN04yN3lMMkFxY0lvOXFoZWZuWUpEaVFvMkdJZWVObXhLT19VaXRxZ3AxNWNDVXdYNjhJeXhB?oc=5"" target=""_blank"">Biocon Biologics bags US FDA approval for Jobevne to treat cancer</a>&nbsp;&nbsp;<font color=""#6f6f6f"">IndiaMedToday</font>",https://news.google.com/rss/articles/CBMilwFBVV95cUxOVHA3WFp6THIzMHYwOVd6SGtZZ0ItbEJSeDZraE9IVDJFWElCeWI5SEE5RW4yV3RrOVZwWE1YV1RRMkhTSVJTNDNyeTJSYWxSWXNNNmdacm1BOFlJZ2RKLXEtN04yN3lMMkFxY0lvOXFoZWZuWUpEaVFvMkdJZWVObXhLT19VaXRxZ3AxNWNDVXdYNjhJeXhB?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.635131,0.0,0.5,0.4,0.0,0.0,0.2,0.038494041157190274,0.35438636535008744,0.038494041157190274,0.0,0.9615059588428098,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,17.615482123471573
2025-04-11,2025-04-11 07:00:00,Biocon Biologics secures FDA approval for cancer drug Jobevne - BusinessLine,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics secures FDA approval for cancer drug Jobevne</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BusinessLine</font>",https://news.google.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?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.382401,0.0,0.5,0.4,0.0,0.0,0.2,0.0,0.2968478600184123,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,17.5
2025-04-11,2025-04-11 07:00:00,Biocon arm secures USFDA approval for Everolimus Tablets for prophylaxis of organ rejection in adult... - Medical Dialogues,"<a href=""https://news.google.com/rss/articles/CBMi-AFBVV95cUxQTnJFODM5dTc5QTljSWlWY0VfcTRaQ2x3OUpYRFdFNnNLZXNYQUQySXNLbjdPU1lNZktpSU1PWkFvU2ZiN0hSSjV3T2tRZWZIdGhTT0V4MjNpeXdxcl9icERxcHh3d0hPU2RmaTlJUm9YQlBlaExDQUhndm1JdmF0M0Y3RUItUGhrMDBnYXd4blFfQVV1T3BvVnl0X3p4TU5Fd1JwQWJ1WndZVFZYUzJLZ0pBc3RJV1VFV20xZy1Sc1FrZVRSODI1MEJwSHl1ZnVwLVJHVFdva0d2WjdRN2xOdEppcVU3NHpYc1RvVHYwMjZ2X2dEVVhaWNIB_gFBVV95cUxNanRkWDhvVDZ0Znk3aFdsYVdKbnc5SDNwWDBFaThURGdKU3NLM1k2UUxaNUhxQ3N1RURVellYNkVxNEdIZ3NtalhwMHV3M2s0Q3JIakdwNTk2OFFFQzY5SG9Dek5IWFdTdktwZDBHdk1GTHNXWHZFMzNPaXJNTHVuUDFFTXFNUUhrcVZHUXVBUzZIUmgtaF9HMU5UNUpxbmxpTmJlYWJRdlpxb0EwSkpNMWFDR0tlQk5yMjl4aTcyektuY2ZPTUVwd29tYzQ4YVV0dElhWmRJLTFla2p5VVk2ZVpzd0VEb3hCYkRLQ3djVjVBVEdSXzVhaEkzX3FOZw?oc=5"" target=""_blank"">Biocon arm secures USFDA approval for Everolimus Tablets for prophylaxis of organ rejection in adult...</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Medical Dialogues</font>",https://news.google.com/rss/articles/CBMi-AFBVV95cUxQTnJFODM5dTc5QTljSWlWY0VfcTRaQ2x3OUpYRFdFNnNLZXNYQUQySXNLbjdPU1lNZktpSU1PWkFvU2ZiN0hSSjV3T2tRZWZIdGhTT0V4MjNpeXdxcl9icERxcHh3d0hPU2RmaTlJUm9YQlBlaExDQUhndm1JdmF0M0Y3RUItUGhrMDBnYXd4blFfQVV1T3BvVnl0X3p4TU5Fd1JwQWJ1WndZVFZYUzJLZ0pBc3RJV1VFV20xZy1Sc1FrZVRSODI1MEJwSHl1ZnVwLVJHVFdva0d2WjdRN2xOdEppcVU3NHpYc1RvVHYwMjZ2X2dEVVhaWNIB_gFBVV95cUxNanRkWDhvVDZ0Znk3aFdsYVdKbnc5SDNwWDBFaThURGdKU3NLM1k2UUxaNUhxQ3N1RURVellYNkVxNEdIZ3NtalhwMHV3M2s0Q3JIakdwNTk2OFFFQzY5SG9Dek5IWFdTdktwZDBHdk1GTHNXWHZFMzNPaXJNTHVuUDFFTXFNUUhrcVZHUXVBUzZIUmgtaF9HMU5UNUpxbmxpTmJlYWJRdlpxb0EwSkpNMWFDR0tlQk5yMjl4aTcyektuY2ZPTUVwd29tYzQ4YVV0dElhWmRJLTFla2p5VVk2ZVpzd0VEb3hCYkRLQ3djVjVBVEdSXzVhaEkzX3FOZw?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634617,0.0,0.25,0.4,0.0,0.0,0.15,0.13346825465631543,0.4477025903065999,0.13346825465631543,0.0,0.8665317453436846,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,17.400404763968947
2025-04-10,2025-04-10 07:00:00,Biocon share price rises 4% on US FDA approval for cancer drug - TradingView,"<a href=""https://news.google.com/rss/articles/CBMiwgFBVV95cUxPREctU2RCYWp1b2ppUDdoUU5FaW9YRzlzem5sNFJydXVUQjlfeUpMbVVQM0swT1NNb2Q4VHM0dGFHUVNLV25YaXVpTUFoOUlnaDNyZm8xaEN4aXNXZklERDhXU2dWYVRlVkx6NGRENjZaaGlleTc1QzQ1UUtZQjRESVl5RlpmbDBTdXVGSUxUbWluTEE1RTd0Q2VUWVVhV210VjRaOUIzRXViNGVwMTVaY1Ftd3BtQVZSZGFYc1VQRlhUdw?oc=5"" target=""_blank"">Biocon share price rises 4% on US FDA approval for cancer drug</a>&nbsp;&nbsp;<font color=""#6f6f6f"">TradingView</font>",https://news.google.com/rss/articles/CBMiwgFBVV95cUxPREctU2RCYWp1b2ppUDdoUU5FaW9YRzlzem5sNFJydXVUQjlfeUpMbVVQM0swT1NNb2Q4VHM0dGFHUVNLV25YaXVpTUFoOUlnaDNyZm8xaEN4aXNXZklERDhXU2dWYVRlVkx6NGRENjZaaGlleTc1QzQ1UUtZQjRESVl5RlpmbDBTdXVGSUxUbWluTEE1RTd0Q2VUWVVhV210VjRaOUIzRXViNGVwMTVaY1Ftd3BtQVZSZGFYc1VQRlhUdw?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633351,0.0,0.25,0.4,0.16666666666666666,0.0,0.175,-0.0032993888453661533,0.26899527203241985,0.0,0.0032993888453661533,0.9967006111546338,0,0,0,4.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,17.259898166536097
2025-04-10,2025-04-10 07:00:00,Bevacizumab Biosimilar Granted FDA Approval for Several Cancer Types - Oncology Nursing News,"<a href=""https://news.google.com/rss/articles/CBMipwFBVV95cUxOZmVadG5WTFdOc3FFaDRFQW1MaEloQy1JXzdVYlRLSGVET1pwUFlRM2MyN2JSUE5Qdm9xeVFvbmp2NU04WmdwTDVrbkp3NnVuc0xUVFJieWVodzlQM3UyX0ljRXZUTHlHb2JEYkUzMFdVLXRLUmJvaGgzQ3p3UzlEMEYwSHJ1aU14WGZ5TElkWW0ta1lpT2FPSVhRRHNDMnp3YlNzZ2JrZw?oc=5"" target=""_blank"">Bevacizumab Biosimilar Granted FDA Approval for Several Cancer Types</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Oncology Nursing News</font>",https://news.google.com/rss/articles/CBMipwFBVV95cUxOZmVadG5WTFdOc3FFaDRFQW1MaEloQy1JXzdVYlRLSGVET1pwUFlRM2MyN2JSUE5Qdm9xeVFvbmp2NU04WmdwTDVrbkp3NnVuc0xUVFJieWVodzlQM3UyX0ljRXZUTHlHb2JEYkUzMFdVLXRLUmJvaGgzQ3p3UzlEMEYwSHJ1aU14WGZ5TElkWW0ta1lpT2FPSVhRRHNDMnp3YlNzZ2JrZw?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633166,0.0,0.0,0.6,0.0,0.0,0.15,-0.02268057189737886,0.34448881486256916,0.0,0.02268057189737886,0.9773194281026212,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,17.068041715692136
2024-12-02,2024-12-02 08:00:00,Biocon Biologics receives FDA approval for biosimilar YESINTEK - Express Pharma,"<a href=""https://news.google.com/rss/articles/CBMilwFBVV95cUxQZ2tnSEZ4MEhBRnJQOUNUSDVDczVqSnhtTEFPOTFNS3dueUgwNWltV0J0LVhpQWlkc0ZpUVpWRkpQd2x1UDFlbEdkWFE5czE5Qlh3VjVqeFBSQWhmREJMMzI2RVNLRFoxc2NfdlNncEs3OTVJeU1MY1VIZlJKOEdMa0VlYkRLci1mc3pfQjFGcWc2ZVY1NlY00gGcAUFVX3lxTE9MUXN2eDg1Sm9JcVBpZjN0QTBrTVZ0elMwZUo3bmhLMEdBVWJTdVZMNWFGdk9YTG5GWUpDaEx3MjRwUnZlZXBQQlozX2JtWTRHRngxQ19GbWtyRGJTMjdrTndBcXFWZ1JfaGpod0lTcm13ZFhkMVBFcjk5R0E0VGVObkxQWWFaSVBMN1NwSUdkeHBWaHlPUDItWVhidQ?oc=5"" target=""_blank"">Biocon Biologics receives FDA approval for biosimilar YESINTEK</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Express Pharma</font>",https://news.google.com/rss/articles/CBMilwFBVV95cUxQZ2tnSEZ4MEhBRnJQOUNUSDVDczVqSnhtTEFPOTFNS3dueUgwNWltV0J0LVhpQWlkc0ZpUVpWRkpQd2x1UDFlbEdkWFE5czE5Qlh3VjVqeFBSQWhmREJMMzI2RVNLRFoxc2NfdlNncEs3OTVJeU1MY1VIZlJKOEdMa0VlYkRLci1mc3pfQjFGcWc2ZVY1NlY00gGcAUFVX3lxTE9MUXN2eDg1Sm9JcVBpZjN0QTBrTVZ0elMwZUo3bmhLMEdBVWJTdVZMNWFGdk9YTG5GWUpDaEx3MjRwUnZlZXBQQlozX2JtWTRHRngxQ19GbWtyRGJTMjdrTndBcXFWZ1JfaGpod0lTcm13ZFhkMVBFcjk5R0E0VGVObkxQWWFaSVBMN1NwSUdkeHBWaHlPUDItWVhidQ?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634251,0.0,0.5,0.6,0.0,0.0,0.25,0.3499928025747396,0.5146505928357442,0.3499928025747396,0.0,0.6500071974252604,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,17.04997840772422
2017-07-21,2017-07-21 07:00:00,Merck Wins Tentative FDA Approval of Follow-on Insulin Glargine - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMipwFBVV95cUxNeENEVU9FU1ZTNWZud2FUN2hsc3Q3Z21iZjZhRm1ZdmNHMXNtTmRObXI2SXBfajJmQlRoMlJKMVpwWFdGU1Mxay02YWZiQ3ZFdXgwWnhHMkdGNFpIMDVfUTNqeG5yangwY2loNUk0S3FPOWNhV3J4VkNUZm1GS29aSlVnMjVMMzhMYlREVDY2X3hSZ1k5aFRMVGxfMEdjWExuZ0Jzd2RkMA?oc=5"" target=""_blank"">Merck Wins Tentative FDA Approval of Follow-on Insulin Glargine</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMipwFBVV95cUxNeENEVU9FU1ZTNWZud2FUN2hsc3Q3Z21iZjZhRm1ZdmNHMXNtTmRObXI2SXBfajJmQlRoMlJKMVpwWFdGU1Mxay02YWZiQ3ZFdXgwWnhHMkdGNFpIMDVfUTNqeG5yangwY2loNUk0S3FPOWNhV3J4VkNUZm1GS29aSlVnMjVMMzhMYlREVDY2X3hSZ1k5aFRMVGxfMEdjWExuZ0Jzd2RkMA?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.587179,0.2,0.0,0.6,0.0,0.0,0.21000000000000002,0.7554204981428512,0.5259986400286357,0.7554204981428512,0.0,0.24457950185714883,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.866261494428553
2024-12-01,2024-12-01 08:00:00,Biocon Biologics secures US FDA approval to commercialise YESINTEK - BusinessLine,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics secures US FDA approval to commercialise YESINTEK</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BusinessLine</font>",https://news.google.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?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633997,0.0,0.5,0.4,0.0,0.0,0.2,0.4262753608243194,0.5903752045313517,0.4262753608243194,0.0,0.5737246391756806,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.77882608247296
2025-03-24,2025-03-24 07:00:00,Biocon Pharma gets USFDA approval for BP-raising injection in adults with acute hypotension - Medical Dialogues,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Pharma gets USFDA approval for BP-raising injection in adults with acute hypotension</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Medical Dialogues</font>",https://news.google.com/rss/articles/CBMi4AFBVV95cUxOb1BZbnc2QWszVloyenhfV05UbVNsVzk0a0w5TVZsVU1SWVdING1UYUFISHY4ZEJfLWx3dVp2dXBxT0FLbm5zc19QVkN1MjlWREFZaHUzSGttU19BTVJoUWhYRkhCZmEtOTVCVkY1OVNwSm5aMUFLVjFybnZ0NUdDNXJxYjJxNDVoRHF6WWI5MGtoczlWeGtjU0RaeS1HMFQ0YWJGQUphMTdCN3BXU2ZUd3lUcGJ2R1NpQTZNSThEQzkyOFFjT1hBbWdnZEU4b09zR05MVVN3bXJJZDU5UkFsSNIB5gFBVV95cUxNWndQQUk3ZEpqYTVXeTN5OW1PeTIwckNyQ3FwZXZaUjhLcC16Z2ZUWUF1SWx3T0hRaWd3SWpqdUMyUkhHc2NlajhRajFJd0xUdkZQMFZYTTN3UTR4TFRMeUtqdk00T21MVEs2UzZBZG1EeEFwMUR1dnNoRGNYVWRQc1N3S0RheWNRc0Exd3VHOF9vUFFFNWJlZWhyZEFtckJ0WWZENjdXc0l0ZEs1Ykg1dURwNEZUOWVSbF9yaDlrODcwb0JtWUtDUXlwOXprNFJKSktXRDh1d3hZMHZqeFExOHVQTVlkUQ?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.382751,0.0,0.5,0.4,0.0,0.0,0.2,0.40221564053102116,0.4955650234540303,0.40221564053102116,0.0,0.5977843594689789,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.706646921593062
2024-12-02,2024-12-02 08:00:00,Biocon Shares Rally 4% as Subsidiary Receives USFDA Approval - Equitypandit,"<a href=""https://news.google.com/rss/articles/CBMikwFBVV95cUxNaFJkbmZMcXBWSTBXcktrelhhbnBDOEFjMkRmRzg4M0Z3VmZxRjFhekc4U21YRmlvNUtmSG5tRDN4OVVyVV9MZDdpNkJrSnZvV2ZaTDRsZ3JsR2s3VUFoRW5YWWRaMEdqWEdPckpRaGhkamF6UmRSNllKWWlub1BVVEFWaHVJMGlNNzZQWWotbS1tOGM?oc=5"" target=""_blank"">Biocon Shares Rally 4% as Subsidiary Receives USFDA Approval</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Equitypandit</font>",https://news.google.com/rss/articles/CBMikwFBVV95cUxNaFJkbmZMcXBWSTBXcktrelhhbnBDOEFjMkRmRzg4M0Z3VmZxRjFhekc4U21YRmlvNUtmSG5tRDN4OVVyVV9MZDdpNkJrSnZvV2ZaTDRsZ3JsR2s3VUFoRW5YWWRaMEdqWEdPckpRaGhkamF6UmRSNllKWWlub1BVVEFWaHVJMGlNNzZQWWotbS1tOGM?oc=5,Google News,Biocon regulatory filing,regulatory,2025-06-27T05:41:53.451463,0.0,0.25,0.4,0.0,0.0,0.15,0.46860432573163613,0.5291644493738811,0.46860432573163613,0.0,0.5313956742683639,0,0,0,4.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.40581297719491
2020-06-12,2020-06-12 07:00:00,"Biocon and Mylan receive US FDA approval for Semglee, an insulin glargine injection - Express Pharma","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon and Mylan receive US FDA approval for Semglee, an insulin glargine injection</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Express Pharma</font>",https://news.google.com/rss/articles/CBMisgFBVV95cUxOTk1oVUE4dUU3MWZESDFmbmg0d0I3bG5nc1BkenBxVDRYSWgwbGZEb1NyZDdxNUotUUNieEZ4MTJGSlNfbGpJV2VsT0k5QUh3V3VWNHpWZzZyUE9aRXRoRmRySGxMcVc4TmZoY1dYdUpuQ3B4SS1LODVnRTB1R0phUUZMQ19XSGdOQjVtbGhFUnM5VGtPMTlfZXplX255YWRwZUJxWF83TG1YdE9SWEszTXdB0gG3AUFVX3lxTE1ZOElQQ1pUOVZ6OHdObXk4T0dzRmhWaDlrUmxaSVpsWExQbm95dXQzdmwzQTRhNXp0MzNnRzFhWG5zaDFMcFJQVFh4MlA0bEFCeDVaSlljUkdGemRJcEZRQU5YbTRHOUhnTko4bWJuTV9UNHgzRVRIMzNRSk52MWJQaXpFUmVtcVA0aV92Ulp1amhnb3IyOTFfVWtzOFpHaW1LSTQ1NEh0V0VDME85eTcyelI5S0VwOA?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413815,0.4,0.25,0.4,0.0,0.0,0.27,0.3855122656532599,0.4672328726768494,0.3855122656532599,0.0,0.6144877343467401,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.35653679695978
2024-12-02,2024-12-02 08:00:00,Biocon's Shares Price Jumps 4% after FDA Approval of Yesintek; Technical Charts & Resistance Levels - topnews.in,"<a href=""https://news.google.com/rss/articles/CBMiugFBVV95cUxPM1p0dkQwbWFUZzN3YkVzclVDOUFRQ3hCM0NYUEU2S3QzZl9PVHk3RFR6WUlfWkY4dHZrTjhDRWh0WEZTS25Cck16aHVCSWRNZVRIcEV1SmdnR3NZQ1FRa3I5REhhc05WOVVyTTNlV05JaWdobUQ3M0Y4bTk2RjN3YjgwcnpDY0l2MTNiZlFzTjVpOTBRaGtuRnVmZU56Y1dDbE1za0owVmJlay0zRTFhdzIxWlpJR1NvRUE?oc=5"" target=""_blank"">Biocon's Shares Price Jumps 4% after FDA Approval of Yesintek; Technical Charts & Resistance Levels</a>&nbsp;&nbsp;<font color=""#6f6f6f"">topnews.in</font>",https://news.google.com/rss/articles/CBMiugFBVV95cUxPM1p0dkQwbWFUZzN3YkVzclVDOUFRQ3hCM0NYUEU2S3QzZl9PVHk3RFR6WUlfWkY4dHZrTjhDRWh0WEZTS25Cck16aHVCSWRNZVRIcEV1SmdnR3NZQ1FRa3I5REhhc05WOVVyTTNlV05JaWdobUQ3M0Y4bTk2RjN3YjgwcnpDY0l2MTNiZlFzTjVpOTBRaGtuRnVmZU56Y1dDbE1za0owVmJlay0zRTFhdzIxWlpJR1NvRUE?oc=5,Google News,Biocon US market revenue,financial,2025-06-27T05:41:41.753063,0.0,0.25,0.4,0.0,0.0,0.15,0.4314211600578541,0.5747718771298727,0.4314211600578541,0.0,0.5685788399421459,0,0,0,4.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.294263480173562
2020-06-11,2020-06-11 07:00:00,Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection) - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMi0AFBVV95cUxPZWtPRnhZNm1pemVzTi1Kd1pDV2ZqRkdCcTFtaTBGWkhHcWtsVk4wdUZ3RUEwNDJjNFFCWnhZSzdMOUl2NjJPZE12eEZjNzd6eVQxZDk1UHVkZkpTLXRLX0RJeFF0VDJvZFB5WFVjNFRheE1ncjhJb1pWYXhUXzFzaTFaZ3B0eldwajhVUk5abVdJaklYMGRHTUItUU5HcHJYdE9HV3Z6b1J0UkJRMzdHd2t2U1lHMXpzWkhkdVpzM0FTQkF0UVJfaGEzOEppUERi?oc=5"" target=""_blank"">Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi0AFBVV95cUxPZWtPRnhZNm1pemVzTi1Kd1pDV2ZqRkdCcTFtaTBGWkhHcWtsVk4wdUZ3RUEwNDJjNFFCWnhZSzdMOUl2NjJPZE12eEZjNzd6eVQxZDk1UHVkZkpTLXRLX0RJeFF0VDJvZFB5WFVjNFRheE1ncjhJb1pWYXhUXzFzaTFaZ3B0eldwajhVUk5abVdJaklYMGRHTUItUU5HcHJYdE9HV3Z6b1J0UkJRMzdHd2t2U1lHMXpzWkhkdVpzM0FTQkF0UVJfaGEzOEppUERi?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.412836,0.4,0.25,0.4,0.0,0.0,0.27,0.32838439181729145,0.5485157267570496,0.32838439181729145,0.0,0.6716156081827085,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.185153175451873
2024-07-01,2024-07-01 07:00:00,Ahzantive Receives FDA Approval as New Eylea Biosimilar - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMingFBVV95cUxNSTFjQ2dpaXY1RHJPX0JyTldfWWdkSkVOWlBLVHI1MnNCWC1PSnhiSjZTWUtGV3ZEWlNLN1VHQUt6am83cFNEaUE3ajJZS2xnOVVYVmx4NURSdGN0dHFsSjJLeS1vRUsxSDY0T1dXeHgxdTVJeS1LeFVVLVE2OW1ReFZISHZQaXUydzJoWFBpcnF0RnpYTmNuU0F3RWJRZw?oc=5"" target=""_blank"">Ahzantive Receives FDA Approval as New Eylea Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMingFBVV95cUxNSTFjQ2dpaXY1RHJPX0JyTldfWWdkSkVOWlBLVHI1MnNCWC1PSnhiSjZTWUtGV3ZEWlNLN1VHQUt6am83cFNEaUE3ajJZS2xnOVVYVmx4NURSdGN0dHFsSjJLeS1vRUsxSDY0T1dXeHgxdTVJeS1LeFVVLVE2OW1ReFZISHZQaXUydzJoWFBpcnF0RnpYTmNuU0F3RWJRZw?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.635499,0.0,0.0,0.6,0.0,0.0,0.15,0.3582976445252201,0.5029185357556198,0.3582976445252201,0.0,0.6417023554747798,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.07489293357566
2021-07-28,2021-07-28 07:00:00,FDA approves Semglee as first biosimilar interchangeable insulin - Regulatory Affairs Professionals Society | RAPS,"<a href=""https://news.google.com/rss/articles/CBMirwFBVV95cUxNVHNqNlBHdFJ3d1NvQzhkZ2l1N0VlN2FWZm8xTDNPYzFLMWNUNC1JdWtZZ1FuZWdUdEYyNkd5WDg3MHJCSFVWeVdIVFZHXy1tQ25jWExZN2kxQ1VXbGdqNmVDN3Fzc256STZ4bktRZi1pWnhtcHY5NkFXbzgtRENkc2RyWHNrbC14WF8zbFNrLTUzSTlrc0FpY0xQTUpyai1GSU95NW5hNlZnOURfMnVN?oc=5"" target=""_blank"">FDA approves Semglee as first biosimilar interchangeable insulin</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Regulatory Affairs Professionals Society | RAPS</font>",https://news.google.com/rss/articles/CBMirwFBVV95cUxNVHNqNlBHdFJ3d1NvQzhkZ2l1N0VlN2FWZm8xTDNPYzFLMWNUNC1JdWtZZ1FuZWdUdEYyNkd5WDg3MHJCSFVWeVdIVFZHXy1tQ25jWExZN2kxQ1VXbGdqNmVDN3Fzc256STZ4bktRZi1pWnhtcHY5NkFXbzgtRENkc2RyWHNrbC14WF8zbFNrLTUzSTlrc0FpY0xQTUpyai1GSU95NW5hNlZnOURfMnVN?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.412806,0.4,0.0,0.6,0.0,0.0,0.27,0.28306715701992463,0.5451967331144544,0.28306715701992463,0.0,0.7169328429800754,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.049201471059774
2021-08-26,2021-08-26 07:00:00,First interchangeable biosimilar insulin's approval to increase competition with payer contracts: GlobalData - ET HealthWorld,"<a href=""https://news.google.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?oc=5"" target=""_blank"">First interchangeable biosimilar insulin's approval to increase competition with payer contracts: GlobalData</a>&nbsp;&nbsp;<font color=""#6f6f6f"">ET HealthWorld</font>",https://news.google.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?oc=5,Google News,Semglee biosimilar approval,drug_fda,2025-06-27T05:41:08.122095,0.0,0.0,0.4,0.0,0.2,0.12,0.7789479426633519,0.6146867801560296,0.7789479426633519,0.0,0.22105205733664812,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.036843827990054
2024-05-21,2024-05-21 07:00:00,"Biocon Biologics gets U.S. FDA approval for biosimilar aflibercept Yesafili, enters US ophthalmology market - ET HealthWorld","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics gets U.S. FDA approval for biosimilar aflibercept Yesafili, enters US ophthalmology market</a>&nbsp;&nbsp;<font color=""#6f6f6f"">ET HealthWorld</font>",https://news.google.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?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.636024,0.0,0.5,0.6,0.0,0.0,0.25,0.33646390303490387,0.5353442128817241,0.33646390303490387,0.0,0.6635360969650961,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.00939170910471
2021-08-02,2021-08-02 07:00:00,Average Net Price for Insulin Glargine Declined After Basaglar Won FDA Approval - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMivgFBVV95cUxNM2JWNFdSUFp3SlpDclRKNF9sejJqRlFTaW11eGpZSy1oYlRqMWphSjJyQnJ4dFlfRko0RFZMWFVKTjJja2pBaDl4emVPazczQmRSTDBuUms3X2w4emdXMXdUM2p1SlVpVHFCSmM0VGFkYmtsNnhFWHlCSDlObG5ZcUNha1lYX2ZXc0Q2SHlsN0JfNVBHd3BKZlpsT192X0JaT01Xa3ZjYS1aWWNBOXFTOV9iNVRDemgzQ1QwcHRB?oc=5"" target=""_blank"">Average Net Price for Insulin Glargine Declined After Basaglar Won FDA Approval</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMivgFBVV95cUxNM2JWNFdSUFp3SlpDclRKNF9sejJqRlFTaW11eGpZSy1oYlRqMWphSjJyQnJ4dFlfRko0RFZMWFVKTjJja2pBaDl4emVPazczQmRSTDBuUms3X2w4emdXMXdUM2p1SlVpVHFCSmM0VGFkYmtsNnhFWHlCSDlObG5ZcUNha1lYX2ZXc0Q2SHlsN0JfNVBHd3BKZlpsT192X0JaT01Xa3ZjYS1aWWNBOXFTOV9iNVRDemgzQ1QwcHRB?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.586948,0.2,0.0,0.6,0.0,0.2,0.23000000000000004,0.402140184570939,0.5001389521326337,0.402140184570939,0.0,0.5978598154290611,0,0,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,16.006420553712818
2024-05-21,2024-05-21 07:00:00,Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMi-wFBVV95cUxOeGRuOEpEaURCa1IyQjZsSzkydERHN2VJYmdHSm1pZFRhMFN4SzdJcDZCVERQbHZJQVczVVJjQUFQNXNyZWpLLTBiVjhuMUhwWWZkVHVPNjlUUUh0X3RHQTAxdHE0WHdhdGVJWDZ5U0ZVMzZydjMxRmtWUng3OWFQSFpIUmw4ME1MYjNiNHEtOEd5aUtFRDh3N3dvd0xfQmNSQmRMNFcxV2ZyWlZFUEFxNUdIOHFMWktOMFgyLTJmVC1pUWxwQUVjVEJVS2xiNnhTRWJCSEZUNzFBbzdCNHNVWTZhMFJqNzYwa0gxVTRBRUlQVmVuZUxFajNKcw?oc=5"" target=""_blank"">Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi-wFBVV95cUxOeGRuOEpEaURCa1IyQjZsSzkydERHN2VJYmdHSm1pZFRhMFN4SzdJcDZCVERQbHZJQVczVVJjQUFQNXNyZWpLLTBiVjhuMUhwWWZkVHVPNjlUUUh0X3RHQTAxdHE0WHdhdGVJWDZ5U0ZVMzZydjMxRmtWUng3OWFQSFpIUmw4ME1MYjNiNHEtOEd5aUtFRDh3N3dvd0xfQmNSQmRMNFcxV2ZyWlZFUEFxNUdIOHFMWktOMFgyLTJmVC1pUWxwQUVjVEJVS2xiNnhTRWJCSEZUNzFBbzdCNHNVWTZhMFJqNzYwa0gxVTRBRUlQVmVuZUxFajNKcw?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634861,0.0,0.5,0.6,0.0,0.0,0.25,0.3297803832834583,0.5461938079516093,0.3297803832834583,0.0,0.6702196167165417,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.989341149850375
2025-02-20,2025-02-20 08:00:00,First Insulin Aspart Biosimilar Receives FDA Approval - AJMC,"<a href=""https://news.google.com/rss/articles/CBMihgFBVV95cUxPd3FKdEVHejF0VUJlUzM3d3pHZ3lxSzRneDNmSHJXNWl6a1h5Z0E5RjFINzJ4bHlFREtuYlRHclNsNkZnN2dXVFdzdkI2ZkcyUXZuUHZxazBJSXNBQ2FiRmRESC1mZUlmNnpYcEhzQi13Z3A4OC1ZTmoxSE9pdmtpT2wwelNLUQ?oc=5"" target=""_blank"">First Insulin Aspart Biosimilar Receives FDA Approval</a>&nbsp;&nbsp;<font color=""#6f6f6f"">AJMC</font>",https://news.google.com/rss/articles/CBMihgFBVV95cUxPd3FKdEVHejF0VUJlUzM3d3pHZ3lxSzRneDNmSHJXNWl6a1h5Z0E5RjFINzJ4bHlFREtuYlRHclNsNkZnN2dXVFdzdkI2ZkcyUXZuUHZxazBJSXNBQ2FiRmRESC1mZUlmNnpYcEhzQi13Z3A4OC1ZTmoxSE9pdmtpT2wwelNLUQ?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.412745,0.0,0.0,0.6,0.0,0.0,0.15,0.31656651649414347,0.5982416102939182,0.31656651649414347,0.0,0.6834334835058565,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.94969954948243
2025-01-07,2025-01-07 08:00:00,"Biocon stock zooms over 8% on Psoriasis drug approval from Japan, Jefferies rating upgrade - Mint","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon stock zooms over 8% on Psoriasis drug approval from Japan, Jefferies rating upgrade</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Mint</font>",https://news.google.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?oc=5,Google News,Biocon analyst upgrade,financial,2025-06-27T05:41:46.697035,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.33222779696877075,0.5421701765378316,0.33222779696877075,0.0,0.6677722030312292,0,0,0,8.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.746683390906313
2021-07-29,2021-07-29 07:00:00,FDA Approves Insulin Glargine-yfgn as First Interchangeable Biosimilar Insulin Product for Diabetes - Pharmacy Times,"<a href=""https://news.google.com/rss/articles/CBMizwFBVV95cUxPTUFDRGVGUW01NW1SOVU2Y2kwSHg3OFpzME0xYVl3a1AyNjNTNHNsYkhmREIzbW1uc0I4cTAyRVVzTWRVcVJfRW9HaTR4SDhxZGlLNVZIQ0lsX3JGd290cFkzTjgwTDVQNzJZV2FiYmV3WmhiY3QzemhOYklaeUJlY2xWRUZ5XzBNWURuOUFlTV9EZE9OTFg5c3ZaLURVeEcxUnBKV0RsNGJEQ3Y5TFdrWURObkdaMFQ1QU12a1Vtb2JVQ0IyZ1pZdlJSQUtHeE0?oc=5"" target=""_blank"">FDA Approves Insulin Glargine-yfgn as First Interchangeable Biosimilar Insulin Product for Diabetes</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Pharmacy Times</font>",https://news.google.com/rss/articles/CBMizwFBVV95cUxPTUFDRGVGUW01NW1SOVU2Y2kwSHg3OFpzME0xYVl3a1AyNjNTNHNsYkhmREIzbW1uc0I4cTAyRVVzTWRVcVJfRW9HaTR4SDhxZGlLNVZIQ0lsX3JGd290cFkzTjgwTDVQNzJZV2FiYmV3WmhiY3QzemhOYklaeUJlY2xWRUZ5XzBNWURuOUFlTV9EZE9OTFg5c3ZaLURVeEcxUnBKV0RsNGJEQ3Y5TFdrWURObkdaMFQ1QU12a1Vtb2JVQ0IyZ1pZdlJSQUtHeE0?oc=5,Google News,insulin glargine-yfgn FDA,drug_fda,2025-06-27T05:41:11.426852,0.4,0.0,0.4,0.0,0.0,0.22000000000000003,0.3342704948800662,0.4616838507228427,0.3342704948800662,0.0,0.6657295051199338,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.702811484640197
2021-07-28,2021-07-28 07:00:00,FDA Approves Semglee Insulin Glargine as First Interchangeable Biosimilar - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMitgFBVV95cUxNY1NaRzFiMjg5akRNbXB5eUhGSGRIdVhCT2g1eThvRUYxeDFnQUxleTIzMVV0TFFqVENXLXZueEVFeUI3YUE2bk1kNEpZY2hYcTg5THBjUFlUbzRsSzFVN1R2TFVxODF0elVFaE5GUTBLLTNKRHJPVTl6Z2FBT1NzT2dlMTZjVk9feUhvbDJXaDRKSC1SWkJPOVY0b3hiVGV1blRIRlMyaXBzUVRpS2dVeTR5TjktZw?oc=5"" target=""_blank"">FDA Approves Semglee Insulin Glargine as First Interchangeable Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMitgFBVV95cUxNY1NaRzFiMjg5akRNbXB5eUhGSGRIdVhCT2g1eThvRUYxeDFnQUxleTIzMVV0TFFqVENXLXZueEVFeUI3YUE2bk1kNEpZY2hYcTg5THBjUFlUbzRsSzFVN1R2TFVxODF0elVFaE5GUTBLLTNKRHJPVTl6Z2FBT1NzT2dlMTZjVk9feUhvbDJXaDRKSC1SWkJPOVY0b3hiVGV1blRIRlMyaXBzUVRpS2dVeTR5TjktZw?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413103,0.4,0.0,0.4,0.0,0.0,0.22000000000000003,0.32886441959287316,0.4447669656117757,0.32886441959287316,0.0,0.6711355804071268,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.686593258778618
2022-11-17,2022-11-17 08:00:00,FDA approves second interchangeable insulin glargine biosimilar for patients with diabetes - Healio,"<a href=""https://news.google.com/rss/articles/CBMiwwFBVV95cUxOTEc1aEdUZmZ0Z2VDUDc1c1R1bGROYXhyZE9YQmcyRjJ2bTdSYlExVUx3cFBUcEpKZTkxYzZtYkJtUGdyTFlDTHAzSFBONHZaOWh3YkJDb0tsU09fYnNzTXUyc3JmS2g2V2dHdnh6ZFNlcmF6RUYzU1VKQ0I4Ri1yNGdOekxLMnFSckpXYXprWHpFUVl5ejQyeC1WWWJTZXRBc0FFdUVDN1VJT2RrLTZPeHZEWlloVzBKbWNDTEpjenNFNGc?oc=5"" target=""_blank"">FDA approves second interchangeable insulin glargine biosimilar for patients with diabetes</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Healio</font>",https://news.google.com/rss/articles/CBMiwwFBVV95cUxOTEc1aEdUZmZ0Z2VDUDc1c1R1bGROYXhyZE9YQmcyRjJ2bTdSYlExVUx3cFBUcEpKZTkxYzZtYkJtUGdyTFlDTHAzSFBONHZaOWh3YkJDb0tsU09fYnNzTXUyc3JmS2g2V2dHdnh6ZFNlcmF6RUYzU1VKQ0I4Ri1yNGdOekxLMnFSckpXYXprWHpFUVl5ejQyeC1WWWJTZXRBc0FFdUVDN1VJT2RrLTZPeHZEWlloVzBKbWNDTEpjenNFNGc?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413153,0.4,0.0,0.4,0.0,0.0,0.22000000000000003,0.323091117168382,0.4490003664334615,0.323091117168382,0.0,0.676908882831618,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.669273351505145
2021-08-03,2021-08-03 07:00:00,"Semglee, a Biosimilar Insulin to Glargine, Receives FDA Approval - Diabetes In Control","<a href=""https://news.google.com/rss/articles/CBMingFBVV95cUxQTmlfcWFyQTh5WEJpWEJueHFGeEdNN1YtV0hTTldVN3VRcGZvY24tems3TjRvNHFBakZTNFduWWtGUTc3eER6SklScFV0dmpoZTB5U0JXZlR6aEFBN0Zmbi04dkYzSlZkcEpoWE90WkNtNzNNVXNTTFdsM3ZXU0JVMmtxSFNXYmc3VnIwbVV5Z1lyVFVrX3pnRnEwbEdHdw?oc=5"" target=""_blank"">Semglee, a Biosimilar Insulin to Glargine, Receives FDA Approval</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Diabetes In Control</font>",https://news.google.com/rss/articles/CBMingFBVV95cUxQTmlfcWFyQTh5WEJpWEJueHFGeEdNN1YtV0hTTldVN3VRcGZvY24tems3TjRvNHFBakZTNFduWWtGUTc3eER6SklScFV0dmpoZTB5U0JXZlR6aEFBN0Zmbi04dkYzSlZkcEpoWE90WkNtNzNNVXNTTFdsM3ZXU0JVMmtxSFNXYmc3VnIwbVV5Z1lyVFVrX3pnRnEwbEdHdw?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413026,0.2,0.0,0.6,0.0,0.0,0.21000000000000002,0.3428736819117232,0.5253363347371419,0.3428736819117232,0.0,0.6571263180882768,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.62862104573517
2021-07-30,2021-07-30 07:00:00,USFDA okays Biocon insulin Semglee as first interchangeable biosimilar drug - Business Standard,"<a href=""https://news.google.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?oc=5"" target=""_blank"">USFDA okays Biocon insulin Semglee as first interchangeable biosimilar drug</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Semglee interchangeable insulin,drug_fda,2025-06-27T05:41:09.803129,0.2,0.25,0.4,0.0,0.0,0.21000000000000002,0.3184071880676982,0.5761720951716105,0.3184071880676982,0.0,0.6815928119323018,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.555221564203094
2024-05-21,2024-05-21 07:00:00,Biocon Biologics announces getting US FDA approval for eye treatment drug - Business Standard,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics announces getting US FDA approval for eye treatment drug</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.635711,0.0,0.5,0.4,0.0,0.0,0.2,0.33831297057368337,0.53241826060613,0.33831297057368337,0.0,0.6616870294263166,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.51493891172105
2021-07-29,2021-07-29 07:00:00,Diabetes cure: USFDA approves Biocon's long-acting insulin Semglee as first interchangeable biosimilar... - Moneycontrol,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Diabetes cure: USFDA approves Biocon's long-acting insulin Semglee as first interchangeable biosimilar...</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Moneycontrol</font>",https://news.google.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?oc=5,Google News,Semglee biosimilar approval,drug_fda,2025-06-27T05:41:08.122213,0.2,0.25,0.4,0.0,0.0,0.21000000000000002,0.28535621094211144,0.5121895363398961,0.28535621094211144,0.0,0.7146437890578885,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.456068632826334
2024-05-21,2024-05-21 07:00:00,"Biocon, Samsung win FDA nods for interchangeable Eylea biosimilars - BioWorld MedTech","<a href=""https://news.google.com/rss/articles/CBMiqgFBVV95cUxQa0otRWlDRzdwanUzQkw1a0E3VUExMmJra2RHZGUxUEoybzdWZWRmNkZMNzJueFE5M1VIN3FDSkV0NlJZNDJ1RExEQkhCUE82WE1GN2JKYl9ZYU1tWmdCTWpvY3lLOGRoUXZ4eGNPQlBnMUxBZlhqZDBhZURtNEFJYmhSaVFndnlaTWE3VkNxb0lFTVVkZnRZWUo4S3RfWlBnUVVNaWFXa19GQQ?oc=5"" target=""_blank"">Biocon, Samsung win FDA nods for interchangeable Eylea biosimilars</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BioWorld MedTech</font>",https://news.google.com/rss/articles/CBMiqgFBVV95cUxQa0otRWlDRzdwanUzQkw1a0E3VUExMmJra2RHZGUxUEoybzdWZWRmNkZMNzJueFE5M1VIN3FDSkV0NlJZNDJ1RExEQkhCUE82WE1GN2JKYl9ZYU1tWmdCTWpvY3lLOGRoUXZ4eGNPQlBnMUxBZlhqZDBhZURtNEFJYmhSaVFndnlaTWE3VkNxb0lFTVVkZnRZWUo4S3RfWlBnUVVNaWFXa19GQQ?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.635927,0.0,0.25,0.4,0.0,0.0,0.15,0.43506496378846027,0.7362507322099474,0.43506496378846027,0.0,0.5649350362115397,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.305194891365382
2020-01-07,2020-01-07 08:00:00,"Novo Nordisk Launches Authorized Generic Insulins, Gets FDA Approval for Fast-Acting Insulin in Pediatric Population - Center for Biosimilars","<a href=""https://news.google.com/rss/articles/CBMi7AFBVV95cUxPUi1kd21KYzV2bzg4elZhSzhXZWd4SjJZajE2WUFqdmo0dDF0cUxkajhZZTFIdFBsUWZ3QVJtQzdPTGhCSG1jNXFHTVpSejd3bWU5SmZ1VXpMbTNOY1Jfd1Jlb29VOEYyMDBaMUJjQnNqLVdMcmtITkswWnVHQ1hldFFBbWU2RzJQS0Y0X0x3R0t6RTFPWHBmaUFueXVibkg2Ry1xNUhiRUVLNVVTeklTUkY4QmVvZ2tZVzVFQXJjeDhRWWJMWWZRcTVrQUMtMWMzWjhDaHl0S3J3c3ExYkFmUFotd2tGQW0yTl9FOQ?oc=5"" target=""_blank"">Novo Nordisk Launches Authorized Generic Insulins, Gets FDA Approval for Fast-Acting Insulin in Pediatric Population</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMi7AFBVV95cUxPUi1kd21KYzV2bzg4elZhSzhXZWd4SjJZajE2WUFqdmo0dDF0cUxkajhZZTFIdFBsUWZ3QVJtQzdPTGhCSG1jNXFHTVpSejd3bWU5SmZ1VXpMbTNOY1Jfd1Jlb29VOEYyMDBaMUJjQnNqLVdMcmtITkswWnVHQ1hldFFBbWU2RzJQS0Y0X0x3R0t6RTFPWHBmaUFueXVibkg2Ry1xNUhiRUVLNVVTeklTUkY4QmVvZ2tZVzVFQXJjeDhRWWJMWWZRcTVrQUMtMWMzWjhDaHl0S3J3c3ExYkFmUFotd2tGQW0yTl9FOQ?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.587525,0.0,0.0,0.6,0.0,0.0,0.15,0.42017468564625565,0.42908013867978695,0.42017468564625565,0.0,0.5798253143537444,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.260524056938767
2021-11-16,2021-11-16 08:00:00,Biocon Biologics launches interchangeable biosimilars SEMGLEE and Insulin Glargine injection in US - BioSpectrum India,"<a href=""https://news.google.com/rss/articles/CBMi5AFBVV95cUxOaVBUS1VZaXVJc1BJb21DTWstRS1WT0V6UWszcnN2OXFZeEpjdnBZbjNQY1VyTGxYSC1YSkFlQlptTFIyYldOQlZYYzhtT0VtYzc0WW5jS3VTcGVXUGx0YVRSYnFkZ2lDck03SFNCVFJJZ3puZkJlQUQ2QXF4RWE1UlhZYkg3Z1B0YjZpem5LMmVDNTV5VWNlUHVUZGlrNEx6cXRYNjBGdFZhYTNjcTUtYkVlRlA4bURodXFOdURqVHZ3Zm1jRFFaaDlNUjhDeG41M1Q1UmRDV3JhNmxCWXhFVWNsSDQ?oc=5"" target=""_blank"">Biocon Biologics launches interchangeable biosimilars SEMGLEE and Insulin Glargine injection in US</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BioSpectrum India</font>",https://news.google.com/rss/articles/CBMi5AFBVV95cUxOaVBUS1VZaXVJc1BJb21DTWstRS1WT0V6UWszcnN2OXFZeEpjdnBZbjNQY1VyTGxYSC1YSkFlQlptTFIyYldOQlZYYzhtT0VtYzc0WW5jS3VTcGVXUGx0YVRSYnFkZ2lDck03SFNCVFJJZ3puZkJlQUQ2QXF4RWE1UlhZYkg3Z1B0YjZpem5LMmVDNTV5VWNlUHVUZGlrNEx6cXRYNjBGdFZhYTNjcTUtYkVlRlA4bURodXFOdURqVHZ3Zm1jRFFaaDlNUjhDeG41M1Q1UmRDV3JhNmxCWXhFVWNsSDQ?oc=5,Google News,Semglee interchangeable insulin,drug_fda,2025-06-27T05:41:09.803173,0.4,0.5,0.2,0.0,0.0,0.27,0.0,0.30154949426651,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.2
2019-12-03,2019-12-03 08:00:00,Biocon gets FDA approval to produce pegfilgrastim in India - Fierce Pharma,"<a href=""https://news.google.com/rss/articles/CBMitAFBVV95cUxPVlFlbHpoSGZRU2RObzdFU1NSTnRYdzNIUkQwbU9sX09HSUZ6VVNzbkh0LVRCOFBXMGFvaFV2YVFKS091V3padVZOb0FiVDF5RGtqR1ZRUTJwdndqazFTQ1JqZC1jRHFUd2dZa21jbzE5UFFLRlBWNUx6UkxSN3dhUEdNdDBGWVNpbTV4WVhRajFTNUhvR1FjMV9qMk5JbEpidkZYRnI2Z1pWVjZOS2U4QW9JXzg?oc=5"" target=""_blank"">Biocon gets FDA approval to produce pegfilgrastim in India</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMitAFBVV95cUxPVlFlbHpoSGZRU2RObzdFU1NSTnRYdzNIUkQwbU9sX09HSUZ6VVNzbkh0LVRCOFBXMGFvaFV2YVFKS091V3padVZOb0FiVDF5RGtqR1ZRUTJwdndqazFTQ1JqZC1jRHFUd2dZa21jbzE5UFFLRlBWNUx6UkxSN3dhUEdNdDBGWVNpbTV4WVhRajFTNUhvR1FjMV9qMk5JbEpidkZYRnI2Z1pWVjZOS2U4QW9JXzg?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.422033,0.0,0.25,0.4,0.0,0.0,0.15,0.35383772201082503,0.5090582267761231,0.35383772201082503,0.0,0.6461622779891749,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.061513166032475
2022-11-18,2022-11-18 08:00:00,FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar - BioPharma Dive,"<a href=""https://news.google.com/rss/articles/CBMimwFBVV95cUxQdDlLRjh5NkZkdF9pZl9PODg2cDA1NXZoWGxRUjNlNEdkV0toQnFrS2h5MllSeWk0cjZHTjk1T2VFeU1JWTdNV3lhMzNpOXl6TXZ6dVRMcnRSRzVJSEdibjluTF9QamVlQlZBcDdzcVFBZTlpUVRQM3VIWG9WS19sdzNJOUNBLTFqYkxuYXZJMXMwQ1FSb0E2RjRrTQ?oc=5"" target=""_blank"">FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BioPharma Dive</font>",https://news.google.com/rss/articles/CBMimwFBVV95cUxQdDlLRjh5NkZkdF9pZl9PODg2cDA1NXZoWGxRUjNlNEdkV0toQnFrS2h5MllSeWk0cjZHTjk1T2VFeU1JWTdNV3lhMzNpOXl6TXZ6dVRMcnRSRzVJSEdibjluTF9QamVlQlZBcDdzcVFBZTlpUVRQM3VIWG9WS19sdzNJOUNBLTFqYkxuYXZJMXMwQ1FSb0E2RjRrTQ?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413287,0.2,0.0,0.4,0.0,0.0,0.16,0.32010471022444853,0.45318930139541624,0.32010471022444853,0.0,0.6798952897755515,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,15.060314130673346
2021-07-29,2021-07-29 07:00:00,"FDA Approves Semglee, Its First Interchangeable Biosimilar Insulin Product - HCPLive","<a href=""https://news.google.com/rss/articles/CBMinwFBVV95cUxQWXl3bFgzTDRpczZtTUxhMEhaOTVmTUgxU2pVOUtUVEpiUVB1US1nLWpvYzBVX0ptSmxkeXlISnQxdTR6RXQ5anFRZGtuMFQ3bk8xeFFaaUFHYzFaY0dNei1tX2lpYUNacFZMZ0xYbi1ZZGtDT2xZN3FnaDVSSkxvSGpQQm8xeXUwNjgxMUNFRjk4eGNlZ2IxeUJNQktVTmc?oc=5"" target=""_blank"">FDA Approves Semglee, Its First Interchangeable Biosimilar Insulin Product</a>&nbsp;&nbsp;<font color=""#6f6f6f"">HCPLive</font>",https://news.google.com/rss/articles/CBMinwFBVV95cUxQWXl3bFgzTDRpczZtTUxhMEhaOTVmTUgxU2pVOUtUVEpiUVB1US1nLWpvYzBVX0ptSmxkeXlISnQxdTR6RXQ5anFRZGtuMFQ3bk8xeFFaaUFHYzFaY0dNei1tX2lpYUNacFZMZ0xYbi1ZZGtDT2xZN3FnaDVSSkxvSGpQQm8xeXUwNjgxMUNFRjk4eGNlZ2IxeUJNQktVTmc?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.412898,0.2,0.0,0.4,0.0,0.0,0.16,0.2838781561808581,0.5436391842736138,0.2838781561808581,0.0,0.7161218438191419,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.951634468542574
2021-07-29,2021-07-29 07:00:00,An FDA First: Semglee Is Approved As An Interchangeable Biosimilar - Managed Healthcare Executive,"<a href=""https://news.google.com/rss/articles/CBMiswFBVV95cUxPeHJNYWVrWmkwZ1NQaHJ6RXdMcEt5NldsTDlyWVY2S293cmdwNXR2S2MybEtHM0pXQ2xQYzNocjFLcjJna2U5eXVaandtVXJ4Mnh3UmtlUjRSOGpzdUpYeV9fR0c0Q1RONG5CQ0U4NzhhdjRVcXZNd3U4WTZwanhtWWo1MWJCNV9kNUFFYmJtQ1BHRks5azRyR1VVV3V5V2tZZTZYNl9fZ0d2Zldpbm5ySGV0UQ?oc=5"" target=""_blank"">An FDA First: Semglee Is Approved As An Interchangeable Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Managed Healthcare Executive</font>",https://news.google.com/rss/articles/CBMiswFBVV95cUxPeHJNYWVrWmkwZ1NQaHJ6RXdMcEt5NldsTDlyWVY2S293cmdwNXR2S2MybEtHM0pXQ2xQYzNocjFLcjJna2U5eXVaandtVXJ4Mnh3UmtlUjRSOGpzdUpYeV9fR0c0Q1RONG5CQ0U4NzhhdjRVcXZNd3U4WTZwanhtWWo1MWJCNV9kNUFFYmJtQ1BHRks5azRyR1VVV3V5V2tZZTZYNl9fZ0d2Zldpbm5ySGV0UQ?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.412925,0.2,0.0,0.4,0.0,0.0,0.16,0.28191908813670474,0.5808598263952467,0.28191908813670474,0.0,0.7180809118632953,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.945757264410114
2021-07-29,2021-07-29 07:00:00,FDA OKs First Interchangeable Insulin Biosimilar - MedPage Today,"<a href=""https://news.google.com/rss/articles/CBMiZkFVX3lxTE9tRWtfUjlNb0lkSUxrZHlZZjZQRV9QMWlxUnhlcmlUSXFheE9YVGdTZFd5cERReExSbXVabnhxQlZQUmtPNUxJTDd0WmY4RFNOMlV6a0U2a2pOTndSQXUwYTNodjktZw?oc=5"" target=""_blank"">FDA OKs First Interchangeable Insulin Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">MedPage Today</font>",https://news.google.com/rss/articles/CBMiZkFVX3lxTE9tRWtfUjlNb0lkSUxrZHlZZjZQRV9QMWlxUnhlcmlUSXFheE9YVGdTZFd5cERReExSbXVabnhxQlZQUmtPNUxJTDd0WmY4RFNOMlV6a0U2a2pOTndSQXUwYTNodjktZw?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.412977,0.4,0.0,0.4,0.0,0.0,0.22000000000000003,0.025389639306991053,0.3646865222189162,0.025389639306991053,0.0,0.974610360693009,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.776168917920973
2019-11-25,2019-11-25 08:00:00,"FDA Releases Draft Guidance on Insulin Biosimilars, Interchangeable Insulins - Center for Biosimilars","<a href=""https://news.google.com/rss/articles/CBMiuAFBVV95cUxPTVhMVlR1czBWSzFaU09TVFZWTnZGVThkR1NDUER6eWoxYXVUVEl3THVUUTBzZVJNUnNnQ3V4M3NnOG80UHhoQ2RlS0xKVHlhMEI5MUVmOU0wdk9xamVPVm9fb0hhZ0xicVV0YUdKWmg1MDEtVE9JUDEzb2JmSm9QcG4xU1N4azV2MGl0allaX21hWXE5LTBlclZEQTBjTWlWZkUzcUZGMURCanBlM0owZE9TUHJRMVNy?oc=5"" target=""_blank"">FDA Releases Draft Guidance on Insulin Biosimilars, Interchangeable Insulins</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMiuAFBVV95cUxPTVhMVlR1czBWSzFaU09TVFZWTnZGVThkR1NDUER6eWoxYXVUVEl3THVUUTBzZVJNUnNnQ3V4M3NnOG80UHhoQ2RlS0xKVHlhMEI5MUVmOU0wdk9xamVPVm9fb0hhZ0xicVV0YUdKWmg1MDEtVE9JUDEzb2JmSm9QcG4xU1N4azV2MGl0allaX21hWXE5LTBlclZEQTBjTWlWZkUzcUZGMURCanBlM0owZE9TUHJRMVNy?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.587022,0.4,0.0,0.4,0.0,0.0,0.22000000000000003,-0.004440103888783311,0.33365919325086807,0.0,0.004440103888783311,0.9955598961112166,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.71332031166635
2021-08-06,2021-08-06 07:00:00,Biosimilar and Interchangeable Semglee Insulin Could Save U.S. Healthcare Hundreds of Millions - Managed Healthcare Executive,"<a href=""https://news.google.com/rss/articles/CBMi2AFBVV95cUxNd2xqMW5ndHp6VVV2cDdFaTV2QzFWbk9TTU9oSmwzU3puc3k0Vm5sLVhfQUVSSzdTLUxobmtmbS1CN0drTGhISGF1cFhYZGJ2N0t6ZjVsOU00M05MQk1aWFVjOXNsWXo1NWpmM0VoYlJyS19rVDd2eHhHSU9seGNERFhrS3ZMWm5JRXdQb1NXcWIzTlBydEJGNF9mSGpyaDVNcnlTU1EwcmNHVG5JcDJBamlIQVY1Z0tKMzBGZEpWUFd6enZ2VUR1ZTVsaGZQZ2IyR0hwdWlYWEk?oc=5"" target=""_blank"">Biosimilar and Interchangeable Semglee Insulin Could Save U.S. Healthcare Hundreds of Millions</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Managed Healthcare Executive</font>",https://news.google.com/rss/articles/CBMi2AFBVV95cUxNd2xqMW5ndHp6VVV2cDdFaTV2QzFWbk9TTU9oSmwzU3puc3k0Vm5sLVhfQUVSSzdTLUxobmtmbS1CN0drTGhISGF1cFhYZGJ2N0t6ZjVsOU00M05MQk1aWFVjOXNsWXo1NWpmM0VoYlJyS19rVDd2eHhHSU9seGNERFhrS3ZMWm5JRXdQb1NXcWIzTlBydEJGNF9mSGpyaDVNcnlTU1EwcmNHVG5JcDJBamlIQVY1Z0tKMzBGZEpWUFd6enZ2VUR1ZTVsaGZQZ2IyR0hwdWlYWEk?oc=5,Google News,Semglee interchangeable insulin,drug_fda,2025-06-27T05:41:09.801786,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.3415870933183843,0.5497869318644205,0.3415870933183843,0.0,0.6584129066816157,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.624761279955152
2021-08-04,2021-08-04 07:00:00,"FDA Approvals Roundup: Semglee, Saphnelo, Uptravi - Regulatory Affairs Professionals Society | RAPS","<a href=""https://news.google.com/rss/articles/CBMiqgFBVV95cUxQb3JBVkpMS3Q4TlIydHdYNGpPa29CelpOejFSVXFwQ0hobzdNOGdYTlc4c2ZPbXpFTDZxYU1lbGl6SzBvOTZZUFRTMnRzbHJxbDB4S0xVYWdrOGhSdE9oTGFpYUlOSFo4bkdrUjdSem0wVVBkUVNadUNLX3dGTU53bi1QQWtvS1M2LU5GU2tHbE9odG1XZ3cxNWU5cW55cUtVVnpNTUZJOEJzZw?oc=5"" target=""_blank"">FDA Approvals Roundup: Semglee, Saphnelo, Uptravi</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Regulatory Affairs Professionals Society | RAPS</font>",https://news.google.com/rss/articles/CBMiqgFBVV95cUxQb3JBVkpMS3Q4TlIydHdYNGpPa29CelpOejFSVXFwQ0hobzdNOGdYTlc4c2ZPbXpFTDZxYU1lbGl6SzBvOTZZUFRTMnRzbHJxbDB4S0xVYWdrOGhSdE9oTGFpYUlOSFo4bkdrUjdSem0wVVBkUVNadUNLX3dGTU53bi1QQWtvS1M2LU5GU2tHbE9odG1XZ3cxNWU5cW55cUtVVnpNTUZJOEJzZw?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413368,0.2,0.0,0.6,0.0,0.0,0.21000000000000002,0.0,0.31471367677052814,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.6
2022-11-18,2022-11-18 08:00:00,FDA Approves Second Interchangeable Lantus Biosimilar - Managed Healthcare Executive,"<a href=""https://news.google.com/rss/articles/CBMiowFBVV95cUxQc2Q0OWlxR2hTVVNzcUNWNGx1S01OWThjNzRmUnQybDdaeldnTXp3QzhtaFYyWi1FQkNmRmd6ejRLOTFuaWdVdUN0WjJJQWpuUTJNd1YzdjJVRVpRcGdkX3RNU1FQc0UzU1VMRE12YXRTbFlxRDRNNnB6cjlnWHE1Y2VvT1k2MVBudWFKUHpFc1FYdU13TDEwS2Y1UXpMY1ZkTHpj?oc=5"" target=""_blank"">FDA Approves Second Interchangeable Lantus Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Managed Healthcare Executive</font>",https://news.google.com/rss/articles/CBMiowFBVV95cUxQc2Q0OWlxR2hTVVNzcUNWNGx1S01OWThjNzRmUnQybDdaeldnTXp3QzhtaFYyWi1FQkNmRmd6ejRLOTFuaWdVdUN0WjJJQWpuUTJNd1YzdjJVRVpRcGdkX3RNU1FQc0UzU1VMRE12YXRTbFlxRDRNNnB6cjlnWHE1Y2VvT1k2MVBudWFKUHpFc1FYdU13TDEwS2Y1UXpMY1ZkTHpj?oc=5,Google News,insulin glargine-yfgn FDA,drug_fda,2025-06-27T05:41:11.427342,0.0,0.0,0.4,0.0,0.2,0.12,0.28752894514816685,0.5045336563428243,0.28752894514816685,0.0,0.7124710548518332,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.562586835444499
2021-11-16,2021-11-16 08:00:00,Viatris launched 2 versions of its interchangeable insulin biosimilar. Why? - Fierce Pharma,"<a href=""https://news.google.com/rss/articles/CBMixAFBVV95cUxOdFpTLV9rQ25MZF9wZEJla0dmOFlnbFhRV2RSZU91ZzNwTUt4U2RjRi1jRm5saEgtYUgycjJnT0hib3kxQmRuYmdtTWIzVDVfUmkwQkg1Y21XTDFJalAxUGpUc01ETV9JLVBEaWowenp3X0tfY1RBNVd3eUVKUFl1RXZvLTFsTnZkR2NIYVFiMTJiOGpGWXRxSWFNTUVpRW1GZ3pEb1NXN1BjcGNQT2labUJEV0JQcXBSTjdKcEtnU1hQcmNP?oc=5"" target=""_blank"">Viatris launched 2 versions of its interchangeable insulin biosimilar. Why?</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMixAFBVV95cUxOdFpTLV9rQ25MZF9wZEJla0dmOFlnbFhRV2RSZU91ZzNwTUt4U2RjRi1jRm5saEgtYUgycjJnT0hib3kxQmRuYmdtTWIzVDVfUmkwQkg1Y21XTDFJalAxUGpUc01ETV9JLVBEaWowenp3X0tfY1RBNVd3eUVKUFl1RXZvLTFsTnZkR2NIYVFiMTJiOGpGWXRxSWFNTUVpRW1GZ3pEb1NXN1BjcGNQT2labUJEV0JQcXBSTjdKcEtnU1hQcmNP?oc=5,Google News,Semglee interchangeable insulin,drug_fda,2025-06-27T05:41:09.801583,0.4,0.0,0.2,0.0,0.0,0.17,0.1050146673652106,0.43336882813771566,0.1050146673652106,0.0,0.8949853326347894,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.515044002095632
2021-07-29,2021-07-29 07:00:00,Semglee Approved as First Interchangeable Biosimilar Insulin Product - Medical Professionals Reference,"<a href=""https://news.google.com/rss/articles/CBMitAFBVV95cUxQWGpTY29Mam1qV1dSWFZPQUlpQ3NQM24tRTZuYjAzQVRWZFNFMnRvNjRxSDlfdmNIVjRtMm85VWpBLXppRkVFT1ZNN0YxMm1UUFZ5UlVHV2NuYmdlcnkyRlJQeDAwSnVkSVlEODJjelFqZXRoZFpvR25jeHA3bV9GNVdwemRaUWpnNXJxd1p3OW9wLTdwclJFdU1XVWpEZC1oUGRDRFNZd2pOV1hhNUF1T3lqTkw?oc=5"" target=""_blank"">Semglee Approved as First Interchangeable Biosimilar Insulin Product</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Medical Professionals Reference</font>",https://news.google.com/rss/articles/CBMitAFBVV95cUxQWGpTY29Mam1qV1dSWFZPQUlpQ3NQM24tRTZuYjAzQVRWZFNFMnRvNjRxSDlfdmNIVjRtMm85VWpBLXppRkVFT1ZNN0YxMm1UUFZ5UlVHV2NuYmdlcnkyRlJQeDAwSnVkSVlEODJjelFqZXRoZFpvR25jeHA3bV9GNVdwemRaUWpnNXJxd1p3OW9wLTdwclJFdU1XVWpEZC1oUGRDRFNZd2pOV1hhNUF1T3lqTkw?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413317,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.27727202707734955,0.5692227533022562,0.27727202707734955,0.0,0.7227279729226505,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.431816081232048
2024-05-29,2024-05-29 07:00:00,Latest FDA biosimilar approvals ushering in more treatment options - Ophthalmology Times,"<a href=""https://news.google.com/rss/articles/CBMiqgFBVV95cUxNSUJVQmxadnRPT21zTHJVTEx6V1VyVlRvRDl1SklfYTlUT0Qxak5OQ0UyVjR4MV84OFpRY1RuTGVOcTNpR1AxNUUtckJ5NG5fQkg1SEFrRmM3b0pQYmlaRUZBcHpJNldPVWZpSjVPNF9BU1lxdzlaRkNwQXlhcTlYeGxGUm9wN21teFNlZVB1dHlJblN3TnQwMWFFd3h3cWhtaDIxekN5VlFLQQ?oc=5"" target=""_blank"">Latest FDA biosimilar approvals ushering in more treatment options</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Ophthalmology Times</font>",https://news.google.com/rss/articles/CBMiqgFBVV95cUxNSUJVQmxadnRPT21zTHJVTEx6V1VyVlRvRDl1SklfYTlUT0Qxak5OQ0UyVjR4MV84OFpRY1RuTGVOcTNpR1AxNUUtckJ5NG5fQkg1SEFrRmM3b0pQYmlaRUZBcHpJNldPVWZpSjVPNF9BU1lxdzlaRkNwQXlhcTlYeGxGUm9wN21teFNlZVB1dHlJblN3TnQwMWFFd3h3cWhtaDIxekN5VlFLQQ?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.380995,0.0,0.0,0.6,0.0,0.0,0.15,0.12172943579591836,0.43813012838363646,0.12172943579591836,0.0,0.8782705642040817,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.365188307387754
2021-10-20,2021-10-20 07:00:00,Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMi7AFBVV95cUxQRjVSVzYyZWpQYi04ZWc1SWFLRUQ3amw4dTdqMUZQYU5pMTJJcEE5U291MVVlUEFNZkdyeFQxejRDLTdKQ1Ezc3BvVnBMcHR6T3YycXBGMDhQLWhjZ29GNHFmZmpFSm8wbzdhQnpfQWd1Sk55Sm5GZzFNMTVLQW1aNE1BOUdSRzZ6cDFiOGJwdVgwRGlqcjhOQXk2UnNzd0d0ZkQwMHBEdFRBcGM0UzY1bXpBMXNvMVVuajJaUlB0M3NVYkZkX1dFdmw0dlZhV05IRTRpaG0xVUY3WG03NVE5SURGQm9SZ3hGLVFGeQ?oc=5"" target=""_blank"">Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi7AFBVV95cUxQRjVSVzYyZWpQYi04ZWc1SWFLRUQ3amw4dTdqMUZQYU5pMTJJcEE5U291MVVlUEFNZkdyeFQxejRDLTdKQ1Ezc3BvVnBMcHR6T3YycXBGMDhQLWhjZ29GNHFmZmpFSm8wbzdhQnpfQWd1Sk55Sm5GZzFNMTVLQW1aNE1BOUdSRzZ6cDFiOGJwdVgwRGlqcjhOQXk2UnNzd0d0ZkQwMHBEdFRBcGM0UzY1bXpBMXNvMVVuajJaUlB0M3NVYkZkX1dFdmw0dlZhV05IRTRpaG0xVUY3WG03NVE5SURGQm9SZ3hGLVFGeQ?oc=5,Google News,Semglee interchangeable insulin,drug_fda,2025-06-27T05:41:09.802633,0.4,0.0,0.2,0.0,0.0,0.17,0.025264388717635772,0.3664944900406732,0.025264388717635772,0.0,0.9747356112823642,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,1.6,0.0,fda_approval,2.5,14.275793166152907
2021-10-21,2021-10-21 07:00:00,Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in US - The Economic Times,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in US</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Economic Times</font>",https://news.google.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?oc=5,Google News,Semglee formulary coverage,competitive,2025-06-27T05:41:33.339548,0.2,0.25,0.2,0.0,0.0,0.16,0.01690306223524849,0.35058297978507147,0.01690306223524849,0.0,0.9830969377647515,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,1.6,0.0,fda_approval,2.5,14.150709186705745
2021-07-23,2021-07-23 07:00:00,Biocon Updates on Semglee Interchangeable Status - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMilAFBVV95cUxQdHU1b0ZXWl8xcFJyRHlqYXFncGE5RlJEcE9mOTd2NEJXZEItREJrblFhaWZuZl84eU5QUGlIYmYyM3FKenpMZ3B1enlLRWVsbWdIOEQ4NVZYWVFhSXhxNGdEa1RSSWtjQ1BCV1VkUlprLTd1UEgzWi1Va1dwZHcwWk41cjE2amlHSjc4UmEwWktLU2E5?oc=5"" target=""_blank"">Biocon Updates on Semglee Interchangeable Status</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMilAFBVV95cUxQdHU1b0ZXWl8xcFJyRHlqYXFncGE5RlJEcE9mOTd2NEJXZEItREJrblFhaWZuZl84eU5QUGlIYmYyM3FKenpMZ3B1enlLRWVsbWdIOEQ4NVZYWVFhSXhxNGdEa1RSSWtjQ1BCV1VkUlprLTd1UEgzWi1Va1dwZHcwWk41cjE2amlHSjc4UmEwWktLU2E5?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413343,0.2,0.25,0.2,0.0,0.0,0.16,-0.004407439435532521,0.3361320111486647,0.0,0.004407439435532521,0.9955925605644674,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.5,0.0,0.0,0.0,fda_approval,2.5,14.113222318306597
2022-07-06,2022-07-06 07:00:00,Viatris starts yet another insulin biosimilar recall over potential missing labels - Fierce Pharma,"<a href=""https://news.google.com/rss/articles/CBMiugFBVV95cUxOM3gxV3NwMUNuWFhnSmZlUXFvZHdib1d0MklwczV1UWdCSkdrRXZYOVpMdi1NblhuVVNoMFNOSzdrS1l6alFzc1JxN3J4d0FXN3BrNlJsaFJ5dE82aldzMURNWk54emhOaUFjODUyVkVhcGxEWHlQTEJHWWdUMnYySlVXc1NxaElOZ0YtMXlJZ0doVlhWOVhyMWlwbHBucklwTGIzdmtzYm5RbTE4UWVmQndZdWVmMndsalE?oc=5"" target=""_blank"">Viatris starts yet another insulin biosimilar recall over potential missing labels</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMiugFBVV95cUxOM3gxV3NwMUNuWFhnSmZlUXFvZHdib1d0MklwczV1UWdCSkdrRXZYOVpMdi1NblhuVVNoMFNOSzdrS1l6alFzc1JxN3J4d0FXN3BrNlJsaFJ5dE82aldzMURNWk54emhOaUFjODUyVkVhcGxEWHlQTEJHWWdUMnYySlVXc1NxaElOZ0YtMXlJZ0doVlhWOVhyMWlwbHBucklwTGIzdmtzYm5RbTE4UWVmQndZdWVmMndsalE?oc=5,Google News,Semglee interchangeable insulin,drug_fda,2025-06-27T05:41:09.802813,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,-0.19346016544457478,0.48901176347732545,0.0,0.19346016544457478,0.8065398345554252,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.2,regulatory_issues,2.2,12.680380496333724
2025-05-08,2025-05-08 07:00:00,"Biocon Q4 net profit surges 153%, biosimilars, generics drive growth - Moneycontrol","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Q4 net profit surges 153%, biosimilars, generics drive growth</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Moneycontrol</font>",https://news.google.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?oc=5,Google News,Biocon quarterly earnings,financial,2025-06-27T05:41:35.043295,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.44096566562575884,0.5787487626075745,0.44096566562575884,0.0,0.5590343343742412,0,1,0,153.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,10.572896996877276
2023-09-20,2023-09-20 07:00:00,"For Biocon Biologics' CEO, the Humira biosimilar clash isn't only about market share - Fierce Pharma","<a href=""https://news.google.com/rss/articles/CBMiqAFBVV95cUxNLV9vb1c1Qlp6YTZ6NjhrZVlyeW5lNWV6LV9DczRPYU9CSml0V2RNNWFLTzlGUVpiLVotRktvUnV4Z1dPZ0c2ZnRjU1JteHRoUkZpNUNwOTI0RWFyWVIwaC1QNVlnWkxKNVRGb3QxUDJLUlhrZTdDWE1tY1NFY2NEMXFvbmZma3I3YWxLY3Z1RzU5bzBScVV1M0pZbjVaSk5NdGdHWkV0Qlk?oc=5"" target=""_blank"">For Biocon Biologics' CEO, the Humira biosimilar clash isn't only about market share</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMiqAFBVV95cUxNLV9vb1c1Qlp6YTZ6NjhrZVlyeW5lNWV6LV9DczRPYU9CSml0V2RNNWFLTzlGUVpiLVotRktvUnV4Z1dPZ0c2ZnRjU1JteHRoUkZpNUNwOTI0RWFyWVIwaC1QNVlnWkxKNVRGb3QxUDJLUlhrZTdDWE1tY1NFY2NEMXFvbmZma3I3YWxLY3Z1RzU5bzBScVV1M0pZbjVaSk5NdGdHWkV0Qlk?oc=5,Google News,Biocon insulin market share,competitive,2025-06-27T05:41:26.941778,0.0,0.5,0.2,0.0,0.2,0.16999999999999998,0.18877176648700178,0.48985589876174923,0.18877176648700178,0.0,0.8112282335129982,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.6,0.0,market_penetration,1.6,10.266315299461004
2023-10-18,2023-10-18 07:00:00,Biocon shares fall most in three months as Malaysia unit may face approval delays post USFDA inspection - CNBC TV18,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon shares fall most in three months as Malaysia unit may face approval delays post USFDA inspection</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.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?oc=5,Google News,Biocon insulin market share,competitive,2025-06-27T05:41:26.942001,0.0,0.25,0.4,0.0,0.0,0.15,-0.03333156392383274,0.7195416516727872,0.0,0.03333156392383274,0.9666684360761673,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.7,0.0,0.0,0.0,0.0,fda_inspection,1.7,10.099994691771498
2025-05-13,2025-05-13 07:00:00,"Biocon sees mid-teens revenue growth on biosimilars, generics push - Mint","<a href=""https://news.google.com/rss/articles/CBMisgFBVV95cUxPZUgzNl80Mm1nM0xFb3hZVXJtTkNfUUNBV0YwMGdfZDB4N2tNYWo4V0RYeDhtMjJLaEc1QVRSUHRXLTBMaHdsMU50bTFwcFlQeWRwMG1pR1Y0Z2hyQ1djdDJMbW1KcGwtQ1NYVEdUdmJmVWNPeUpBRkNydm9wdHl3aEpnTFpIM2x2QVF4OG5hdGNpeXNtbUlDU3B3bGpEZzM2LU5sTmpaWVVDc1AxTmxkdS1B?oc=5"" target=""_blank"">Biocon sees mid-teens revenue growth on biosimilars, generics push</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Mint</font>",https://news.google.com/rss/articles/CBMisgFBVV95cUxPZUgzNl80Mm1nM0xFb3hZVXJtTkNfUUNBV0YwMGdfZDB4N2tNYWo4V0RYeDhtMjJLaEc1QVRSUHRXLTBMaHdsMU50bTFwcFlQeWRwMG1pR1Y0Z2hyQ1djdDJMbW1KcGwtQ1NYVEdUdmJmVWNPeUpBRkNydm9wdHl3aEpnTFpIM2x2QVF4OG5hdGNpeXNtbUlDU3B3bGpEZzM2LU5sTmpaWVVDc1AxTmxkdS1B?oc=5,Google News,Biocon biologics revenue,financial,2025-06-27T05:41:38.241845,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.26978889919243754,0.5011839642206828,0.26978889919243754,0.0,0.7302111008075625,1,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,10.059366697577312
2023-09-20,2023-09-20 07:00:00,"Biocon Biologics gains EU approval for Aflibercept biosimilar, YESAFILI - Business Standard","<a href=""https://news.google.com/rss/articles/CBMi1gFBVV95cUxPdjdmaEJsMEVqcTE1SE5yYWVxSi1aN1RyaDV4bFRfTzFJU3l2RkYtMXBVN2s4RWVVSWVHY2V1SF93NGYzUjc2ZnduNnFVV3A4SFJQT09mMGs3RmVDMnhrT1l1clJtaTZLSjVwbXFmQTNONFBTRzVUTWUxckdnNGVuNDdsSkQ0TG1CVVdZZHRQNS03M2hYekxETnpZTjM2UUdHbVpja0ExYy1KYXplaWJGaUJ5S2N4MjBTbGpjWGwxQU90UEU3VzZidnpNY19ZTTYyRXY5X0pR0gHbAUFVX3lxTE85V0ZQU1ZBVmV2X0tQOThXUzVDSUdyR3FnSnFIR3RYV2w2ZDhnT3V5T0VTWFpRT25yNTVmTHZKd011bElmbE5GWlpBclpDSUswYksxTC1yZXdwQ256bTFnRUhwcktldW5oYzc2X0xzSG9ZYms2ckVHZElaNzNKdEJkalk3VEdCRnpuc3VXVHVJM0hjY1p2R3ZoMEM3S2ZqM0dLM0xlUGRMY2RrZVhrN2ZpcUlyd1p4d25OdDlZczhJbzVJc25xd0dWSlFhNENPZ20xdGp5d19Qem9qUQ?oc=5"" target=""_blank"">Biocon Biologics gains EU approval for Aflibercept biosimilar, YESAFILI</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon biosimilar strategy,strategic,2025-06-27T05:42:11.119222,0.0,0.5,0.4,0.0,0.0,0.2,0.82536299768347,0.547958254814148,0.82536299768347,0.0,0.17463700231653,0,1,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,9.47608899305041
2023-07-04,2023-07-04 07:00:00,Biosimilar Humira likely to boost US revenues for Biocon Biologics - Business Standard,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biosimilar Humira likely to boost US revenues for Biocon Biologics</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon biologics revenue,financial,2025-06-27T05:41:38.242738,0.0,0.5,0.2,0.16666666666666666,0.0,0.175,0.8198042075951921,0.5309028902689615,0.8198042075951921,0.0,0.18019579240480788,1,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,9.209412622785576
2021-11-23,2021-11-23 08:00:00,OptumRx Excludes the Diabetes Biosimilar Semglee from Formulary - Managed Healthcare Executive,"<a href=""https://news.google.com/rss/articles/CBMisAFBVV95cUxPdktpX0xDWUJQTU9HWHZXa2hXbmp1Q3ZDVDZzdnZPM1owTUh4MGRqSWFMS3A2TjRxb2VkZUF4UmRMbExxNXUtd3J3RTVCUDhDQmEtejFlX3NaRlJWR1d0NU1LS1d0WGJaTHF2c0ZDZVZjc25Fc1p0NEF3c1Y0X3l1Zmw3Y3puU3ZTREhtb0ZVWFgzcDZUNzdURExOb3c0X1JiSVNnTzREdmIya1hCTkdnaQ?oc=5"" target=""_blank"">OptumRx Excludes the Diabetes Biosimilar Semglee from Formulary</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Managed Healthcare Executive</font>",https://news.google.com/rss/articles/CBMisAFBVV95cUxPdktpX0xDWUJQTU9HWHZXa2hXbmp1Q3ZDVDZzdnZPM1owTUh4MGRqSWFMS3A2TjRxb2VkZUF4UmRMbExxNXUtd3J3RTVCUDhDQmEtejFlX3NaRlJWR1d0NU1LS1d0WGJaTHF2c0ZDZVZjc25Fc1p0NEF3c1Y0X3l1Zmw3Y3puU3ZTREhtb0ZVWFgzcDZUNzdURExOb3c0X1JiSVNnTzREdmIya1hCTkdnaQ?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413542,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.0,0.29389967521031696,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.6,0.0,market_penetration,1.6,9.1
2021-07-23,2021-07-23 07:00:00,"Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr; - Biocon","<a href=""https://news.google.com/rss/articles/CBMiWEFVX3lxTE5kbmhFVFFBZEtlYmk4T2RRVlBTVTNEcW5hVVV3Zkk2YWhlbHJhT2lJOUhWeXRvWTdXQzBIZ1NJWnZyMGtOc3ZOU0RGcUdfcFpiall0SUc3cUQ?oc=5"" target=""_blank"">Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Biocon</font>",https://news.google.com/rss/articles/CBMiWEFVX3lxTE5kbmhFVFFBZEtlYmk4T2RRVlBTVTNEcW5hVVV3Zkk2YWhlbHJhT2lJOUhWeXRvWTdXQzBIZ1NJWnZyMGtOc3ZOU0RGcUdfcFpiall0SUc3cUQ?oc=5,Google News,Biocon revenue guidance,financial,2025-06-27T05:41:36.734668,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.9392366409301758,0.3130788803100586,0.9392366409301758,0.0,0.06076335906982422,1,0,0,6.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,9.067709922790527
2023-02-14,2023-02-14 08:00:00,"Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18% - Biocon","<a href=""https://news.google.com/rss/articles/CBMiWEFVX3lxTE9hMEZZcmFuWjJzNnFJRDdGNVdKLWk2c2JpVnoyY01MS1RRNlVOcHR2X0sxVWdpcDlMZHN4SVpGWThVbHU5clB4WVRjYjVaU0tQV3paYmQ5X1g?oc=5"" target=""_blank"">Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18%</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Biocon</font>",https://news.google.com/rss/articles/CBMiWEFVX3lxTE9hMEZZcmFuWjJzNnFJRDdGNVdKLWk2c2JpVnoyY01MS1RRNlVOcHR2X0sxVWdpcDlMZHN4SVpGWThVbHU5clB4WVRjYjVaU0tQV3paYmQ5X1g?oc=5,Google News,Biocon quarterly earnings,financial,2025-06-27T05:41:35.043948,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.922931969165802,0.307643989721934,0.922931969165802,0.0,0.077068030834198,1,0,0,36.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,9.018795907497406
2023-11-10,2023-11-10 08:00:00,"Biocon Q2FY24 Revenue at Rs 3,620 Cr, Up 52%; Biosimilars Up 97%; Research Services Up 18% EBITDA at Rs 900 Cr, Up 68%; Core EBITDA at Rs 1,100 Cr, Up 35% Net Profit at Rs 126 Cr, Up 168% - Biocon","<a href=""https://news.google.com/rss/articles/CBMiWEFVX3lxTE5hSUUxcjJfNHNDT3puS3dzSGJ0R1NSa0tIODdHZkZ6WkxxaHJKNmZnRDNrLU5tWFlFN3RHMFoyNkl3WVdsM2tKeTRiTHFnTHZORXQtOXNLc20?oc=5"" target=""_blank"">Biocon Q2FY24 Revenue at Rs 3,620 Cr, Up 52%; Biosimilars Up 97%; Research Services Up 18% EBITDA at Rs 900 Cr, Up 68%; Core EBITDA at Rs 1,100 Cr, Up 35% Net Profit at Rs 126 Cr, Up 168%</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Biocon</font>",https://news.google.com/rss/articles/CBMiWEFVX3lxTE5hSUUxcjJfNHNDT3puS3dzSGJ0R1NSa0tIODdHZkZ6WkxxaHJKNmZnRDNrLU5tWFlFN3RHMFoyNkl3WVdsM2tKeTRiTHFnTHZORXQtOXNLc20?oc=5,Google News,Biocon quarterly earnings,financial,2025-06-27T05:41:35.043878,0.0,0.25,0.2,0.3333333333333333,0.0,0.15,0.8391557281454605,0.5475485794703165,0.8391557281454605,0.0,0.16084427185453953,1,1,0,52.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,9.01746718443638
2023-08-10,2023-08-10 07:00:00,"Biocon Q1FY24 Revenue at Rs 3,516 Cr, Up 59%; Biosimilars Up 106%; Research Services Up 25% - Biocon","<a href=""https://news.google.com/rss/articles/CBMiWEFVX3lxTE1FZGNCM3N4NHhNa01VTkZDaGRLVTZqelBVSDNHeDBhMzdYZ3lDQ3hPUDZRVVhEYUlBMlFjNlJJdEwzazNSMnZtckdEdHhnQ3lPdXZSZ1hwVkg?oc=5"" target=""_blank"">Biocon Q1FY24 Revenue at Rs 3,516 Cr, Up 59%; Biosimilars Up 106%; Research Services Up 25%</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Biocon</font>",https://news.google.com/rss/articles/CBMiWEFVX3lxTE1FZGNCM3N4NHhNa01VTkZDaGRLVTZqelBVSDNHeDBhMzdYZ3lDQ3hPUDZRVVhEYUlBMlFjNlJJdEwzazNSMnZtckdEdHhnQ3lPdXZSZ1hwVkg?oc=5,Google News,Biocon insulin market share,competitive,2025-06-27T05:41:26.941557,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.915063738822937,0.3050212462743123,0.915063738822937,0.0,0.08493626117706299,1,0,0,59.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,8.995191216468811
2023-05-23,2023-05-23 07:00:00,"Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31% - Biocon","<a href=""https://news.google.com/rss/articles/CBMiWEFVX3lxTE0xaWhvUHVSMW1qMG85cGtrWURJamlKRlFuLTFjY0NhbmdmNHpwcFBNY09EcDVPcl9JbGVjenFQOVRiU0FoVU01X3RYdTVfYW94TTBSZ202eWM?oc=5"" target=""_blank"">Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Biocon</font>",https://news.google.com/rss/articles/CBMiWEFVX3lxTE0xaWhvUHVSMW1qMG85cGtrWURJamlKRlFuLTFjY0NhbmdmNHpwcFBNY09EcDVPcl9JbGVjenFQOVRiU0FoVU01X3RYdTVfYW94TTBSZ202eWM?oc=5,Google News,Biocon revenue guidance,financial,2025-06-27T05:41:36.734625,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.897727370262146,0.29924245675404865,0.897727370262146,0.0,0.102272629737854,1,0,0,59.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,8.943182110786438
2024-02-08,2024-02-08 08:00:00,"Biocon Q3FY24 Revenue at Rs 4,519 Cr, Up 50%; Biosimilars Up 65%; Research Services Up 9%; EBITDA at Rs 1,492 Cr, Up 106%; Net Profit at Rs 660 Cr Pre-Paid USD 200 Mn towards Debt Reduction - Biocon","<a href=""https://news.google.com/rss/articles/CBMiWEFVX3lxTFBnRGxwWVZQblc5MkRZNGZnS1RteHBKa25vSWFQZ0VPLS1lWXlzb0hrSTlxNFNCQmRBbjViTktCblBpM0xlT0FieUxweXgzRm1qZ1drSUdyc3M?oc=5"" target=""_blank"">Biocon Q3FY24 Revenue at Rs 4,519 Cr, Up 50%; Biosimilars Up 65%; Research Services Up 9%; EBITDA at Rs 1,492 Cr, Up 106%; Net Profit at Rs 660 Cr Pre-Paid USD 200 Mn towards Debt Reduction</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Biocon</font>",https://news.google.com/rss/articles/CBMiWEFVX3lxTFBnRGxwWVZQblc5MkRZNGZnS1RteHBKa25vSWFQZ0VPLS1lWXlzb0hrSTlxNFNCQmRBbjViTktCblBpM0xlT0FieUxweXgzRm1qZ1drSUdyc3M?oc=5,Google News,Biocon insulin market share,competitive,2025-06-27T05:41:26.941847,0.0,0.25,0.2,0.3333333333333333,0.0,0.15,0.8096389395531531,0.3808679341634114,0.8096389395531531,0.0,0.19036106044684686,1,1,0,50.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,8.92891681865946
2025-02-01,2025-02-01 08:00:00,Biocon Biologics investors are more confident after revenue growth: Mittal - Business Standard,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics investors are more confident after revenue growth: Mittal</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon biologics revenue,financial,2025-06-27T05:41:38.242027,0.0,0.5,0.0,0.16666666666666666,0.0,0.125,0.5054564072166466,0.5926444893700736,0.5054564072166466,0.0,0.49454359278335336,1,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,8.76636922164994
2019-03-12,2019-03-12 07:00:00,Biocon biosimilar plant criticized again by the FDA - Fierce Pharma,"<a href=""https://news.google.com/rss/articles/CBMilAFBVV95cUxPa3I5RS1UMDh2TldyQk5zQ2dycXF4Tl8zVXZabEVpNFAwd19hQThONUFRNHZFenF1VGJIcHZjMU9kdU4tR2NvRnBkZFc3bldKOWpxWldJN3F3WjVQVUROMDVzZjh5SmdiRDkybEpDaDBOdDBMYnBleVBBUld3LURlRUEzbmtXSE1LdTFfMmRrSnhXU3Vv?oc=5"" target=""_blank"">Biocon biosimilar plant criticized again by the FDA</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMilAFBVV95cUxPa3I5RS1UMDh2TldyQk5zQ2dycXF4Tl8zVXZabEVpNFAwd19hQThONUFRNHZFenF1VGJIcHZjMU9kdU4tR2NvRnBkZFc3bldKOWpxWldJN3F3WjVQVUROMDVzZjh5SmdiRDkybEpDaDBOdDBMYnBleVBBUld3LURlRUEzbmtXSE1LdTFfMmRrSnhXU3Vv?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.421690,0.0,0.25,0.4,0.0,0.0,0.15,-0.739737574229164,0.48190574007034304,0.0,0.739737574229164,0.260262425770836,0,1,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,8.719212722687491
2025-03-06,2025-03-06 08:00:00,Biocon Biologics partners with US non-profit co to make diabetes treatment cheaper for Americans - CNBC TV18,"<a href=""https://news.google.com/rss/articles/CBMi_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?oc=5"" target=""_blank"">Biocon Biologics partners with US non-profit co to make diabetes treatment cheaper for Americans</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.com/rss/articles/CBMi_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?oc=5,Google News,Biocon insulin market share,competitive,2025-06-27T05:41:26.941410,0.0,0.5,0.0,0.16666666666666666,0.0,0.125,0.35020739921546906,0.46679014692306514,0.35020739921546906,0.0,0.6497926007845309,0,1,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,8.300622197646408
2023-05-24,2023-05-24 07:00:00,"Biocon Biologics crosses $1 billion revenue, Kiran Mazumdar-Shaw says biosimilars a key growth driver - CNBC TV18","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics crosses $1 billion revenue, Kiran Mazumdar-Shaw says biosimilars a key growth driver</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.com/rss/articles/CBMizgFBVV95cUxOLURnT3NFNzJOalc5MzZvUUN5U2VtdDlWTTl0OXJMMTQ5NWxCbk9MNmxRbUEyTlRlSnVtOVZ5amdDc1J2cnV1R0R0UkFWT2lmZWZBZEdQY19DcndSV01EM250LTdacndUdHZsSVgxb0NjdG5ZMmxmWEdUZ3hPWVNNMWVEaEswQVVONUtQd2JueDdXSUJCenktRHhmeHB6bDN1SHYwUUZRUmR2U2k0WG9GV0dQNkg3bUZlbG1yaUVCLWpSeFJyYllqTDdTUjYyZ9IB0wFBVV95cUxPVFlGVVhGQ0FkNW9LaXU4MmNXY1JTZXFjWlBzcFBGR3VMb1ZRVF9peW9nMTB3ZWlzZG01eG02TGdNN3ZHbVlVLUJTR3paaHlHWm9kc3BFSkU5b256dVFoajNVT2pKcEZzOU1PZEI3NmRFTnQ3TFJvalI3T29pOHYyQW9Ib1ZMSG9wV0pKU2tfWVBFeW44aTRCbTFPTGY1Z2FlaHJyUHBUWGFoX1UxTmFJRUVqcXgwNFA1cm92Q2NFUTNyWEtCRGtFaWpqMGgxeEtQdDFj?oc=5,Google News,Biocon revenue guidance,financial,2025-06-27T05:41:36.734737,0.0,0.75,0.2,0.16666666666666666,0.0,0.225,0.2605575861233202,0.5189404461860657,0.2605575861233202,0.0,0.7394424138766797,1,0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,8.031672758369961
2024-08-09,2024-08-09 05:58:34,Biocon Share Price Falls As Q1 Revenue Misses Estimates - NDTV Profit,"<a href=""https://news.google.com/rss/articles/CBMilAFBVV95cUxNRThTUmV5ZWtNaHp5NnFEYnNSSjVfSmZDMEZGU05QSi13UDNubFlrT1ZqQkh5ZmRKOUp1UmltWGxBLWZIdTJRUkJLQklTckVhZWR5eWtybXpMQkNsWXBMNDJxQnhJSDRJOG44NjYydW16el82cXJrMXBwTXRZekwyMTZ3Z0FrWHJVbHZYV25BcXRoOC1q?oc=5"" target=""_blank"">Biocon Share Price Falls As Q1 Revenue Misses Estimates</a>&nbsp;&nbsp;<font color=""#6f6f6f"">NDTV Profit</font>",https://news.google.com/rss/articles/CBMilAFBVV95cUxNRThTUmV5ZWtNaHp5NnFEYnNSSjVfSmZDMEZGU05QSi13UDNubFlrT1ZqQkh5ZmRKOUp1UmltWGxBLWZIdTJRUkJLQklTckVhZWR5eWtybXpMQkNsWXBMNDJxQnhJSDRJOG44NjYydW16el82cXJrMXBwTXRZekwyMTZ3Z0FrWHJVbHZYV25BcXRoOC1q?oc=5,Google News,Biocon revenue guidance,financial,2025-06-27T05:41:36.734486,0.0,0.25,0.0,0.5,0.0,0.125,-0.18794475021362295,0.5630482500712076,0.0,0.18794475021362295,0.8120552497863771,1,1,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,7.813834250640869
2024-03-05,2024-03-05 00:14:53,FDA rejects Mylan and Biocon’s insulin glargine again - BioProcess International,"<a href=""https://news.google.com/rss/articles/CBMinAFBVV95cUxOSlg5Tk1ZS2lGZmFra3RMTlNPU0dXY0wxWTRIaFFBa3owVUZWMlppbFR5UlN6aVJpZW1qTzFGMlpJWXY2V0dud0RBMEVxeHR2VC03TjFVYXJoVktURm1tOUUtbHlBS19oV19oZmxVbGE0aEVKUUtSUlFyWGNpLWxmbDhlNHhYUnowSi1leEJqcjFudkx2UE9WeWJfZmY?oc=5"" target=""_blank"">FDA rejects Mylan and Biocon’s insulin glargine again</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BioProcess International</font>",https://news.google.com/rss/articles/CBMinAFBVV95cUxOSlg5Tk1ZS2lGZmFra3RMTlNPU0dXY0wxWTRIaFFBa3owVUZWMlppbFR5UlN6aVJpZW1qTzFGMlpJWXY2V0dud0RBMEVxeHR2VC03TjFVYXJoVktURm1tOUUtbHlBS19oV19oZmxVbGE0aEVKUUtSUlFyWGNpLWxmbDhlNHhYUnowSi1leEJqcjFudkx2UE9WeWJfZmY?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.381197,0.2,0.25,0.2,0.0,0.0,0.16,-0.3915271595694563,0.47966051756540934,0.0,0.3915271595694563,0.6084728404305437,0,1,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,7.7745814787083685
2025-06-24,2025-06-24 15:01:23,"Biocon Biologics Collaborates With National Cancer Society Malaysia, Rolls Out Program To Expand Affordable Access to Biosimilars - TheCSRUniverse","<a href=""https://news.google.com/rss/articles/CBMi9wFBVV95cUxPRzNCY3J0aFpwS19abXNIb1c1NUtJTENEbVVfSDB4d3h5QlJ1bHYyYzhPMjNMS2dqbU5SSDhsc0Q1c0l4bTVsVHhRX3ZxN193VExNeVhubE1PY29odFVjOHZXSzlkWVdtbnJfbzJUZVktdG1uNWtySUlFMkFuVUU2OXh4R0dSX2NQZDFKeU1pWXJzejFWRFVoOG1EaDI0VVExcGNlOFdGMjlGQlpFYXBRVnhTWnlPZ0hTV2VlYTd4MnJJSUI2SklZRUFtZmg2aFY2dlpXMUFDT2hrMmtpcnpwYjNmYWF5ZkVvYU80eFZmZXBLXzZqNFdv?oc=5"" target=""_blank"">Biocon Biologics Collaborates With National Cancer Society Malaysia, Rolls Out Program To Expand Affordable Access to Biosimilars</a>&nbsp;&nbsp;<font color=""#6f6f6f"">TheCSRUniverse</font>",https://news.google.com/rss/articles/CBMi9wFBVV95cUxPRzNCY3J0aFpwS19abXNIb1c1NUtJTENEbVVfSDB4d3h5QlJ1bHYyYzhPMjNMS2dqbU5SSDhsc0Q1c0l4bTVsVHhRX3ZxN193VExNeVhubE1PY29odFVjOHZXSzlkWVdtbnJfbzJUZVktdG1uNWtySUlFMkFuVUU2OXh4R0dSX2NQZDFKeU1pWXJzejFWRFVoOG1EaDI0VVExcGNlOFdGMjlGQlpFYXBRVnhTWnlPZ0hTV2VlYTd4MnJJSUI2SklZRUFtZmg2aFY2dlpXMUFDT2hrMmtpcnpwYjNmYWF5ZkVvYU80eFZmZXBLXzZqNFdv?oc=5,Google News,Biocon quality issues,regulatory,2025-06-27T05:41:51.799968,0.0,0.5,0.2,0.0,0.0,0.15,-0.4097919215819564,0.4395499126434326,0.0,0.4097919215819564,0.5902080784180437,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,7.729375764745869
2021-01-22,2021-01-22 08:00:00,"Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore - Biocon","<a href=""https://news.google.com/rss/articles/CBMiWEFVX3lxTFBaemtkU0FXUHBxWUlrU3IxMXhodU1xNUg5eHFoajVaZXdaYkR1VnhvM2wxcVFVSmprTjFIVmtoR0xKV1FzaFUxdEM1d19JQ2puNXkyVXplMFE?oc=5"" target=""_blank"">Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Biocon</font>",https://news.google.com/rss/articles/CBMiWEFVX3lxTFBaemtkU0FXUHBxWUlrU3IxMXhodU1xNUg5eHFoajVaZXdaYkR1VnhvM2wxcVFVSmprTjFIVmtoR0xKV1FzaFUxdEM1d19JQ2puNXkyVXplMFE?oc=5,Google News,Biocon revenue guidance,financial,2025-06-27T05:41:36.734961,0.0,0.25,0.2,0.3333333333333333,0.0,0.15,-0.11078400468437094,0.5252009436889931,0.0,0.11078400468437094,0.8892159953156291,1,1,0,7.0,1879.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,6.832352014053113
2021-10-25,2021-10-25 07:00:00,"Biocon Biologics Reports Biosimilar Revenues, Manufacturing Site Corrective Plan - Center for Biosimilars","<a href=""https://news.google.com/rss/articles/CBMivgFBVV95cUxOdV81c0RjU1I1LWF1TlBFdjdTRUx2MGR5ZnJtZmhNNl9pcVdxcEVZd3ZkS21WU2dpOU1DWDU3c1J5eHA4cDUyaU1DelBFbUdIdDlVZGlMNW1ocGxoNDZBT0pBQjNZZHdBMHFtZVRsdnE2TkNEYjMyS0xHejdCcmRiWVJUZGFGSTJWMGc5T2dsNDZaN2pQdDZpRlpqN05Ib29lckJVQXNMbENlb1ZMZ3NYRGdodHh3SDBXem5sNExR?oc=5"" target=""_blank"">Biocon Biologics Reports Biosimilar Revenues, Manufacturing Site Corrective Plan</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMivgFBVV95cUxOdV81c0RjU1I1LWF1TlBFdjdTRUx2MGR5ZnJtZmhNNl9pcVdxcEVZd3ZkS21WU2dpOU1DWDU3c1J5eHA4cDUyaU1DelBFbUdIdDlVZGlMNW1ocGxoNDZBT0pBQjNZZHdBMHFtZVRsdnE2TkNEYjMyS0xHejdCcmRiWVJUZGFGSTJWMGc5T2dsNDZaN2pQdDZpRlpqN05Ib29lckJVQXNMbENlb1ZMZ3NYRGdodHh3SDBXem5sNExR?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413419,0.0,0.5,0.2,0.16666666666666666,0.0,0.175,-0.004402732764687973,0.33649134768380057,0.0,0.004402732764687973,0.9955972672353121,1,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,6.763208198294064
2025-05-21,2025-05-21 07:00:00,Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan - BioSpectrum Asia,"<a href=""https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVENIcWJjOHRHUkdaNEl6RlFvOWM1Z1A1dklpckxNUzdvRG5OdnpNQnUtRk5sQllURnNJekdJNXRncEJqRHFZNE5EeTMwbXcwTVM0bjluNk5DakdVQTJlUU1HdDVJN0dhSi1XWTJ1c0xMZzlmcU1NTlF5N05GYWRLNTNsRW5jczQ3SkxNSThrNXNpZHk0SHNCQ1pXUTBjSEZsRFFOckxNNGRpcl9fVjYyMWdwWExmUFRtc21DOE9MNGhtY2tPRk5nNA?oc=5"" target=""_blank"">Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BioSpectrum Asia</font>",https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVENIcWJjOHRHUkdaNEl6RlFvOWM1Z1A1dklpckxNUzdvRG5OdnpNQnUtRk5sQllURnNJekdJNXRncEJqRHFZNE5EeTMwbXcwTVM0bjluNk5DakdVQTJlUU1HdDVJN0dhSi1XWTJ1c0xMZzlmcU1NTlF5N05GYWRLNTNsRW5jczQ3SkxNSThrNXNpZHk0SHNCQ1pXUTBjSEZsRFFOckxNNGRpcl9fVjYyMWdwWExmUFRtc21DOE9MNGhtY2tPRk5nNA?oc=5,Google News,Biocon US expansion,strategic,2025-06-27T05:42:12.837217,0.0,0.5,0.2,0.0,0.0,0.15,0.7264207705767246,0.46538194414774575,0.7264207705767246,0.0,0.2735792294232754,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,6.679262311730174
2025-04-28,2025-04-28 07:00:00,"Zydus Lifesciences, Biocon, and Aurobindo Pharma Shares Rise on Fresh Regulatory Approvals - Equitypandit","<a href=""https://news.google.com/rss/articles/CBMiugFBVV95cUxNU1ZBMkczS3B4SWZ5WGVoVzBWcmNqUHdkTU53MXdTSFVBaWdMMFZyUW42NE5NRjc4Z0NudGItQnNqdFVEc3lkZmpQVF96RFlnY0dpdlkzRkphRkZTUkNKd2xOSEJvdXpMaW9Wc3VmOGJLeEdndmpmQjFhakpfbTlvRWJiRDBiMTNwSE9rcVVRa1ZJREdXYkVyb3MydkYyNkU2RzJyN2NEN0hBNHNMUVRvejctem5uVUt6SkE?oc=5"" target=""_blank"">Zydus Lifesciences, Biocon, and Aurobindo Pharma Shares Rise on Fresh Regulatory Approvals</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Equitypandit</font>",https://news.google.com/rss/articles/CBMiugFBVV95cUxNU1ZBMkczS3B4SWZ5WGVoVzBWcmNqUHdkTU53MXdTSFVBaWdMMFZyUW42NE5NRjc4Z0NudGItQnNqdFVEc3lkZmpQVF96RFlnY0dpdlkzRkphRkZTUkNKd2xOSEJvdXpMaW9Wc3VmOGJLeEdndmpmQjFhakpfbTlvRWJiRDBiMTNwSE9rcVVRa1ZJREdXYkVyb3MydkYyNkU2RzJyN2NEN0hBNHNMUVRvejctem5uVUt6SkE?oc=5,Google News,Biocon investment recommendation,sentiment,2025-06-27T05:42:17.979621,0.0,0.25,0.4,0.0,0.0,0.15,0.6949905053182015,0.5725940698305766,0.6949905053182015,0.0,0.3050094946817985,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,6.584971515954605
2025-04-10,2025-04-10 07:00:00,"Biocon Biologics gets US FDA nod for Jobevne, a biosimilar for cancer treatment - Fortune India","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics gets US FDA nod for Jobevne, a biosimilar for cancer treatment</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fortune India</font>",https://news.google.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?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634752,0.0,0.5,0.4,0.0,0.0,0.2,-0.4465811202220318,0.5635312196095784,0.0,0.4465811202220318,0.5534188797779682,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,6.339743360666096
2024-05-15,2024-05-15 07:00:00,"Q4 FY24 results: RVNL, MOIL, Biocon among 84 firms to post earnings today - Business Standard","<a href=""https://news.google.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?oc=5"" target=""_blank"">Q4 FY24 results: RVNL, MOIL, Biocon among 84 firms to post earnings today</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon quarterly earnings,financial,2025-06-27T05:41:35.044594,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.0,0.30739855766296387,0.0,0.0,1.0,0,1,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,6.25
2020-01-24,2020-01-24 08:00:00,US to lead Biocon Biologics' drive towards $1 billion revenue - Business Standard,"<a href=""https://news.google.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?oc=5"" target=""_blank"">US to lead Biocon Biologics' drive towards $1 billion revenue</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon biologics revenue,financial,2025-06-27T05:41:38.242765,0.0,0.5,0.0,0.16666666666666666,0.0,0.125,0.0,0.2781878709793091,0.0,0.0,1.0,1,0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,6.25
2025-04-11,2025-04-11 07:00:00,FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer - Pharmaceutical Technology,"<a href=""https://news.google.com/rss/articles/CBMiggFBVV95cUxPa1I1NEtvSzM5bTVveFF6dV9nNDNfUmdtMENDdTZMSUpMbnVCWV9qS2hoWnh3dlVPVXF1aWp1RXI4NjcwQWpkbzljcjduWlo0WE1SZHBIcHEtTnRkOHdFZlN2dnFkVFRWLTJwZVpmMGtlNUdkRTVIOEhfY3pnZ2d6aUhn?oc=5"" target=""_blank"">FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Pharmaceutical Technology</font>",https://news.google.com/rss/articles/CBMiggFBVV95cUxPa1I1NEtvSzM5bTVveFF6dV9nNDNfUmdtMENDdTZMSUpMbnVCWV9qS2hoWnh3dlVPVXF1aWp1RXI4NjcwQWpkbzljcjduWlo0WE1SZHBIcHEtTnRkOHdFZlN2dnFkVFRWLTJwZVpmMGtlNUdkRTVIOEhfY3pnZ2d6aUhn?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.380791,0.0,0.5,0.4,0.0,0.0,0.2,-0.28824951187745507,0.5032724220593771,0.0,0.28824951187745507,0.7117504881225449,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,5.864748535632366
2025-04-10,2025-04-10 07:00:00,Biocon unit gets U.S. FDA nod for cancer drug biosimilar - Business Standard,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon unit gets U.S. FDA nod for cancer drug biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon US expansion,strategic,2025-06-27T05:42:12.838110,0.0,0.25,0.4,0.0,0.0,0.15,-0.4403430452611331,0.5715144273122151,0.0,0.4403430452611331,0.5596569547388669,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,5.8210291357834
2025-04-10,2025-04-10 07:00:00,FDA Approves Biocon Biologics' Bevacizumab Biosimilar - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMimgFBVV95cUxOLXg5SmhvUG5XNFdIOUhnbUZIaEgzSnZjR01VRlhRTzVrQnBNX2NpakRSZ2lLejRPWm1WaUM0TEhTTFh0Z0xSVEUtVnMxOTJZVWNhTVM0cExOM0ltUktxTGtBam9VX3A1V1lLdzVXRDlHU3BGSjl6dlozTEplUjRFTkNyVGY5X3V5Y0laRHA5TXljbGlfSHRiWmdB?oc=5"" target=""_blank"">FDA Approves Biocon Biologics' Bevacizumab Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMimgFBVV95cUxOLXg5SmhvUG5XNFdIOUhnbUZIaEgzSnZjR01VRlhRTzVrQnBNX2NpakRSZ2lLejRPWm1WaUM0TEhTTFh0Z0xSVEUtVnMxOTJZVWNhTVM0cExOM0ltUktxTGtBam9VX3A1V1lLdzVXRDlHU3BGSjl6dlozTEplUjRFTkNyVGY5X3V5Y0laRHA5TXljbGlfSHRiWmdB?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.586753,0.0,0.5,0.4,0.0,0.0,0.2,0.26689299597079924,0.5379929435624017,0.26689299597079924,0.0,0.7331070040292007,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,5.800678987912398
2025-04-11,2025-04-11 07:00:00,BIOCON RECEIVES APPROVAL FOR JOBEVNE (BIOSOMILAR OF BEVACIZUMAB) FROM THE USFDA. - ICICI Direct,"<a href=""https://news.google.com/rss/articles/CBMirgFBVV95cUxQMmhBbk5ub2xnbVdlMmJyNTF5bUJiZ21KeGhyR0xYVFJJdW9CVm40eVM4dWVOUVJHTFB4X3BpRU8xU1dabjNvRG1NMmRmU2VvVXJtWTFETDh1N0VsZUFhRWcwMzB1eG11Rzl0ekU0RmZnZlQyc3FtNDhaSG82b0lBWmQzVndnNWZNNmRzbGxrbGJWVUZiZnp2UFFhTVlqclBKRG1JQU9LajR2U3Bqa1E?oc=5"" target=""_blank"">BIOCON RECEIVES APPROVAL FOR JOBEVNE (BIOSOMILAR OF BEVACIZUMAB) FROM THE USFDA.</a>&nbsp;&nbsp;<font color=""#6f6f6f"">ICICI Direct</font>",https://news.google.com/rss/articles/CBMirgFBVV95cUxQMmhBbk5ub2xnbVdlMmJyNTF5bUJiZ21KeGhyR0xYVFJJdW9CVm40eVM4dWVOUVJHTFB4X3BpRU8xU1dabjNvRG1NMmRmU2VvVXJtWTFETDh1N0VsZUFhRWcwMzB1eG11Rzl0ekU0RmZnZlQyc3FtNDhaSG82b0lBWmQzVndnNWZNNmRzbGxrbGJWVUZiZnp2UFFhTVlqclBKRG1JQU9LajR2U3Bqa1E?oc=5,Google News,Biocon analyst report,sentiment,2025-06-27T05:42:14.487040,0.0,0.25,0.4,0.0,0.0,0.15,0.3629403770060184,0.5003727783415052,0.3629403770060184,0.0,0.6370596229939816,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,5.588821131018055
2025-04-11,2025-04-11 07:00:00,Biocon Stock Soars 4% On USFDA Nod For Cancer Drug Jobevne - BW Businessworld,"<a href=""https://news.google.com/rss/articles/CBMiowFBVV95cUxPZUtFR0NsSWtqazN0N2FPVUlhTENiTWlwVllZMmFJQWY0UmpHTjJoeHZacFp3czZQcVBfOXNSV2o3d1V3VVFfaHdDZWMxYllPclY2TWtLeEIzZ2c5R0FqeG1DRGs5MGh2cGZZV1Nna05yN2Y2bDk2SUNDYlZyVXJkZXgtYWlpenQ3eG5EbXdJV1BCM0tGUE1BekxZeEE5dzJrLUtR?oc=5"" target=""_blank"">Biocon Stock Soars 4% On USFDA Nod For Cancer Drug Jobevne</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BW Businessworld</font>",https://news.google.com/rss/articles/CBMiowFBVV95cUxPZUtFR0NsSWtqazN0N2FPVUlhTENiTWlwVllZMmFJQWY0UmpHTjJoeHZacFp3czZQcVBfOXNSV2o3d1V3VVFfaHdDZWMxYllPclY2TWtLeEIzZ2c5R0FqeG1DRGs5MGh2cGZZV1Nna05yN2Y2bDk2SUNDYlZyVXJkZXgtYWlpenQ3eG5EbXdJV1BCM0tGUE1BekxZeEE5dzJrLUtR?oc=5,Google News,Biocon analyst upgrade,financial,2025-06-27T05:41:46.698251,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,-0.42299063265015985,0.5949597553888957,0.0,0.42299063265015985,0.5770093673498402,0,0,0,4.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,5.51897189795048
2025-04-10,2025-04-10 07:00:00,FDA Approves Biocon’s Avastin Biosimilar - Managed Healthcare Executive,"<a href=""https://news.google.com/rss/articles/CBMikgFBVV95cUxOMHFSOXp6VmFjWTRHYV9uai1FV1FVcHB6dHgxT25ZWVBVem55cUtYMmRRa19pUEhjQUNNeUw2aE9qaDJtLVlkMWdRaUU1d1FEbm9IbWp5NHdkUndJZm44Nnlja0hfd0VFT1c0WVdLOExtaU5PYlJjWnZsM2c4dDN3YkxhVzNvUkM3a0R0cEVmaDJidw?oc=5"" target=""_blank"">FDA Approves Biocon’s Avastin Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Managed Healthcare Executive</font>",https://news.google.com/rss/articles/CBMikgFBVV95cUxOMHFSOXp6VmFjWTRHYV9uai1FV1FVcHB6dHgxT25ZWVBVem55cUtYMmRRa19pUEhjQUNNeUw2aE9qaDJtLVlkMWdRaUU1d1FEbm9IbWp5NHdkUndJZm44Nnlja0hfd0VFT1c0WVdLOExtaU5PYlJjWnZsM2c4dDN3YkxhVzNvUkM3a0R0cEVmaDJidw?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.380618,0.0,0.25,0.4,0.0,0.0,0.15,0.2852001744790894,0.5086533704439798,0.2852001744790894,0.0,0.7147998255209106,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,5.355600523437268
2025-03-05,2025-03-05 08:00:00,Biocon Shares Shot Up 3% on Securing Final Approvals from USFDA - Equitypandit,"<a href=""https://news.google.com/rss/articles/CBMilwFBVV95cUxQMUpYaG9BaDdSYWE1ODBNdmpDRzRGMm9fOWd3NW5LX2Mwd2FXR0cyUUZGMnN3UHNDVjl2X0w5VmVNT2VDeWRFejlmbExhdDhZWGFkM0t4RHFrMjNjM0RzR2VWQVJZMlB2RWFrWU02NmIyakhyR0ttUkZfaVJnbnAzcXVSbGk3eFdCT09TRlRaMU50a05Bc3dV?oc=5"" target=""_blank"">Biocon Shares Shot Up 3% on Securing Final Approvals from USFDA</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Equitypandit</font>",https://news.google.com/rss/articles/CBMilwFBVV95cUxQMUpYaG9BaDdSYWE1ODBNdmpDRzRGMm9fOWd3NW5LX2Mwd2FXR0cyUUZGMnN3UHNDVjl2X0w5VmVNT2VDeWRFejlmbExhdDhZWGFkM0t4RHFrMjNjM0RzR2VWQVJZMlB2RWFrWU02NmIyakhyR0ttUkZfaVJnbnAzcXVSbGk3eFdCT09TRlRaMU50a05Bc3dV?oc=5,Google News,Biocon regulatory filing,regulatory,2025-06-27T05:41:53.452673,0.0,0.25,0.4,0.0,0.0,0.15,0.8754524896885634,0.5789802267074585,0.8754524896885634,0.0,0.12454751031143663,0,0,0,3.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,5.12635746906569
2025-04-16,2025-04-16 07:00:00,Biocon Biologics secures market entry date for Eylea biosimilar - Drug Store News,"<a href=""https://news.google.com/rss/articles/CBMijgFBVV95cUxQZjBZazgtSE8waFpaZG95TDg5QkxJaXdJckNYbFlWOUVIMzhBYlNnTHFyR0JQS2pwejFZS05fM1BDdWgxVlVRMi13a1p0dmdqU1pobmM0MW1fV3dwdTdXSTZqX0N5ZEJ3MVFscl9WeGpRMUpqVTFzYkVWd2lzTmpQU0RnOXVnTTVYS0w0N3ZR?oc=5"" target=""_blank"">Biocon Biologics secures market entry date for Eylea biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Drug Store News</font>",https://news.google.com/rss/articles/CBMijgFBVV95cUxQZjBZazgtSE8waFpaZG95TDg5QkxJaXdJckNYbFlWOUVIMzhBYlNnTHFyR0JQS2pwejFZS05fM1BDdWgxVlVRMi13a1p0dmdqU1pobmM0MW1fV3dwdTdXSTZqX0N5ZEJ3MVFscl9WeGpRMUpqVTFzYkVWd2lzTmpQU0RnOXVnTTVYS0w0N3ZR?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633619,0.0,0.5,0.2,0.0,0.0,0.15,0.2086101635378397,0.49645193812052407,0.2086101635378397,0.0,0.7913898364621603,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,5.125830490613519
2025-04-10,2025-04-10 18:37:27,Biocon Biologics gets FDA nod for Roche's bevacizumab biosimilar - MSN,"<a href=""https://news.google.com/rss/articles/CBMizgFBVV95cUxNb09VdTBIUEdmQkplY2VWOTktY0FjUm1kbXBrV0ZKQ3hmNi1DQVoteGlJTzJUZUtjclhVWl94VnFzX1VocXlXTHI4b0tiaGtxakxBY0VuT3FDZ3Frc0xWbDEwXzhHRTlGaFotSUdBQnBhdVZPNzlOWW8yUWdfeFdoNm9ocGU0dmJJbGp2YnJrZm5zNmtmYTdKbVhPZzV6a01SZnRQVlNzYVpVcUtkUl9mNkhIM2U0T2oxNkdzWDlYcWpGS3pKaEhIZ3FrUi1wdw?oc=5"" target=""_blank"">Biocon Biologics gets FDA nod for Roche's bevacizumab biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">MSN</font>",https://news.google.com/rss/articles/CBMizgFBVV95cUxNb09VdTBIUEdmQkplY2VWOTktY0FjUm1kbXBrV0ZKQ3hmNi1DQVoteGlJTzJUZUtjclhVWl94VnFzX1VocXlXTHI4b0tiaGtxakxBY0VuT3FDZ3Frc0xWbDEwXzhHRTlGaFotSUdBQnBhdVZPNzlOWW8yUWdfeFdoNm9ocGU0dmJJbGp2YnJrZm5zNmtmYTdKbVhPZzV6a01SZnRQVlNzYVpVcUtkUl9mNkhIM2U0T2oxNkdzWDlYcWpGS3pKaEhIZ3FrUi1wdw?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633967,0.0,0.5,0.4,0.0,0.0,0.2,0.0,0.289079487323761,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,5.0
2025-04-10,2025-04-10 07:00:00,Biocon Biologics obtains FDA nod for Avastin biosimilar - Drug Store News,"<a href=""https://news.google.com/rss/articles/CBMigwFBVV95cUxPQkF3Z0xBMFJ2NjdSVF9aMzV2YlhORFdfZV9DUWdYc0ZPa3FkOFlNYi1rV3lhYmYtRFpTUktFNHdhUm4wM1VFd3dnUFg0MndGZmlRVG1iSkpzclJZNl9TMDh3S1ZnNVJGU1E1Z2tUQUt5blVITy1sSzg1VXZnQUhpOHJvcw?oc=5"" target=""_blank"">Biocon Biologics obtains FDA nod for Avastin biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Drug Store News</font>",https://news.google.com/rss/articles/CBMigwFBVV95cUxPQkF3Z0xBMFJ2NjdSVF9aMzV2YlhORFdfZV9DUWdYc0ZPa3FkOFlNYi1rV3lhYmYtRFpTUktFNHdhUm4wM1VFd3dnUFg0MndGZmlRVG1iSkpzclJZNl9TMDh3S1ZnNVJGU1E1Z2tUQUt5blVITy1sSzg1VXZnQUhpOHJvcw?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.382072,0.0,0.5,0.4,0.0,0.0,0.2,0.0,0.3078539768854777,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,5.0
2025-03-05,2025-03-05 08:00:00,Biocon rises after subsidiary gets approval for multiple ANDAs from US FDA - Business Standard,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon rises after subsidiary gets approval for multiple ANDAs from US FDA</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634969,0.0,0.25,0.4,0.0,0.0,0.15,0.8264510585789918,0.5453610515912374,0.8264510585789918,0.0,0.17354894142100818,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.979353175736975
2025-05-13,2025-05-13 07:00:00,Trump’s drug pricing order boosts case for generics and biosimilars: Kiran Mazumdar-Shaw - financialexpress.com,"<a href=""https://news.google.com/rss/articles/CBMi4gFBVV95cUxQWHpWazU3VXpiTzdYUlEtcnBoSVhHb2VwT0pXOTNPTHJCMV94cHVDb2JUZ0lvOGI5OGRXd1Q1T0F4bXhhZU5fY1gtem4zN0RwbjBuUnJXN2w3V3hUSGZ2RmlOdGQwUkxBemxOOTFvSDhXbERVbk54VE8xTjZ1WWJzRU9VRjNiQlJWcXRmWTViMUJGTHEyb0ZYNDczRHFDM2FlWFhiUDcya2Vidm5ya1hTZEY0ajdySVZHOGFScXl3OFRNNXpiSzFrcTRDTkdWY1RqMlBsS0JRY2xCc3ZLaTlaYjRn?oc=5"" target=""_blank"">Trump’s drug pricing order boosts case for generics and biosimilars: Kiran Mazumdar-Shaw</a>&nbsp;&nbsp;<font color=""#6f6f6f"">financialexpress.com</font>",https://news.google.com/rss/articles/CBMi4gFBVV95cUxQWHpWazU3VXpiTzdYUlEtcnBoSVhHb2VwT0pXOTNPTHJCMV94cHVDb2JUZ0lvOGI5OGRXd1Q1T0F4bXhhZU5fY1gtem4zN0RwbjBuUnJXN2w3V3hUSGZ2RmlOdGQwUkxBemxOOTFvSDhXbERVbk54VE8xTjZ1WWJzRU9VRjNiQlJWcXRmWTViMUJGTHEyb0ZYNDczRHFDM2FlWFhiUDcya2Vidm5ya1hTZEY0ajdySVZHOGFScXl3OFRNNXpiSzFrcTRDTkdWY1RqMlBsS0JRY2xCc3ZLaTlaYjRn?oc=5,Google News,Biocon US market revenue,financial,2025-06-27T05:41:41.752791,0.0,0.25,0.2,0.0,0.2,0.12,0.22329957907701334,0.46379361944198605,0.22329957907701334,0.0,0.7767004209229866,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.86989873723104
2025-04-11,2025-04-11 07:00:00,Biocon shares jump 5.5% as USFDA clears biosimilar Cancer drug JOBEVNE - Mint,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon shares jump 5.5% as USFDA clears biosimilar Cancer drug JOBEVNE</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Mint</font>",https://news.google.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?oc=5,Google News,Biocon analyst upgrade,financial,2025-06-27T05:41:46.697645,0.0,0.25,0.4,0.0,0.0,0.15,0.06443742723464957,0.4883458090782165,0.06443742723464957,0.0,0.9355625727653505,0,0,0,5.5,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.693312281703949
2025-04-10,2025-04-10 07:00:00,"Biocon Biologics gets US FDA nod for Jobevne, expands oncology portfolio - Business Standard","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics gets US FDA nod for Jobevne, expands oncology portfolio</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.com/rss/articles/CBMi1wFBVV95cUxPbWVtN05WM25wZzJENjBMd3huSW1NVnlKTWNXOUh1TzN2OVpIOC1XN05DTDdnVjJHaHVXaGF1Um5fZ3Y5Y2UtbWtIRWVLYi1DbjRHZm9fV1V6SkQwMk1jRGV5NjNoYXFRU3JpenJZZFhLLVR0THlRVUxydmdGTGE5YVFGbDhERW4tUm4zV2lPRTdWNzFQc2VqU3JpUjVYS04xc2h0VTVYcEVMOUdTSUZXOHF3c3E5My1lTEpzN2tqQUwwN1BKcTE4RDdxd29wd00ta0ZQSm1zTdIB3AFBVV95cUxQdUJrU1ZhdXRYTV9TRVFGUjZxdDhrQVJSUUM0enJMTzdKb2MtMGw5UEZkV2l1ZmlQa2o2NlJmeDMwdGtpUzhLUF9Idmdfb2pIR19CS0hrMXBQcHhQNF85Q2U1WUY3REhpQTA4RlRtOHhOR0RtdDBBRkxDMjZ5ME9mbklCbFpyV1QxMHpqRHNXVnNXM2JqWTNNSEM4eW45SU5XeXBrOHJ1QjVSa2pja0dxSnlpdjJILTZCdzBMYldiVllIZkxXY0c5T1JlbzZzS3J0ck5yU25KbG5tTkVC?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634061,0.0,0.5,0.2,0.0,0.0,0.15,0.04469283729701527,0.3052337725321452,0.04469283729701527,0.0,0.9553071627029848,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.634078511891046
2025-05-16,2025-05-16 07:00:00,Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches - insights.citeline.com,"<a href=""https://news.google.com/rss/articles/CBMiigJBVV95cUxPWW56eDNkTFVjZjVmanFvdTFmWmlDdnUtVTg4cDk1c3RnWE80QkJyRDRZTTBrLWZXMlR2MU9QLWNucDBielZwbHJYa25sT1pQY21KaHR1TUFSRVV0MF9CS2lVT25JT09vTTFxWkFpZXo2U0diZTBEZkM1dmkwSVFfOXlnOHJ4NHVMUF9jNVZMMU9Iekt2M2UyYlRtWUxNYjVzb2h3WGFaVld5T1BvQlRfNGpxX3c0a3VCcnYyRDl1a3h6UjN0WEtPNGxrMlpmM1JYTHlURmItQWszb1dVb2t0YllDZi1UZ0dmNnJXMUYtd3VONGJYODBfZUxZanhOcDlXVElwMzZsUzNvUQ?oc=5"" target=""_blank"">Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches</a>&nbsp;&nbsp;<font color=""#6f6f6f"">insights.citeline.com</font>",https://news.google.com/rss/articles/CBMiigJBVV95cUxPWW56eDNkTFVjZjVmanFvdTFmWmlDdnUtVTg4cDk1c3RnWE80QkJyRDRZTTBrLWZXMlR2MU9QLWNucDBielZwbHJYa25sT1pQY21KaHR1TUFSRVV0MF9CS2lVT25JT09vTTFxWkFpZXo2U0diZTBEZkM1dmkwSVFfOXlnOHJ4NHVMUF9jNVZMMU9Iekt2M2UyYlRtWUxNYjVzb2h3WGFaVld5T1BvQlRfNGpxX3c0a3VCcnYyRDl1a3h6UjN0WEtPNGxrMlpmM1JYTHlURmItQWszb1dVb2t0YllDZi1UZ0dmNnJXMUYtd3VONGJYODBfZUxZanhOcDlXVElwMzZsUzNvUQ?oc=5,Google News,Biocon biosimilar strategy,strategic,2025-06-27T05:42:11.118185,0.0,0.5,0.2,0.0,0.0,0.15,-0.010441502190343318,0.32945386770541074,0.0,0.010441502190343318,0.9895584978096567,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.53132450657103
2025-05-14,2025-05-14 07:00:00,"Biocon’s Kiran Mazumdar-Shaw looking at biosimilar unit merger, IPO plans on hold - Moneycontrol","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon’s Kiran Mazumdar-Shaw looking at biosimilar unit merger, IPO plans on hold</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Moneycontrol</font>",https://news.google.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?oc=5,Google News,Kiran Mazumdar Shaw interview,strategic,2025-06-27T05:42:01.310038,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3142950137456258,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.5
2024-12-04,2024-12-04 08:00:00,FDA gives Biocon Biologics approval for Stelara biosimilar - Drug Store News,"<a href=""https://news.google.com/rss/articles/CBMihwFBVV95cUxNa2JoOGZFUXFOdXlxbkl2NF9FX2ZPTmRYanctRHhUZkRONmIzaVVGU3VJYmJzLWRrcnIzVHRTcDV2LVlMOXlLM1lGcHJuMmFmSmVkdjcya2E4d2drRXJncHpEU0lRR3FDczVOd1JDeUJyTERKbC1ZSzdrcmt6UU1sR3VKX3ZuYjA?oc=5"" target=""_blank"">FDA gives Biocon Biologics approval for Stelara biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Drug Store News</font>",https://news.google.com/rss/articles/CBMihwFBVV95cUxNa2JoOGZFUXFOdXlxbkl2NF9FX2ZPTmRYanctRHhUZkRONmIzaVVGU3VJYmJzLWRrcnIzVHRTcDV2LVlMOXlLM1lGcHJuMmFmSmVkdjcya2E4d2drRXJncHpEU0lRR3FDczVOd1JDeUJyTERKbC1ZSzdrcmt6UU1sR3VKX3ZuYjA?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633411,0.0,0.5,0.6,0.0,0.0,0.25,0.3247656412829981,0.554627646636963,0.3247656412829981,0.0,0.6752343587170019,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.4742969238489945
2021-08-19,2021-08-19 07:00:00,Semglee approval to provide huge opportunities in the US insulin biosimilar market - Indian Pharma Post,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Semglee approval to provide huge opportunities in the US insulin biosimilar market</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Indian Pharma Post</font>",https://news.google.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?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413785,0.4,0.0,0.4,0.0,0.0,0.22000000000000003,0.7544017227073928,0.6341176666153802,0.7544017227073928,0.0,0.2455982772926072,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.463205168122179
2024-12-17,2024-12-17 08:00:00,European agency endorses approval of Biocon Biologics’ biosimilar Ustekinumab - The New Indian Express,"<a href=""https://news.google.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?oc=5"" target=""_blank"">European agency endorses approval of Biocon Biologics’ biosimilar Ustekinumab</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The New Indian Express</font>",https://news.google.com/rss/articles/CBMiygFBVV95cUxNR29tdzdpTncxXzdkWkYyX0tUcG9UbWJYd045enlCcUxtLUhyd295VVpzNzU0MHJpeWtuT3NRN29sdjNHRjFqbEJNTHhjRks5djJzdEZTQzFFblJVTXdERUgwclplajZhTF9PWnFMUmhNQUJmWF9TSEZVV1ZMelJHbmJma3NaREJiTzdYM2gtanV4TndsYmJaOXZNTnNhZzBPVTlwa3NyWWJfazJiSmhhQXBCM28xTDR2QjJycjNXOUtBVUowcGpTMDNR0gHXAUFVX3lxTE40clpYeXEwRWZ0Z184VnFKOFMweGRhT2k4UG5EcWVEdzFuNkgwX2xJN3hiU1FRY3dlZllWYTJmSVRXdUhxOGNZdy1rMmw0N21tY2FFOGFuWkFHcHVqeUl2MGV4eHFlUDBsbXdnR2hLLVFWNjNkcFNJeDlmQVE4WTZQUnFFZDNEbzlUUkxnakJ3Mmw5alRtYm1JZjJvUng4SUozdWZkSU1uSThlYmxYbDdCQmZManhVd1phcDZlMTBXOEVldHpvRmRNMllwa0hxWUpQSGdlQ3d3?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.635162,0.0,0.5,0.4,0.0,0.0,0.2,0.4363813111131921,0.5871013775016323,0.4363813111131921,0.0,0.5636186888868079,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.309143933339577
2025-04-11,2025-04-11 07:00:00,Pharma stock jumps 5% after receiving approval from USFDA for Cancer Drug - Trade Brains,"<a href=""https://news.google.com/rss/articles/CBMiqAFBVV95cUxPc29WTGY1NjBhSEdtaC1RbTg5RGNmTE5sRUgwcFVzN3VadW5lbW9MRWRHd01zOE5OeDZ0dFRIV1gxVERTT1VuR0NtRWNkaEZqSFNqMVN4clJMbVN4WEx2Z1QxLXMxNUIzLWttUVNxaXBzMXpScUdNdlZpbm9lVUhhOUxWZEMwejR6bTRUX1drZEtiRTBXMmExQ2E1YlpiUmlQZGtoWFhmYkE?oc=5"" target=""_blank"">Pharma stock jumps 5% after receiving approval from USFDA for Cancer Drug</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Trade Brains</font>",https://news.google.com/rss/articles/CBMiqAFBVV95cUxPc29WTGY1NjBhSEdtaC1RbTg5RGNmTE5sRUgwcFVzN3VadW5lbW9MRWRHd01zOE5OeDZ0dFRIV1gxVERTT1VuR0NtRWNkaEZqSFNqMVN4clJMbVN4WEx2Z1QxLXMxNUIzLWttUVNxaXBzMXpScUdNdlZpbm9lVUhhOUxWZEMwejR6bTRUX1drZEtiRTBXMmExQ2E1YlpiUmlQZGtoWFhmYkE?oc=5,Google News,Biocon pipeline updates,strategic,2025-06-27T05:42:07.945744,0.0,0.0,0.4,0.16666666666666666,0.0,0.125,0.010020184612274162,0.3749400615374247,0.010020184612274162,0.0,0.9899798153877258,0,0,0,5.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.280060553836822
2021-06-30,2021-06-30 07:00:00,Biosimilar Insulin Glargine Led to Downward Trend in Pricing - Managed Healthcare Executive,"<a href=""https://news.google.com/rss/articles/CBMirAFBVV95cUxOTVNDc3ZLbTZiQUVsOGt5a3huenEybWhlSGppcXBFTGNCN3k5MDFHWEJpcFFuSENDT1dmdjFTb0E2ZEx6QVBKbHpTV0Y4S084X2JOdzJDaXdHMm83YzNKVTMzSllKRGd3YWIzSTBBcWs4ei1ZZmhjWHNsa0UxVkRNRDJncWxqMXhEU1lERF91MWU5TDlQRjg4Zl8waFg5aTZ4YkZjM21LVDhxbTJC?oc=5"" target=""_blank"">Biosimilar Insulin Glargine Led to Downward Trend in Pricing</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Managed Healthcare Executive</font>",https://news.google.com/rss/articles/CBMirAFBVV95cUxOTVNDc3ZLbTZiQUVsOGt5a3huenEybWhlSGppcXBFTGNCN3k5MDFHWEJpcFFuSENDT1dmdjFTb0E2ZEx6QVBKbHpTV0Y4S084X2JOdzJDaXdHMm83YzNKVTMzSllKRGd3YWIzSTBBcWs4ei1ZZmhjWHNsa0UxVkRNRDJncWxqMXhEU1lERF91MWU5TDlQRjg4Zl8waFg5aTZ4YkZjM21LVDhxbTJC?oc=5,Google News,biosimilar insulin pricing,competitive,2025-06-27T05:41:30.483416,0.2,0.0,0.2,0.0,0.2,0.13,-0.9468263983726501,0.31560879945755005,0.0,0.9468263983726501,0.053173601627349854,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.14047919511795
2025-04-15,2025-04-15 07:00:00,How State Substitution Laws Shape Insulin Biosimilar Adoption - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMipgFBVV95cUxQcU5lTXRvbmhrd2JmOC1uLTJZOXIyaU5iamhkVDU3SEpYZ1p4RmJQOS1kVnpjUXdsN1o1Tnp4OTB2Tno3cVZNRThpbWpFNi1mN3pYdG1DUXJrZmxiUWtpbXBOWWFzdXd4UWl6RjhMak1hZWhtb2U0c1NMdm9rUkFySnptZ0dWdFRWb1pGNTJCeUtYdm9CTFVta2RZUWV1bFpranVwZFVB?oc=5"" target=""_blank"">How State Substitution Laws Shape Insulin Biosimilar Adoption</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMipgFBVV95cUxQcU5lTXRvbmhrd2JmOC1uLTJZOXIyaU5iamhkVDU3SEpYZ1p4RmJQOS1kVnpjUXdsN1o1Tnp4OTB2Tno3cVZNRThpbWpFNi1mN3pYdG1DUXJrZmxiUWtpbXBOWWFzdXd4UWl6RjhMak1hZWhtb2U0c1NMdm9rUkFySnptZ0dWdFRWb1pGNTJCeUtYdm9CTFVta2RZUWV1bFpranVwZFVB?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.412777,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,-0.004371769547343762,0.3388745599322849,0.0,0.004371769547343762,0.9956282304526562,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.113115308642032
2020-08-31,2020-08-31 07:00:00,Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMiowJBVV95cUxOWmhETXVZRS1NUWFGS25nY1BpbmNDeUJFcXNjWXUzcUhxRFMtZTB1OU9oQ1JtUXRDVW16MmVUR2hVVjVHYU4wRmtOa0NyNkNGS1pGRE1Xa1NuMjE5NTdHbXVZbmFTWlV6Y0dtOHUtVjhvUF9FSWJuTG4waEVVd1dWMUk1QTUydW9DQ09zWWh3NHlxQzVRZWl1WEgwNm8zYkdLQWJnTjMtZkpPeVhhSFRrNE1VNDc0bDZ0Vk5rOGNNQkE4MWx0aE0zQkZPZWpMZDFUMHlJTHh3RXFFa1AyVFJsRXpmaTNCbXZzODV1YWYtUnd4S3VzcDRaRjdjUEt2U1pKeGsxZWIyVmZkTVEtbVVQXzdiY1o1Q2R2SGZWeEFDcUk5azQ?oc=5"" target=""_blank"">Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMiowJBVV95cUxOWmhETXVZRS1NUWFGS25nY1BpbmNDeUJFcXNjWXUzcUhxRFMtZTB1OU9oQ1JtUXRDVW16MmVUR2hVVjVHYU4wRmtOa0NyNkNGS1pGRE1Xa1NuMjE5NTdHbXVZbmFTWlV6Y0dtOHUtVjhvUF9FSWJuTG4waEVVd1dWMUk1QTUydW9DQ09zWWh3NHlxQzVRZWl1WEgwNm8zYkdLQWJnTjMtZkpPeVhhSFRrNE1VNDc0bDZ0Vk5rOGNNQkE4MWx0aE0zQkZPZWpMZDFUMHlJTHh3RXFFa1AyVFJsRXpmaTNCbXZzODV1YWYtUnd4S3VzcDRaRjdjUEt2U1pKeGsxZWIyVmZkTVEtbVVQXzdiY1o1Q2R2SGZWeEFDcUk5azQ?oc=5,Google News,Biocon Semglee approval,drug_fda,2025-06-27T05:41:13.020367,0.4,0.5,0.0,0.0,0.0,0.22000000000000003,0.6043416952164973,0.40077116486231484,0.6043416952164973,0.0,0.3956583047835027,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.013025085649492
2025-01-07,2025-01-07 08:00:00,Biocon’s Share Price Soars Following Jefferies Upgrade and Regulatory Approval - theafricalogistics.com,"<a href=""https://news.google.com/rss/articles/CBMirgFBVV95cUxOcEQzSWd0LU5iZmkyMjFqLVpodzdyWVBVc3JhbjhoMHNBRUViYlB3aS14YmRicF80VDU3d01QUGF1M0tPcnpXMGs2UWZONmljTHlKOW02MkhoYzc0WXlxR0huRmpiM1ZqdGtnMXFqN05hYTZEeXg1cWtKZ2pZRTZfai1WajlpUzBUX2NFcHNuNXdEMUdhaUFMRkR1bFhLTEoyOWU3b0RTWGMxXzVvU0E?oc=5"" target=""_blank"">Biocon’s Share Price Soars Following Jefferies Upgrade and Regulatory Approval</a>&nbsp;&nbsp;<font color=""#6f6f6f"">theafricalogistics.com</font>",https://news.google.com/rss/articles/CBMirgFBVV95cUxOcEQzSWd0LU5iZmkyMjFqLVpodzdyWVBVc3JhbjhoMHNBRUViYlB3aS14YmRicF80VDU3d01QUGF1M0tPcnpXMGs2UWZONmljTHlKOW02MkhoYzc0WXlxR0huRmpiM1ZqdGtnMXFqN05hYTZEeXg1cWtKZ2pZRTZfai1WajlpUzBUX2NFcHNuNXdEMUdhaUFMRkR1bFhLTEoyOWU3b0RTWGMxXzVvU0E?oc=5,Google News,Biocon analyst upgrade,financial,2025-06-27T05:41:46.698650,0.0,0.25,0.4,0.16666666666666666,0.0,0.175,0.4168934489871204,0.5948012630144756,0.4168934489871204,0.0,0.5831065510128797,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,4.000680346961361
2024-06-24,2024-06-24 07:00:00,Biocon Biologics Expands European Manufacturing Capabilities with EMA Approval - KNN India,"<a href=""https://news.google.com/rss/articles/CBMi1wFBVV95cUxNMTFfUUNZU3BrV1NNSmRDdDlQWEQ4UW1wemlkajgySlNsOUx5YmlaQWNsNnBGMnpFOHVxQVBrSHJEckJreF91VlJVSzBybnYwdC1EeGNZYjl6V0w2VXdaRHdsRTJ1Ukl6c3IwV3diZEIyTmU5N1MyQzlLTDVVSGNHMUhBbHR5S3VOV0xpM2p0NGd5Z0MybVhoQXZ0M3FEZnpVdG1nTHgxWXBWTUhGZzM2ano3T1FvcDNfMHlXRDM0eG5kMlc3T3czZ1JMUEVfNHNCX21FcTF2OA?oc=5"" target=""_blank"">Biocon Biologics Expands European Manufacturing Capabilities with EMA Approval</a>&nbsp;&nbsp;<font color=""#6f6f6f"">KNN India</font>",https://news.google.com/rss/articles/CBMi1wFBVV95cUxNMTFfUUNZU3BrV1NNSmRDdDlQWEQ4UW1wemlkajgySlNsOUx5YmlaQWNsNnBGMnpFOHVxQVBrSHJEckJreF91VlJVSzBybnYwdC1EeGNZYjl6V0w2VXdaRHdsRTJ1Ukl6c3IwV3diZEIyTmU5N1MyQzlLTDVVSGNHMUhBbHR5S3VOV0xpM2p0NGd5Z0MybVhoQXZ0M3FEZnpVdG1nTHgxWXBWTUhGZzM2ano3T1FvcDNfMHlXRDM0eG5kMlc3T3czZ1JMUEVfNHNCX21FcTF2OA?oc=5,Google News,Biocon manufacturing compliance,regulatory,2025-06-27T05:41:50.143126,0.0,0.5,0.2,0.0,0.0,0.15,0.7845521567052918,0.5230032000859578,0.7845521567052918,0.0,0.21544784329470823,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.853656470115875
2024-12-01,2024-12-01 08:00:00,USFDA gives nod to Biocon Biologics’ biosimilar to treat Crohn’s disease - financialexpress.com,"<a href=""https://news.google.com/rss/articles/CBMizAFBVV95cUxPVWwzdTBmZkFFSkdYdEZ6bFdoZ0ZEQWV0dUFhX21mcDNYUjBya1FuOGtKbXAxVm5pVEQyak1YazNwSUhXeG5qT2dzTHdnTlR3OERfNTZ3Y3JFZHRVSlU3M2xVUGhyaTRLNDdRSHZ2d3BOUFc2Qkp6ZG1ROFh1dW9CV2xFNG4wR3dBWkNUVFNFU2l0SWJJbTl1NndHdHZoMnRaanJ6X3FCNU10ODVmZ1pFdVpmTGV4cUI2QWJMT1lUYnRDOGJxV2hKTkExQ2o?oc=5"" target=""_blank"">USFDA gives nod to Biocon Biologics’ biosimilar to treat Crohn’s disease</a>&nbsp;&nbsp;<font color=""#6f6f6f"">financialexpress.com</font>",https://news.google.com/rss/articles/CBMizAFBVV95cUxPVWwzdTBmZkFFSkdYdEZ6bFdoZ0ZEQWV0dUFhX21mcDNYUjBya1FuOGtKbXAxVm5pVEQyak1YazNwSUhXeG5qT2dzTHdnTlR3OERfNTZ3Y3JFZHRVSlU3M2xVUGhyaTRLNDdRSHZ2d3BOUFc2Qkp6ZG1ROFh1dW9CV2xFNG4wR3dBWkNUVFNFU2l0SWJJbTl1NndHdHZoMnRaanJ6X3FCNU10ODVmZ1pFdVpmTGV4cUI2QWJMT1lUYnRDOGJxV2hKTkExQ2o?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634825,0.0,0.5,0.4,0.0,0.0,0.2,0.28123236179996597,0.5158297895431518,0.28123236179996597,0.0,0.7187676382000341,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.843697085399898
2024-12-01,2024-12-01 08:00:00,"USFDA approves Biocon Biologics' biosimilar for Crohn's disease, psoriasis - Business Standard","<a href=""https://news.google.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?oc=5"" target=""_blank"">USFDA approves Biocon Biologics' biosimilar for Crohn's disease, psoriasis</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634316,0.0,0.5,0.4,0.0,0.0,0.2,0.27987453299987725,0.5183323700269064,0.27987453299987725,0.0,0.7201254670001227,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.8396235989996317
2024-12-02,2024-12-02 08:00:00,"U.S. FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 Biosimilar to J&J's Stelara® (Ustekinumab) - PR Newswire","<a href=""https://news.google.com/rss/articles/CBMi3gFBVV95cUxOeDZCWEZ5d1dmanYtSHlFcEFLN2NSaGRjZThjcXZFUklGZW5RdWJaNldORUsyWV9ZRWhSMFNmNUR6dTBnSWdqaUFkbThYYWcxaHFzZGI2bDktLXI2NE82NHlPZTVuRG1Xb0FTZEMtdENoVkpOUmkxcjhRdGdoOXJpNFNtZWVJNDRUY3NCMzhNaDctVlBsV2JNVUJ2SnN0aW81ME1xdmFJck5MQm0tamNlWXlaYWw0YnV4WGpONk9OdVFQV3pzdklRdGhYem55TXlfeHpqZHVtOGdSNzlFcmc?oc=5"" target=""_blank"">U.S. FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 Biosimilar to J&amp;J's Stelara® (Ustekinumab)</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi3gFBVV95cUxOeDZCWEZ5d1dmanYtSHlFcEFLN2NSaGRjZThjcXZFUklGZW5RdWJaNldORUsyWV9ZRWhSMFNmNUR6dTBnSWdqaUFkbThYYWcxaHFzZGI2bDktLXI2NE82NHlPZTVuRG1Xb0FTZEMtdENoVkpOUmkxcjhRdGdoOXJpNFNtZWVJNDRUY3NCMzhNaDctVlBsV2JNVUJ2SnN0aW81ME1xdmFJck5MQm0tamNlWXlaYWw0YnV4WGpONk9OdVFQV3pzdklRdGhYem55TXlfeHpqZHVtOGdSNzlFcmc?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633256,0.0,0.5,0.4,0.0,0.0,0.2,0.2755744097374321,0.5264205415089925,0.2755744097374321,0.0,0.7244255902625679,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.826723229212296
2024-12-02,2024-12-02 08:00:00,"FDA Approves Biocon Biologics Ustekinumab Biosimilar, Yesintek - Center for Biosimilars","<a href=""https://news.google.com/rss/articles/CBMipgFBVV95cUxOMVVUc0JjMzRfeWZuWUJWS1B5cl9XQi1CZ3ZkZVVJVHEtR3hrbHRKUnpRR25lSzJyQjJqc2VCVlo2N2QwZk0yUkZWY1I4dDNObkFDVEN3Z3hMdXNTNGNuY0lQZ3B4VXFRUm9kNWIzdlc4ZnJSVGNOVGlINHk5MjNJVXNfb1FOYmd5UTNFSkpHU1l5bUl6ZUNPUzdoTzlKVmQtTXppNFhB?oc=5"" target=""_blank"">FDA Approves Biocon Biologics Ustekinumab Biosimilar, Yesintek</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMipgFBVV95cUxOMVVUc0JjMzRfeWZuWUJWS1B5cl9XQi1CZ3ZkZVVJVHEtR3hrbHRKUnpRR25lSzJyQjJqc2VCVlo2N2QwZk0yUkZWY1I4dDNObkFDVEN3Z3hMdXNTNGNuY0lQZ3B4VXFRUm9kNWIzdlc4ZnJSVGNOVGlINHk5MjNJVXNfb1FOYmd5UTNFSkpHU1l5bUl6ZUNPUzdoTzlKVmQtTXppNFhB?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633135,0.0,0.5,0.4,0.0,0.0,0.2,0.2659994374740066,0.5398001961284213,0.2659994374740066,0.0,0.7340005625259933,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.7979983124220196
2020-01-29,2020-01-29 08:00:00,FDA faults Biocon small molecule API facility during preapproval review - Fierce Pharma,"<a href=""https://news.google.com/rss/articles/CBMitAFBVV95cUxPd01oaUlvY0xUN25md0JTUVlJb3dBeWdJTzl0MmItaFFjTFJpTnJYN0JUclFvSVVCaTBrb2VnREFDSnluUjkyU1Z5TjVXZ0loQmxDQ0N2SDFhME5UTWF5YjlKbXkxajJfa0o5elh0OFNEOWZnbGVZRkQzaW0ydVFVYm1WUnlQbE9ZclJ4TkhsVnFKdFJYT0E5U2JyNzhfX2hUdTQ3Q2ZOUThyT0YxRDJ0VWswODk?oc=5"" target=""_blank"">FDA faults Biocon small molecule API facility during preapproval review</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMitAFBVV95cUxPd01oaUlvY0xUN25md0JTUVlJb3dBeWdJTzl0MmItaFFjTFJpTnJYN0JUclFvSVVCaTBrb2VnREFDSnluUjkyU1Z5TjVXZ0loQmxDQ0N2SDFhME5UTWF5YjlKbXkxajJfa0o5elh0OFNEOWZnbGVZRkQzaW0ydVFVYm1WUnlQbE9ZclJ4TkhsVnFKdFJYT0E5U2JyNzhfX2hUdTQ3Q2ZOUThyT0YxRDJ0VWswODk?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.421624,0.0,0.25,0.4,0.0,0.0,0.15,-0.7657901585074053,0.6011119713041517,0.0,0.7657901585074053,0.23420984149259472,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.7973704755222157
2020-01-27,2020-01-27 08:00:00,FDA faults Biocon plant during preapproval review - Fierce Pharma,"<a href=""https://news.google.com/rss/articles/CBMilwFBVV95cUxQSDUxYV9tN0xXSUhxSWpEWC1zVjVuOVE4dVQ5UkNjX0dJVWpBcWFfRV9NRVU4dVRSNXM3QWV3VnhGZWY5UUhaRzhqcTFyZ0lwbUdhVHRadGhtSWdZcERxUFVKRDA1RktYRWlBNVExUmZhMjJLcDc2NjU3Ym5VWUswdDFCaG01NVdyQ0Qzc2hWWGxlSmw1dFk4?oc=5"" target=""_blank"">FDA faults Biocon plant during preapproval review</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMilwFBVV95cUxQSDUxYV9tN0xXSUhxSWpEWC1zVjVuOVE4dVQ5UkNjX0dJVWpBcWFfRV9NRVU4dVRSNXM3QWV3VnhGZWY5UUhaRzhqcTFyZ0lwbUdhVHRadGhtSWdZcERxUFVKRDA1RktYRWlBNVExUmZhMjJLcDc2NjU3Ym5VWUswdDFCaG01NVdyQ0Qzc2hWWGxlSmw1dFk4?oc=5,Google News,Biocon manufacturing compliance,regulatory,2025-06-27T05:41:50.143077,0.0,0.25,0.4,0.0,0.0,0.15,-0.69674335947392,0.46290138327280683,0.0,0.69674335947392,0.30325664052608003,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.59023007842176
2023-07-06,2023-07-06 07:00:00,Biocon Biologics expands its footprint in Emerging Markets; takes over commercialization of Biosimilars Business from Viatris - financialexpress.com,"<a href=""https://news.google.com/rss/articles/CBMilAJBVV95cUxPY3NiXzNDbWVTSkxFaGVnVzFKNHN6RFV0eDlmWWttRW4xT0tUU0ZZM3VxODVKNnJuemRtUkxvWEluYVd2QUZDN084Wmd2NW5YSHJhai1qd1U0Si1pNW9QU0FfN2Q1RFg1Z2hJSFJpX1g2b3dVbjJBTDRYd3hQSVpReklkSmt6WnZhVmw2dTJkbzZNMFJtM1k3WWFMTm96bzBMRUo5b3lzSHJvSkMweHFNX01MeVhPSlBWV1NLekRfcHkybV9CR2luS3FjWDhLY3pGWlQ1MlczM0dvRFRZbDRGSUtaTGF3d3FqekMzSm1TYlRraXF3RGhzbWVhT0lRY1JjZHJaanlwa3NuNkJJeEYwVENyN3c?oc=5"" target=""_blank"">Biocon Biologics expands its footprint in Emerging Markets; takes over commercialization of Biosimilars Business from Viatris</a>&nbsp;&nbsp;<font color=""#6f6f6f"">financialexpress.com</font>",https://news.google.com/rss/articles/CBMilAJBVV95cUxPY3NiXzNDbWVTSkxFaGVnVzFKNHN6RFV0eDlmWWttRW4xT0tUU0ZZM3VxODVKNnJuemRtUkxvWEluYVd2QUZDN084Wmd2NW5YSHJhai1qd1U0Si1pNW9QU0FfN2Q1RFg1Z2hJSFJpX1g2b3dVbjJBTDRYd3hQSVpReklkSmt6WnZhVmw2dTJkbzZNMFJtM1k3WWFMTm96bzBMRUo5b3lzSHJvSkMweHFNX01MeVhPSlBWV1NLekRfcHkybV9CR2luS3FjWDhLY3pGWlQ1MlczM0dvRFRZbDRGSUtaTGF3d3FqekMzSm1TYlRraXF3RGhzbWVhT0lRY1JjZHJaanlwa3NuNkJJeEYwVENyN3c?oc=5,Google News,Biocon US expansion,strategic,2025-06-27T05:42:12.838377,0.0,0.5,0.2,0.0,0.0,0.15,0.6938185217114077,0.3393388350168864,0.6938185217114077,0.0,0.3061814782885923,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.581455565134223
2023-11-30,2023-11-30 08:00:00,Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMi-wFBVV95cUxPMVczdGtVNV93TDlNQXd6cG14a2FRX3Z2M0ZsVzA1bzVraEcyMFNPV3k3SktsSGdFcHhSMVJiTkRiS3FLempiWVQ4Nk9PeEZyX0dDVVNYbHRQMWpBMTZTdG5HNGRxdWZzUDlWbm5wYmpBc0ZDcmxCamhJRkEwVG1IUEZZZlpQRnNnaVBQWlhReGVVTGFpdU1xUTdObVBNLXIyUVh5UFJQSUgyUmItd1VlSjRKUHgzSzloYU5uMGtoVEhWZjFmUmUxS3lSbDFwT3NER09fQlZmeHVnY2Rrdy01VEFFZ2RPeDRzdlZQT1pBRDJJejJzSmU4TVJRdw?oc=5"" target=""_blank"">Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi-wFBVV95cUxPMVczdGtVNV93TDlNQXd6cG14a2FRX3Z2M0ZsVzA1bzVraEcyMFNPV3k3SktsSGdFcHhSMVJiTkRiS3FLempiWVQ4Nk9PeEZyX0dDVVNYbHRQMWpBMTZTdG5HNGRxdWZzUDlWbm5wYmpBc0ZDcmxCamhJRkEwVG1IUEZZZlpQRnNnaVBQWlhReGVVTGFpdU1xUTdObVBNLXIyUVh5UFJQSUgyUmItd1VlSjRKUHgzSzloYU5uMGtoVEhWZjFmUmUxS3lSbDFwT3NER09fQlZmeHVnY2Rrdy01VEFFZ2RPeDRzdlZQT1pBRDJJejJzSmU4TVJRdw?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.349295,0.0,0.5,0.2,0.0,0.0,0.15,0.6922576933479931,0.6705430612881979,0.6922576933479931,0.0,0.30774230665200686,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.5767730800439796
2025-01-02,2025-01-02 08:00:00,Biocon arm Biocon Pharma receives approval for Tacrolimus capsules in China - CNBC TV18,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon arm Biocon Pharma receives approval for Tacrolimus capsules in China</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.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?oc=5,Google News,Biocon regulatory filing,regulatory,2025-06-27T05:41:53.451329,0.0,0.5,0.2,0.0,0.0,0.15,0.3482671578703519,0.5172006583531698,0.3482671578703519,0.0,0.6517328421296481,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.544801473611056
2025-01-13,2025-01-13 08:00:00,Biocon Share Price Surges Following Positive USFDA Classification - theafricalogistics.com,"<a href=""https://news.google.com/rss/articles/CBMingFBVV95cUxQT0djZkxkcXVaQXJTZ01UTmZ6QzVkQ3ZRX0dyb2liQ1l5ekdYemlQdE9WOEhJMXBNOGZmU1VCQnJ0RkNhdi03a0Z6SVIxVVdnUXBWdC1neFMyeHk3THhaVmJvLUpxdkRMcVh6bnZIYm0wN0RkVEpxWDN2bEtiVjREaVV2S0lpSWsyajY5TWZ0T0paaURKRjZ6cmZTYVJVQQ?oc=5"" target=""_blank"">Biocon Share Price Surges Following Positive USFDA Classification</a>&nbsp;&nbsp;<font color=""#6f6f6f"">theafricalogistics.com</font>",https://news.google.com/rss/articles/CBMingFBVV95cUxQT0djZkxkcXVaQXJTZ01UTmZ6QzVkQ3ZRX0dyb2liQ1l5ekdYemlQdE9WOEhJMXBNOGZmU1VCQnJ0RkNhdi03a0Z6SVIxVVdnUXBWdC1neFMyeHk3THhaVmJvLUpxdkRMcVh6bnZIYm0wN0RkVEpxWDN2bEtiVjREaVV2S0lpSWsyajY5TWZ0T0paaURKRjZ6cmZTYVJVQQ?oc=5,Google News,Biocon stock price reaction,financial,2025-06-27T05:41:44.925469,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.4251386346430639,0.6289285403598438,0.4251386346430639,0.0,0.5748613653569361,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.5254159039291917
2023-11-30,2023-11-30 08:00:00,Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe - GlobeNewswire,"<a href=""https://news.google.com/rss/articles/CBMijAJBVV95cUxPbzlwdUdBTU5Ddml3eDJXc3Vad0Q2RkRiWmEtaXBKanlWSmozekxEX1VzUGMyZTZkWThCV3MyRGQ2QktablZpcS1pQkFNYnNaQlhiYVpFX1hfZFFWRlRqVU00OHVST3puMTNZMVc2MmRUU2ZSVC1LYzJHSk1CZWN2NUtuWG10Y1ZjVVBJTVBrdUtsVzE0cEFZaVVPaWVMd015QUxXenVnOEVHWDRZNndOOXlnNHoxM19oU1ZvcUN5cmNZSFZWY3pvMWotY2R3SU1RSGFpTE9zNXFrNnVwbkNkN1liaDF1YTRqcktPOUtTdV9FLVNMQUF6Qk9WaFF4RFc5ajJfNzJFcHRVTjhC?oc=5"" target=""_blank"">Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe</a>&nbsp;&nbsp;<font color=""#6f6f6f"">GlobeNewswire</font>",https://news.google.com/rss/articles/CBMijAJBVV95cUxPbzlwdUdBTU5Ddml3eDJXc3Vad0Q2RkRiWmEtaXBKanlWSmozekxEX1VzUGMyZTZkWThCV3MyRGQ2QktablZpcS1pQkFNYnNaQlhiYVpFX1hfZFFWRlRqVU00OHVST3puMTNZMVc2MmRUU2ZSVC1LYzJHSk1CZWN2NUtuWG10Y1ZjVVBJTVBrdUtsVzE0cEFZaVVPaWVMd015QUxXenVnOEVHWDRZNndOOXlnNHoxM19oU1ZvcUN5cmNZSFZWY3pvMWotY2R3SU1RSGFpTE9zNXFrNnVwbkNkN1liaDF1YTRqcktPOUtTdV9FLVNMQUF6Qk9WaFF4RFc5ajJfNzJFcHRVTjhC?oc=5,Google News,Biocon pipeline updates,strategic,2025-06-27T05:42:07.945284,0.0,0.5,0.2,0.0,0.0,0.15,0.6672316381352832,0.6493333842277527,0.6672316381352832,0.0,0.3327683618647168,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.5016949144058493
2023-11-14,2023-11-14 08:00:00,Medicines and Healthcare products Regulatory Agency (MHRA) issues UK marketing approval for Biocon Biologics biosimilar aflibercept (YESAFILI) - Ophthalmology Times,"<a href=""https://news.google.com/rss/articles/CBMiiwJBVV95cUxOVzlPRXlnYkRPWnM2QURUcFQ5UjVqcEEyUXN5UnRTQXRDWldTeGxBTFdRN2puZ2ZhbUZYVnhrVHdqMGo4dUdfMnVMZ2tPQnlOZkpJMkhaODNyTDR6aE5qWkxkMHdiZmplVjFfendUdm54QW15N1hxV2xLd1p3cWFFY3BkcWRrd25IMFQ3SUZLT0Q2ZGpJakljVlZMblRSR0dDaFRYeGUzTFhuaE4zcWh0VDVROU1PY1dybUZvUDAtdUZuanZXUnAtWTlpTDhTdXZfdnR2SFhnNGt6RzdUVEVqaVhseTdKckZHa29BaklXVy1MYmpsSG1acDU4QmwwRnMtMEhWYVZZMGd6bEU?oc=5"" target=""_blank"">Medicines and Healthcare products Regulatory Agency (MHRA) issues UK marketing approval for Biocon Biologics biosimilar aflibercept (YESAFILI)</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Ophthalmology Times</font>",https://news.google.com/rss/articles/CBMiiwJBVV95cUxOVzlPRXlnYkRPWnM2QURUcFQ5UjVqcEEyUXN5UnRTQXRDWldTeGxBTFdRN2puZ2ZhbUZYVnhrVHdqMGo4dUdfMnVMZ2tPQnlOZkpJMkhaODNyTDR6aE5qWkxkMHdiZmplVjFfendUdm54QW15N1hxV2xLd1p3cWFFY3BkcWRrd25IMFQ3SUZLT0Q2ZGpJakljVlZMblRSR0dDaFRYeGUzTFhuaE4zcWh0VDVROU1PY1dybUZvUDAtdUZuanZXUnAtWTlpTDhTdXZfdnR2SFhnNGt6RzdUVEVqaVhseTdKckZHa29BaklXVy1MYmpsSG1acDU4QmwwRnMtMEhWYVZZMGd6bEU?oc=5,Google News,Biocon quality issues,regulatory,2025-06-27T05:41:51.799177,0.0,0.5,0.6,0.0,0.0,0.25,0.33043161068358756,0.5451173480669658,0.33043161068358756,0.0,0.6695683893164124,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.4912948320507624
2021-07-29,2021-07-29 07:00:00,"FDA approves insulin glargine biosimilar injection from Viatris, Biocon Biologics - Drug Delivery Business","<a href=""https://news.google.com/rss/articles/CBMiugFBVV95cUxQS1RCclJpTVRmdUJNWUFybFlRbndWY1g3RTJPd0htSGZrYlpacHRTZGNJS1RlY01iaEN2am5SaXZoalZZM0l5aGlwQWRxSUNxX3lEb2hjQlhFZXB5Z20xMlRJZDhDMWkyT3JNR2pYTzVPUUtyU0VpRnNtV3dOWEJ0bTRTcWFzN3BfOVZNNVVuWTB2Ykt3YzNjOWZJdHBtQVhORWg1VG5NTEo0cVRaR0Z3SUFZOUV0WjcyVnc?oc=5"" target=""_blank"">FDA approves insulin glargine biosimilar injection from Viatris, Biocon Biologics</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Drug Delivery Business</font>",https://news.google.com/rss/articles/CBMiugFBVV95cUxQS1RCclJpTVRmdUJNWUFybFlRbndWY1g3RTJPd0htSGZrYlpacHRTZGNJS1RlY01iaEN2am5SaXZoalZZM0l5aGlwQWRxSUNxX3lEb2hjQlhFZXB5Z20xMlRJZDhDMWkyT3JNR2pYTzVPUUtyU0VpRnNtV3dOWEJ0bTRTcWFzN3BfOVZNNVVuWTB2Ykt3YzNjOWZJdHBtQVhORWg1VG5NTEo0cVRaR0Z3SUFZOUV0WjcyVnc?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413393,0.2,0.5,0.4,0.0,0.0,0.26,0.28581870459660125,0.5075526117324829,0.28581870459660125,0.0,0.7141812954033988,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.457456113789804
2025-02-24,2025-02-24 08:00:00,Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMi5AFBVV95cUxPVVAwQXhELXZfWVVDdGhjRVh1U3lIMDIzVHlxYUl3RXA2azlGX3VDRUo4Znc1X1BITzV4MHZwLXRBQXNfTTdKQTJXd05jSGEwZHpvZVFJYjVlMjU0bE8xY1pXWG5vYTU5NGxpeUhoeXJRSi1uTFRTaDBNQkR5WW9jY2U2cHA5enlJMDZxc3RlWVVKRUwzNXJzYVQwVC1NVm1uMEhFQUIzREc2WkdPOFp6MkhwVk5EaDl0ME9POG9SUTdmUFhJN0xEQURsWjhVbmJPSWJKZkxpV204TEZwUlEyLUQ3bDg?oc=5"" target=""_blank"">Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi5AFBVV95cUxPVVAwQXhELXZfWVVDdGhjRVh1U3lIMDIzVHlxYUl3RXA2azlGX3VDRUo4Znc1X1BITzV4MHZwLXRBQXNfTTdKQTJXd05jSGEwZHpvZVFJYjVlMjU0bE8xY1pXWG5vYTU5NGxpeUhoeXJRSi1uTFRTaDBNQkR5WW9jY2U2cHA5enlJMDZxc3RlWVVKRUwzNXJzYVQwVC1NVm1uMEhFQUIzREc2WkdPOFp6MkhwVk5EaDl0ME9POG9SUTdmUFhJN0xEQURsWjhVbmJPSWJKZkxpV204TEZwUlEyLUQ3bDg?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.633552,0.0,0.5,0.2,0.0,0.0,0.15,0.291979225456456,0.5291342666308085,0.291979225456456,0.0,0.7080207745435441,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.375937676369368
2024-12-02,2024-12-02 08:00:00,"USFDA approves Biocon Biologics Yesintek for Crohn's disease, Ulcerative Colitis, Plaque Psoriasis,... - Medical Dialogues","<a href=""https://news.google.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?oc=5"" target=""_blank"">USFDA approves Biocon Biologics Yesintek for Crohn's disease, Ulcerative Colitis, Plaque Psoriasis,...</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Medical Dialogues</font>",https://news.google.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?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.382649,0.0,0.5,0.2,0.0,0.0,0.15,0.28592543713016133,0.5073631484349569,0.28592543713016133,0.0,0.7140745628698386,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.357776311390484
2024-12-02,2024-12-02 08:00:00,FDA approves Biocon biosimilar Yesintek - The Pharma Letter,"<a href=""https://news.google.com/rss/articles/CBMie0FVX3lxTE5PWjk2aFNwbncyWHJMdHc2cmw5bkUyY0kyNXRGLW9fdkRLODJqUGl3Z1ptQmRmWlFKdTR6Y1ZLUmlMa0dVb0NtRGl5UjI4UUdsc3YzSGlROGxaMFRhZEpPLU5MX1VmVi1ZMks4bE1XS0pWaUE3UlJjQmFCdw?oc=5"" target=""_blank"">FDA approves Biocon biosimilar Yesintek</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Pharma Letter</font>",https://news.google.com/rss/articles/CBMie0FVX3lxTE5PWjk2aFNwbncyWHJMdHc2cmw5bkUyY0kyNXRGLW9fdkRLODJqUGl3Z1ptQmRmWlFKdTR6Y1ZLUmlMa0dVb0NtRGl5UjI4UUdsc3YzSGlROGxaMFRhZEpPLU5MX1VmVi1ZMks4bE1XS0pWaUE3UlJjQmFCdw?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.380947,0.0,0.25,0.4,0.0,0.0,0.15,0.2756813814176148,0.5262162763913473,0.2756813814176148,0.0,0.7243186185823852,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.3270441442528442
2024-05-21,2024-05-21 07:00:00,USFDA approves Biocon Biologics' biosimilar product to treat ophthalmology conditions - The Economic Times,"<a href=""https://news.google.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?oc=5"" target=""_blank"">USFDA approves Biocon Biologics' biosimilar product to treat ophthalmology conditions</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Economic Times</font>",https://news.google.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?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.381607,0.0,0.5,0.4,0.0,0.0,0.2,0.4063460531403358,0.6339136981116401,0.4063460531403358,0.0,0.5936539468596642,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.2190381594210074
2025-02-18,2025-02-18 08:00:00,U.S. FDA approves Merilog insulin biosimilar to address supply shortages - CHOSUNBIZ - Chosun Biz,"<a href=""https://news.google.com/rss/articles/CBMigAFBVV95cUxQYUV1dW1PVVdFYU5iRmk0MFduUFhRVXlfM3A4RGN3YTFhSjZnR3E5YTJaNnJmRW9meEpxTUZxSTFfMjZ5ZUVKMDk4WTFpbUJHS0ZpeGRYRUtRWGdKY2xWQWJxRERNU052OWMwbHJRTkNDZy1HeHNWTnpyZmF5ano3RNIBlAFBVV95cUxPbHg1SDNGQXBzS0dXSVFhYnJ4QTA1Yy1XdDQxOVB2UjFaWGk1R01KblNlTFBBVkxEbXpLaG5HckZXNWdMODNXeDBIbjFlc1UyWC1rbzVhdFdYVTFtdmdsVG40WkkxWnptREJ6SW9wbDFmU2VYemo4NWw0U1N1dnh4NWl2QjdfTDFXbXBzY0NTMEhibnBk?oc=5"" target=""_blank"">U.S. FDA approves Merilog insulin biosimilar to address supply shortages - CHOSUNBIZ</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Chosun Biz</font>",https://news.google.com/rss/articles/CBMigAFBVV95cUxQYUV1dW1PVVdFYU5iRmk0MFduUFhRVXlfM3A4RGN3YTFhSjZnR3E5YTJaNnJmRW9meEpxTUZxSTFfMjZ5ZUVKMDk4WTFpbUJHS0ZpeGRYRUtRWGdKY2xWQWJxRERNU052OWMwbHJRTkNDZy1HeHNWTnpyZmF5ano3RNIBlAFBVV95cUxPbHg1SDNGQXBzS0dXSVFhYnJ4QTA1Yy1XdDQxOVB2UjFaWGk1R01KblNlTFBBVkxEbXpLaG5HckZXNWdMODNXeDBIbjFlc1UyWC1rbzVhdFdYVTFtdmdsVG40WkkxWnptREJ6SW9wbDFmU2VYemo4NWw0U1N1dnh4NWl2QjdfTDFXbXBzY0NTMEhibnBk?oc=5,Google News,biosimilar insulin pricing,competitive,2025-06-27T05:41:30.482803,0.2,0.0,0.4,0.0,0.0,0.16,0.18613824147540933,0.43683878545761107,0.18613824147540933,0.0,0.8138617585245906,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.158414724426228
2023-01-12,2023-01-12 08:00:00,"FDA rejects Biocon insulin biosimilar over data, manufacturing concerns - Fierce Pharma","<a href=""https://news.google.com/rss/articles/CBMingFBVV95cUxONmphTnpGZUFmQkphZmdhLTIzaTNlNTZVRUhndTlfbnM2OU9Ta3ZXMGFoMVY2UGRVV0VoODFvSHVhLXJOaDBGMUtpLTVsOUh6c1pOMlZwVW1XcUlxVUZKSC05c3BPQzV3a2F1cl94SVZUb0VTdUxFcjczV1ZGbld4am5TVkVvVEhaanktSU5TLUZzZ1F2NmsxQ19VRk1Ldw?oc=5"" target=""_blank"">FDA rejects Biocon insulin biosimilar over data, manufacturing concerns</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMingFBVV95cUxONmphTnpGZUFmQkphZmdhLTIzaTNlNTZVRUhndTlfbnM2OU9Ta3ZXMGFoMVY2UGRVV0VoODFvSHVhLXJOaDBGMUtpLTVsOUh6c1pOMlZwVW1XcUlxVUZKSC05c3BPQzV3a2F1cl94SVZUb0VTdUxFcjczV1ZGbld4am5TVkVvVEhaanktSU5TLUZzZ1F2NmsxQ19VRk1Ldw?oc=5,Google News,Biocon Semglee approval,drug_fda,2025-06-27T05:41:13.020242,0.2,0.25,0.4,0.0,0.0,0.21000000000000002,-0.3486486578335146,0.5386514927864074,0.0,0.3486486578335146,0.6513513421664854,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.145945973500544
2024-08-29,2024-08-29 07:00:00,"Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan - PR Newswire","<a href=""https://news.google.com/rss/articles/CBMi_wFBVV95cUxPR0hCT1RPc3EzTzc5ZFNycUN1VFlTa3FvR1NvVU9LN3Uya1dqamZjMjNrWDloVnBDSVF6VmFQUmxpS1FQT2d1X1k0TzRsdjVlbkpvQURralVGUU5mcDVlNWdqRjBuWjNwekZ6T3NVY1ZodFZPVVBGdVhkM1B4Vmt6ZTFvVXZ0c3c1OXRHNzdNcnhiSzdKcll1dVRnOFk1TTZSSllfbTlaT1RPY3FSZ0VLelo4X0RaalZ0cFRRUEVJZGZaQmVMZVVfS3Y3QVJNTzJRWU9BWDJmYlZaX2ttZVhQOEtTQTBUOFJVdGVrdnI4Y3plemx6SjVHWWJKR0wyZ0k?oc=5"" target=""_blank"">Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi_wFBVV95cUxPR0hCT1RPc3EzTzc5ZFNycUN1VFlTa3FvR1NvVU9LN3Uya1dqamZjMjNrWDloVnBDSVF6VmFQUmxpS1FQT2d1X1k0TzRsdjVlbkpvQURralVGUU5mcDVlNWdqRjBuWjNwekZ6T3NVY1ZodFZPVVBGdVhkM1B4Vmt6ZTFvVXZ0c3c1OXRHNzdNcnhiSzdKcll1dVRnOFk1TTZSSllfbTlaT1RPY3FSZ0VLelo4X0RaalZ0cFRRUEVJZGZaQmVMZVVfS3Y3QVJNTzJRWU9BWDJmYlZaX2ttZVhQOEtTQTBUOFJVdGVrdnI4Y3plemx6SjVHWWJKR0wyZ0k?oc=5,Google News,Biocon regulatory filing,regulatory,2025-06-27T05:41:53.451607,0.0,0.5,0.2,0.0,0.0,0.15,0.21006180953510445,0.49302117424011227,0.21006180953510445,0.0,0.7899381904648956,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.1301854286053135
2022-11-16,2022-11-16 08:00:00,Biocon Biologics secures regulatory approvals for acquisition of Viatris' biosimilar business - The Economic Times,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics secures regulatory approvals for acquisition of Viatris' biosimilar business</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Economic Times</font>",https://news.google.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?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.349894,0.0,0.5,0.6,0.0,0.0,0.25,0.20678005240555228,0.529503908390469,0.20678005240555228,0.0,0.7932199475944477,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.1203401572166567
2023-09-06,2023-09-06 07:00:00,"Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule - PR Newswire","<a href=""https://news.google.com/rss/articles/CBMipAJBVV95cUxONkplbm56SHNtcElRSWN3cnpqMWo0MnZTc2dBcDcxSV9iNlFIZFFCbjV5dm42Sjd2cDVSclFvNHpJNTRMU3o0Wm1uYVFpV2VQZDN6SWtrTkpjcnpma0FSR1ByaXZHcVllM0VOdlF0RXhYSTBFSFd6VGUwaVlkQUduRkNuSUtDQ0RsbGdSUTBwelpoYTdwVGV6d1dob2NxWmRJMjYwZXJVVWZObTFHRzZKNWhZX0h2VFZZclJ5Yk14VndFZVRqSF9OWGdJaUNvYkZqS1hsNTVUbFVVVVBGWTgxMHNrclhDeC1fQlF4V3pwQ09JR0pVLWNlYV95dlAtU2V4ajl6M09ZRGxMMnFUYUozVHNSeVVwQXJFRzd6b0ZhRG1GWFg3?oc=5"" target=""_blank"">Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMipAJBVV95cUxONkplbm56SHNtcElRSWN3cnpqMWo0MnZTc2dBcDcxSV9iNlFIZFFCbjV5dm42Sjd2cDVSclFvNHpJNTRMU3o0Wm1uYVFpV2VQZDN6SWtrTkpjcnpma0FSR1ByaXZHcVllM0VOdlF0RXhYSTBFSFd6VGUwaVlkQUduRkNuSUtDQ0RsbGdSUTBwelpoYTdwVGV6d1dob2NxWmRJMjYwZXJVVWZObTFHRzZKNWhZX0h2VFZZclJ5Yk14VndFZVRqSF9OWGdJaUNvYkZqS1hsNTVUbFVVVVBGWTgxMHNrclhDeC1fQlF4V3pwQ09JR0pVLWNlYV95dlAtU2V4ajl6M09ZRGxMMnFUYUozVHNSeVVwQXJFRzd6b0ZhRG1GWFg3?oc=5,Google News,Biocon US expansion,strategic,2025-06-27T05:42:12.837470,0.0,0.5,0.2,0.0,0.0,0.15,0.5311597525793548,0.35314170913696286,0.5311597525793548,0.0,0.46884024742064523,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.093479257738064
2025-01-12,2025-01-12 08:00:00,Biocon shares jump 4% as USFDA classifies Biocon Biologics site in Malaysia as voluntary action indicated; all you need to know - Upstox,"<a href=""https://news.google.com/rss/articles/CBMilAJBVV95cUxOWkdvaVNRTTNvcEwybG4zMlplQjBkV2cxOEdMdWhkcWppOHo0cGlWeDJTZEdOUV9Tcm96ZUNLT2dQb2h1U1FWdDJsSHdyOEJ6eVVHalFodVBaaE16MERnUjdxWV9KejhjZ19pV3ltVGJVZGRJV1h6QzdMUEdIVVd1RHJrSlRZQTRDRlJqSkE3ZDRkaVdRc3RndkktQ05VTk9RYjZhSWhGaWtvWmJzY0JuaHZ3OHRRcmVBYzBPbF9OcFpSeE1uY2w5Y09wWnVpQllkODlkNWxxT1RqV3ZIeVBvMGp4YkdBVWZOQmVFci00ZFZ2YkFnUU01MHdlOUQzVFBEN2x2T1pqUDJ0V3licEIyMk93bTM?oc=5"" target=""_blank"">Biocon shares jump 4% as USFDA classifies Biocon Biologics site in Malaysia as voluntary action indicated; all you need to know</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Upstox</font>",https://news.google.com/rss/articles/CBMilAJBVV95cUxOWkdvaVNRTTNvcEwybG4zMlplQjBkV2cxOEdMdWhkcWppOHo0cGlWeDJTZEdOUV9Tcm96ZUNLT2dQb2h1U1FWdDJsSHdyOEJ6eVVHalFodVBaaE16MERnUjdxWV9KejhjZ19pV3ltVGJVZGRJV1h6QzdMUEdIVVd1RHJrSlRZQTRDRlJqSkE3ZDRkaVdRc3RndkktQ05VTk9RYjZhSWhGaWtvWmJzY0JuaHZ3OHRRcmVBYzBPbF9OcFpSeE1uY2w5Y09wWnVpQllkODlkNWxxT1RqV3ZIeVBvMGp4YkdBVWZOQmVFci00ZFZ2YkFnUU01MHdlOUQzVFBEN2x2T1pqUDJ0V3licEIyMk93bTM?oc=5,Google News,Biocon insulin market share,competitive,2025-06-27T05:41:26.942163,0.0,0.5,0.2,0.0,0.0,0.15,0.19740945551487782,0.47592677143944634,0.19740945551487782,0.0,0.8025905444851222,0,0,0,4.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.0922283665446333
2024-08-05,2024-08-05 07:00:00,Biocon gets US FDA report after Vizag facility scan; no more regulatory action needed - CNBC TV18,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon gets US FDA report after Vizag facility scan; no more regulatory action needed</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.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?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.421111,0.0,0.25,0.4,0.0,0.0,0.15,-0.18757968160900382,0.4993662561416626,0.0,0.18757968160900382,0.8124203183909962,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.0627390448270115
2024-06-25,2024-06-25 07:00:00,Biocon Biologics receives approval from EMA to manufacture biosimilar Bevacizumab - BusinessLine,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics receives approval from EMA to manufacture biosimilar Bevacizumab</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BusinessLine</font>",https://news.google.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?oc=5,Google News,Biocon GMP compliance,regulatory,2025-06-27T05:41:59.639188,0.0,0.5,0.4,0.0,0.0,0.2,0.3347580688345991,0.5380721783955892,0.3347580688345991,0.0,0.665241931165401,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.0042742065037973
2025-01-13,2025-01-13 08:00:00,Biocon share price jumps over 4% after US FDA clears Malaysian insulin facility - Mint,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon share price jumps over 4% after US FDA clears Malaysian insulin facility</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Mint</font>",https://news.google.com/rss/articles/CBMi3gFBVV95cUxNNFNtTGxYS2tiZUtvRjJTaTg2WDk4cmcyRWxPM0x5eUwxandFX3h2ZjJ1eFdiV1ozWmd3SnEyNEp6OEQ1ZUNZTS04WGlZVzJiTzdQSmNuUGFVTno2NnQwdUE4dkhnZVJORUVtc20tdVBLVmxJS3JTdGpMamhTNk5NYlY5R3ktd0IxNE1xNGktTWg3QXJOekJZRm1JcjBpWlBnV2ZVWFh3d2xBSHBUYWhVYmRGbVk5M25fZ2ZBb3puMkN0dHExdjFMcjFFM2I1MnAtWTBHeEl3cG16bWVnQmfSAeMBQVVfeXFMTkdHUGhTLVE4SmFnVWNueTFYTmNLLTljQWhxZWJQSWJBMU1JblMteHFCcXpua2xnNTgyUWZ1Z0ZqaURNaWJLWV9fSjVfUHAyVU9mR1NtOU9ldTlCRjNrOXBFcEtNUjdENnI2QWpSOS1HMU42NHNwaG02OEdjeFpLVkRSMG93dEl3NkpkU252TUlPNkY0aGp6b21UTmJBSHg1THFJQUd5cHFFcGdMYXctSkphRjVpQm1GVXYzR3FaQ25VMFV6amF2N29MQXpwUG9IWUpEbzYyT3RDSlhybmxtME15bHc?oc=5,Google News,Biocon insulin market share,competitive,2025-06-27T05:41:26.941345,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.25028641937630475,0.4994727786064148,0.25028641937630475,0.0,0.7497135806236952,0,0,0,4.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.000859258128914
2025-02-24,2025-02-24 08:00:00,Biocon Biologics launches Stelara biosimilar YESINTEK in US for autoimmune diseases - CNBC TV18,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics launches Stelara biosimilar YESINTEK in US for autoimmune diseases</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.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?oc=5,Google News,Biocon US market revenue,financial,2025-06-27T05:41:41.753391,0.0,0.5,0.4,0.0,0.0,0.2,0.0,0.30874993403752643,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,3.0
2021-07-30,2021-07-30 07:00:00,"Semglee, first-of-its-kind insulin product made by India’s Biocon, gets US approval - ThePrint","<a href=""https://news.google.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?oc=5"" target=""_blank"">Semglee, first-of-its-kind insulin product made by India’s Biocon, gets US approval</a>&nbsp;&nbsp;<font color=""#6f6f6f"">ThePrint</font>",https://news.google.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?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413724,0.2,0.25,0.2,0.0,0.0,0.16,0.45155675788764166,0.7082357815424601,0.45155675788764166,0.0,0.5484432421123584,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.9546702736629253
2024-06-24,2024-06-24 07:00:00,Biocon Biologics Receives EMA Approval for New Biosimilar Facility - newskarnataka.com,"<a href=""https://news.google.com/rss/articles/CBMirwFBVV95cUxOVkg4Z2c3bWp6N2pCTzVxMlBUXzNHTkIwNjgzRmZHazhsdExKNV9sYjQ5Q3NJWm5KbXpBMUk5MHRUbWlSZUxWOEc5Um1ETzZLMTBLWk9ZXzI4MUU1aDVuV2pxTnBfR3V5M01BUlJreFVpVjRxdkllY1FIcldSQ2ZvanNnVm1yQ1Rzb1gzZm9LTUFSa3hwNEw3YUh2dno5WUJBcVByc3hSc1dmbGRRMTV3?oc=5"" target=""_blank"">Biocon Biologics Receives EMA Approval for New Biosimilar Facility</a>&nbsp;&nbsp;<font color=""#6f6f6f"">newskarnataka.com</font>",https://news.google.com/rss/articles/CBMirwFBVV95cUxOVkg4Z2c3bWp6N2pCTzVxMlBUXzNHTkIwNjgzRmZHazhsdExKNV9sYjQ5Q3NJWm5KbXpBMUk5MHRUbWlSZUxWOEc5Um1ETzZLMTBLWk9ZXzI4MUU1aDVuV2pxTnBfR3V5M01BUlJreFVpVjRxdkllY1FIcldSQ2ZvanNnVm1yQ1Rzb1gzZm9LTUFSa3hwNEw3YUh2dno5WUJBcVByc3hSc1dmbGRRMTV3?oc=5,Google News,Biocon manufacturing compliance,regulatory,2025-06-27T05:41:50.144260,0.0,0.5,0.4,0.0,0.0,0.2,0.3179573663381975,0.575167754017223,0.3179573663381975,0.0,0.6820426336618025,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.9538720990145926
2024-07-02,2024-07-02 07:00:00,"FDA grants approvals to Stelara, Neupogen, Eylea biosimilars - BioWorld MedTech","<a href=""https://news.google.com/rss/articles/CBMioAFBVV95cUxQeEQzQXQ0YnZuSWRVclJyWjFOVG1DMVdvVDdFbUtwWWd4dDI1VVJYbWpIeW9LX01BZFdWVzM4WVlmX09YOU1pb0ExVDFBVjExVnp2bXU3OXlsNzl3V2xVUjlIdDlQVEJMSExDd2p2R2JnQndwVHVGSGh1MVdraWhTcTZVZEFCZVhIRUlTaU54cnNlbUVNVlVOMVlqNGZ5UTQ4?oc=5"" target=""_blank"">FDA grants approvals to Stelara, Neupogen, Eylea biosimilars</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BioWorld MedTech</font>",https://news.google.com/rss/articles/CBMioAFBVV95cUxQeEQzQXQ0YnZuSWRVclJyWjFOVG1DMVdvVDdFbUtwWWd4dDI1VVJYbWpIeW9LX01BZFdWVzM4WVlmX09YOU1pb0ExVDFBVjExVnp2bXU3OXlsNzl3V2xVUjlIdDlQVEJMSExDd2p2R2JnQndwVHVGSGh1MVdraWhTcTZVZEFCZVhIRUlTaU54cnNlbUVNVlVOMVlqNGZ5UTQ4?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.635806,0.0,0.0,0.6,0.0,0.0,0.15,0.14659983743639302,0.4039619077046712,0.14659983743639302,0.0,0.853400162563607,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.939799512309179
2024-12-05,2024-12-05 08:00:00,"Growth Trends in the Insulin Biosimilar Market, Forecast to 2034 - GlobeNewswire","<a href=""https://news.google.com/rss/articles/CBMi1gFBVV95cUxOTVlPYjZxMnd4Y2w5TW1POGJVZ2dFWXpDek5kSkJwdHpUMXZUemc2Yk83c3Z2S1JzU3dUeU9RcTA2R1JNVFFRbWFyN3RBY2F3X0RaellfaDl1TTZYeC1BVzJTbmMzNUlmakxnbXB0UkozQzg5ZXhOemFIdTNXVnNaSVlCemttS292RmhrVGNrbkZ3cGpWT3JGaVpld3dwdmt4WlNYY3VlbzNsdVc3bmF4SzZBc1dZRDlyYloxd3lubVUza2FoVWNrN29zRWJQd1plQ2NSVklR?oc=5"" target=""_blank"">Growth Trends in the Insulin Biosimilar Market, Forecast to 2034</a>&nbsp;&nbsp;<font color=""#6f6f6f"">GlobeNewswire</font>",https://news.google.com/rss/articles/CBMi1gFBVV95cUxOTVlPYjZxMnd4Y2w5TW1POGJVZ2dFWXpDek5kSkJwdHpUMXZUemc2Yk83c3Z2S1JzU3dUeU9RcTA2R1JNVFFRbWFyN3RBY2F3X0RaellfaDl1TTZYeC1BVzJTbmMzNUlmakxnbXB0UkozQzg5ZXhOemFIdTNXVnNaSVlCemttS292RmhrVGNrbkZ3cGpWT3JGaVpld3dwdmt4WlNYY3VlbzNsdVc3bmF4SzZBc1dZRDlyYloxd3lubVUza2FoVWNrN29zRWJQd1plQ2NSVklR?oc=5,Google News,Biocon insulin market share,competitive,2025-06-27T05:41:26.941507,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.25950503551390786,0.5210452650070191,0.25950503551390786,0.0,0.7404949644860921,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.8785151065417236
2023-07-03,2023-07-03 07:00:00,"After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States - Biocon","<a href=""https://news.google.com/rss/articles/CBMi8gFBVV95cUxQNGlnUTZrU1BKeFdPT2xhblFnRkhReFlMT2Iwai16S3h3ZDN1QVRmU1Z0bjhzZ1BJa1ZkWkVxd2p0c0RtSVlaQkc5UC1uTGo5UENnZXVIeDczbDZ4VC1EbFZSOGtVVHY2c3NSOGtBOHZmb29va01rVTZlbFlWamZpTFJWbjF1U1dEMlVUNFloOWxXSWRmdlozUFRuT3lGcHlMcmtIX2pHUUFRWlNUYnNGV21lRDJmRnJxN2lUNExnSUE2RUFnWmNjRTVTTFVXSU1nOGFoZ2pmYjRwN0IzOGJsNUV1U016NUlGX0VtTURNcVV2Zw?oc=5"" target=""_blank"">After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Biocon</font>",https://news.google.com/rss/articles/CBMi8gFBVV95cUxQNGlnUTZrU1BKeFdPT2xhblFnRkhReFlMT2Iwai16S3h3ZDN1QVRmU1Z0bjhzZ1BJa1ZkWkVxd2p0c0RtSVlaQkc5UC1uTGo5UENnZXVIeDczbDZ4VC1EbFZSOGtVVHY2c3NSOGtBOHZmb29va01rVTZlbFlWamZpTFJWbjF1U1dEMlVUNFloOWxXSWRmdlozUFRuT3lGcHlMcmtIX2pHUUFRWlNUYnNGV21lRDJmRnJxN2lUNExnSUE2RUFnWmNjRTVTTFVXSU1nOGFoZ2pmYjRwN0IzOGJsNUV1U016NUlGX0VtTURNcVV2Zw?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.349554,0.0,0.5,0.2,0.0,0.0,0.15,0.4450300379943684,0.7171726190203712,0.4450300379943684,0.0,0.5549699620056316,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.8350901139831053
2025-01-13,2025-01-13 08:00:00,"Biocon stock soars 4% after USFDA clears Malaysia unit, ends regulatory hurdles - Moneycontrol","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon stock soars 4% after USFDA clears Malaysia unit, ends regulatory hurdles</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Moneycontrol</font>",https://news.google.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?oc=5,Google News,Biocon analyst upgrade,financial,2025-06-27T05:41:46.697213,0.0,0.25,0.4,0.16666666666666666,0.0,0.175,0.021837851764869798,0.35778259773254395,0.021837851764869798,0.0,0.9781621482351301,0,0,0,4.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.8155135552946096
2024-06-24,2024-06-24 07:00:00,Biocon Biologics gets EMA nod to manufacture biosimilar Bevacizumab used in cancer treatment - CNBC TV18,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics gets EMA nod to manufacture biosimilar Bevacizumab used in cancer treatment</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.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?oc=5,Google News,Biocon manufacturing compliance,regulatory,2025-06-27T05:41:50.143431,0.0,0.5,0.2,0.0,0.0,0.15,-0.43193702545328794,0.5826367931048075,0.0,0.43193702545328794,0.5680629745467121,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.795811076359864
2021-02-04,2021-02-04 08:00:00,Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries - Biocon,"<a href=""https://news.google.com/rss/articles/CBMiyAFBVV95cUxPLTRGUGdEcmZ0akRsLXE0a0ZSSmd5S19oQW9pUS1zUy1rNWFzdFRMTE9JNjZiT0l2TUdHb0F4WFBPS1dTdnY1ZjhyWUFJN29TQ1MzSnlwVndpTGlhdC12UDk5RmQxRE8tZ0VOWjhiazgxRE5JclJPbVhMVzdEcW1GRnRJcHBlQVpVZU9jdExpc0VhNjdVejd1VEhtNUs3dzNSRHpBT1hFUEtEaWVVOW05emFjMlFNcTVDT1NZZ09kQjFOM3JCVmhzVw?oc=5"" target=""_blank"">Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Biocon</font>",https://news.google.com/rss/articles/CBMiyAFBVV95cUxPLTRGUGdEcmZ0akRsLXE0a0ZSSmd5S19oQW9pUS1zUy1rNWFzdFRMTE9JNjZiT0l2TUdHb0F4WFBPS1dTdnY1ZjhyWUFJN29TQ1MzSnlwVndpTGlhdC12UDk5RmQxRE8tZ0VOWjhiazgxRE5JclJPbVhMVzdEcW1GRnRJcHBlQVpVZU9jdExpc0VhNjdVejd1VEhtNUs3dzNSRHpBT1hFUEtEaWVVOW05emFjMlFNcTVDT1NZZ09kQjFOM3JCVmhzVw?oc=5,Google News,Biocon strategic partnership,strategic,2025-06-27T05:42:03.008866,0.0,0.5,0.2,0.0,0.0,0.15,-0.42597586156861245,0.5907902912775675,0.0,0.42597586156861245,0.5740241384313876,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.7779275847058376
2025-02-14,2025-02-14 08:00:00,Biosimilars Fuel Price Cuts in European Insulin Glargine Markets - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTGpvd2U2SkdRUnRwNE9ERGpKQlVBX2d1ck5aY1RNQU5TZlNuLXJkdmtlZGdWV2czQ2lkcHl4VVFtb1d2YzIxWUplVmxUYVRzdkdXX0h2ZGRwWkNmTTR2M0pKZmpuVzcycjVTb1ZOVUdyOVhXaDJoNVh6R1ZaQUZoSDByS0lKazB2RWdjaUpUWnBEZ1ZWemVyT0JFOGxKV29RWWpxbVdYU0xEQQ?oc=5"" target=""_blank"">Biosimilars Fuel Price Cuts in European Insulin Glargine Markets</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTGpvd2U2SkdRUnRwNE9ERGpKQlVBX2d1ck5aY1RNQU5TZlNuLXJkdmtlZGdWV2czQ2lkcHl4VVFtb1d2YzIxWUplVmxUYVRzdkdXX0h2ZGRwWkNmTTR2M0pKZmpuVzcycjVTb1ZOVUdyOVhXaDJoNVh6R1ZaQUZoSDByS0lKazB2RWdjaUpUWnBEZ1ZWemVyT0JFOGxKV29RWWpxbVdYU0xEQQ?oc=5,Google News,Semglee biosimilar approval,drug_fda,2025-06-27T05:41:08.121573,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,-0.22359544715706695,0.4159489732424418,0.0,0.22359544715706695,0.7764045528429331,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.770786341471201
2024-02-09,2024-02-09 08:00:00,Biocon Biologics partners with Sandoz Australia for cancer biosimilars - BioSpectrum Asia,"<a href=""https://news.google.com/rss/articles/CBMivgFBVV95cUxPaE1SWEt2NTZXckhna3JRY2s0NXhhQUg1VkJnVDlFU0tpV1JJczRVMkdoMHNPY0hwMXQtaXFhY0Q4d0ZwcXRzSTkwLUpnS2l1UndueVNPRkZNX2hiakdGdExjMldFalFMcUZYdzNtUjZmZ1pFZjZWamJpaVdiV2FaamwtU2tGUG1zTnYzNkUxTnNWSGxuU1Y4QlU3M0VPUW1xZTlNUklBZFpLQ0U0ZF9NWHVYVWNCaG5QWUt5aEZR?oc=5"" target=""_blank"">Biocon Biologics partners with Sandoz Australia for cancer biosimilars</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BioSpectrum Asia</font>",https://news.google.com/rss/articles/CBMivgFBVV95cUxPaE1SWEt2NTZXckhna3JRY2s0NXhhQUg1VkJnVDlFU0tpV1JJczRVMkdoMHNPY0hwMXQtaXFhY0Q4d0ZwcXRzSTkwLUpnS2l1UndueVNPRkZNX2hiakdGdExjMldFalFMcUZYdzNtUjZmZ1pFZjZWamJpaVdiV2FaamwtU2tGUG1zTnYzNkUxTnNWSGxuU1Y4QlU3M0VPUW1xZTlNUklBZFpLQ0U0ZF9NWHVYVWNCaG5QWUt5aEZR?oc=5,Google News,Biocon strategic partnership,strategic,2025-06-27T05:42:03.008733,0.0,0.5,0.2,0.0,0.0,0.15,-0.4197749746168271,0.599517404683431,0.0,0.4197749746168271,0.5802250253831729,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.7593249238504813
2023-04-28,2023-04-28 07:00:00,Biocon Biologics’ new monoclonal antibodies manufacturing facility receives EU GMP certification for cancer biosimilar - financialexpress.com,"<a href=""https://news.google.com/rss/articles/CBMiiwJBVV95cUxPcTU1ZzNRdnRFaVd6QURBUkgwLVZUYUc0Z1RzbTJuSC1kYUcyd1pkUi1WWXROYV9NWi1JTGFmNDdabXUwTEVhQkRRWWp2eG9VcXhwZWRBSGFMUEtGM19Jd2VaWXZrc1h6S3h1b0w5cmZOZ1ppUkxkeG9HMVV6dTRXV0J0SUNJcmRXUlFlVThKeVJHbTJkQUVEWVFzUFp5YlEzNDF6OUpGQzM5LV9CVFd6Z1N2OWdmMnJ6SG12blZNZDgyMDUySkNqdG9NQUVieUlESV8wQlJna3g4bHZ1WlNwRm91U21HNy04aWNLbEFOaFpSMnVHUEVHa3Zhc1lzV2Y0Wmo0bThBdVE4cHc?oc=5"" target=""_blank"">Biocon Biologics’ new monoclonal antibodies manufacturing facility receives EU GMP certification for cancer biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">financialexpress.com</font>",https://news.google.com/rss/articles/CBMiiwJBVV95cUxPcTU1ZzNRdnRFaVd6QURBUkgwLVZUYUc0Z1RzbTJuSC1kYUcyd1pkUi1WWXROYV9NWi1JTGFmNDdabXUwTEVhQkRRWWp2eG9VcXhwZWRBSGFMUEtGM19Jd2VaWXZrc1h6S3h1b0w5cmZOZ1ppUkxkeG9HMVV6dTRXV0J0SUNJcmRXUlFlVThKeVJHbTJkQUVEWVFzUFp5YlEzNDF6OUpGQzM5LV9CVFd6Z1N2OWdmMnJ6SG12blZNZDgyMDUySkNqdG9NQUVieUlESV8wQlJna3g4bHZ1WlNwRm91U21HNy04aWNLbEFOaFpSMnVHUEVHa3Zhc1lzV2Y0Wmo0bThBdVE4cHc?oc=5,Google News,Biocon manufacturing compliance,regulatory,2025-06-27T05:41:50.143179,0.0,0.5,0.2,0.0,0.0,0.15,-0.40053486309160585,0.621437995373119,0.0,0.40053486309160585,0.5994651369083941,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.7016045892748175
2025-02-17,2025-02-17 08:00:00,Sanofi Leapfrogs Biocon To Land First US Rapid-Acting Insulin Biosimilar - insights.citeline.com,"<a href=""https://news.google.com/rss/articles/CBMi_gFBVV95cUxQVVRWUVRHVjVfYy1pRXNlQ3RrVjAyMWNFM3ZoWkFHYU5rekU2dU1KSmhhTXFkeDZVTlZZVWZhdnNPQ19hZWhfNTBES1pZaGt3cXZlMThJNWo2X2RhX0YxY3B4VVdjV256Y1NwaWRpcjROdkV5cERWTEpkUVMwQjlWYkw3Z2J4ZU5JMnV4SVd1Q2FyWVE4TG95bWxVamUwUlF4eFNsWU5lSDY5ZjBRS1pWS0F6ZHRlNVdzMldPOTNkN0ZZQmNvQ2x0dlRicXc3Mk1DS24zVVFfcW0wMFBUUU80YzFMYkdWN0ZaMDZReVdSZ2g2NWpZbzQxTk1xMkNnUQ?oc=5"" target=""_blank"">Sanofi Leapfrogs Biocon To Land First US Rapid-Acting Insulin Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">insights.citeline.com</font>",https://news.google.com/rss/articles/CBMi_gFBVV95cUxQVVRWUVRHVjVfYy1pRXNlQ3RrVjAyMWNFM3ZoWkFHYU5rekU2dU1KSmhhTXFkeDZVTlZZVWZhdnNPQ19hZWhfNTBES1pZaGt3cXZlMThJNWo2X2RhX0YxY3B4VVdjV256Y1NwaWRpcjROdkV5cERWTEpkUVMwQjlWYkw3Z2J4ZU5JMnV4SVd1Q2FyWVE4TG95bWxVamUwUlF4eFNsWU5lSDY5ZjBRS1pWS0F6ZHRlNVdzMldPOTNkN0ZZQmNvQ2x0dlRicXc3Mk1DS24zVVFfcW0wMFBUUU80YzFMYkdWN0ZaMDZReVdSZ2g2NWpZbzQxTk1xMkNnUQ?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.382303,0.2,0.25,0.2,0.0,0.0,0.16,0.009974037872652922,0.33420099020004274,0.009974037872652922,0.0,0.9900259621273471,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.629922113617959
2025-02-18,2025-02-18 08:00:00,"FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog - Fierce Pharma","<a href=""https://news.google.com/rss/articles/CBMiqAFBVV95cUxPNnJEU3B0VDBCSWY1SEtJWFVSNzM3QUlmd2RVRExYb0lfTXVmdURVaV9hb08zLWVTZ0VtTWh3ZV9TQzVmeDdaMVcyekFhcEFnVWk3QXdKeHJDa3FhejR6a3dTaWVwdG1tYXFfWlpmaGRBTllWWkhSd1c2eEhheGprUk1fVk9xcmVyWWIxYXJISUpZN2dpWWpKWmhNczNveGVHN0pOMUtmZEs?oc=5"" target=""_blank"">FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMiqAFBVV95cUxPNnJEU3B0VDBCSWY1SEtJWFVSNzM3QUlmd2RVRExYb0lfTXVmdURVaV9hb08zLWVTZ0VtTWh3ZV9TQzVmeDdaMVcyekFhcEFnVWk3QXdKeHJDa3FhejR6a3dTaWVwdG1tYXFfWlpmaGRBTllWWkhSd1c2eEhheGprUk1fVk9xcmVyWWIxYXJISUpZN2dpWWpKWmhNczNveGVHN0pOMUtmZEs?oc=5,Google News,insulin glargine-yfgn FDA,drug_fda,2025-06-27T05:41:11.426700,0.2,0.0,0.4,0.0,0.0,0.16,0.009956082946532495,0.3348036924997966,0.009956082946532495,0.0,0.9900439170534675,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.6298682488395975
2016-01-11,2016-01-11 08:00:00,FDA Approves New Insulin Glargine Basaglar – The First “Biosimilar” Insulin in the US - diaTribe,"<a href=""https://news.google.com/rss/articles/CBMisgFBVV95cUxNcGpGNHlYVEZhNlBtalcxelRrampsWTQzUFdubzZIeTlIQUtvS0R0WDRsZlV3VzNSY1hPeHFyZUlSamc0QXE5eTFucGpRdEg1UkRjRGpKdDE5SUlmZG9TQ2NNZU03N0hnM29WajNrY2lONTk0Q1hVZ2hoNDJtYkY5cFprUDhQRzV4V3NENm1aTUtmdUpvYmQyRUZ2aW1WTHRpOFBocnFKZnFaNFlLOWpDTThR?oc=5"" target=""_blank"">FDA Approves New Insulin Glargine Basaglar – The First “Biosimilar” Insulin in the US</a>&nbsp;&nbsp;<font color=""#6f6f6f"">diaTribe</font>",https://news.google.com/rss/articles/CBMisgFBVV95cUxNcGpGNHlYVEZhNlBtalcxelRrampsWTQzUFdubzZIeTlIQUtvS0R0WDRsZlV3VzNSY1hPeHFyZUlSamc0QXE5eTFucGpRdEg1UkRjRGpKdDE5SUlmZG9TQ2NNZU03N0hnM29WajNrY2lONTk0Q1hVZ2hoNDJtYkY5cFprUDhQRzV4V3NENm1aTUtmdUpvYmQyRUZ2aW1WTHRpOFBocnFKZnFaNFlLOWpDTThR?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.587356,0.2,0.0,0.4,0.0,0.2,0.18,0.27593346138807456,0.5545882755106145,0.27593346138807456,0.0,0.7240665386119254,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.6278003841642237
2023-10-09,2023-10-09 07:00:00,FDA hits Biocon's insulin copycat with a CRL as plant awaits pre-approval inspection - Fierce Pharma,"<a href=""https://news.google.com/rss/articles/CBMitwFBVV95cUxPNmZTQWVscmJKUVNMTmtvei0wVWs3UjBIODNmZGd3ZWhwazdBQ19zdHAwaVFoNzdvWGpaeDloc2tqSzZVVFdJRms2WDg5TW1DTTlDTGZWMWM5WWhkaGRHUjd5alhtOFZsb1FWN0tZdTdBU3RNOC1ESUtIWWFfWml6eTJDWGg3QkZmQjdvSk1OeThSVy05MW9YNGtyLTRyTmFJM0kyWGZKR2tSUGVycDB0SmdOZEVWSGs?oc=5"" target=""_blank"">FDA hits Biocon's insulin copycat with a CRL as plant awaits pre-approval inspection</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMitwFBVV95cUxPNmZTQWVscmJKUVNMTmtvei0wVWs3UjBIODNmZGd3ZWhwazdBQ19zdHAwaVFoNzdvWGpaeDloc2tqSzZVVFdJRms2WDg5TW1DTTlDTGZWMWM5WWhkaGRHUjd5alhtOFZsb1FWN0tZdTdBU3RNOC1ESUtIWWFfWml6eTJDWGg3QkZmQjdvSk1OeThSVy05MW9YNGtyLTRyTmFJM0kyWGZKR2tSUGVycDB0SmdOZEVWSGs?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.380899,0.0,0.25,0.4,0.0,0.0,0.15,0.3563369712966136,0.5666461231867472,0.3563369712966136,0.0,0.6436630287033864,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5690109138898407
2020-09-01,2020-09-01 07:00:00,Semglee: Insulin Glargine “Biosimilar” Approved for Diabetes in the US - Diabetes In Control,"<a href=""https://news.google.com/rss/articles/CBMipAFBVV95cUxOSml6X0d0cjlzclN4UWFKRU9kZlc3c3lSMXBUNG9SR19BVDNmdW41TWxpcHk5RjJad3VpVGlFSnU1YXpXd2Z3VlUtVzZNNGtGbGVLeXE2a09WZjVlZEgyMC1JalJxcFVJQURjQlZxVnh6SEpyWko3aXVlOWtNN2xOeG1TUnlqSjJGTG5OV3dYcnlGUDZwWnlZaURTdUhwdWhXRUlGbA?oc=5"" target=""_blank"">Semglee: Insulin Glargine “Biosimilar” Approved for Diabetes in the US</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Diabetes In Control</font>",https://news.google.com/rss/articles/CBMipAFBVV95cUxOSml6X0d0cjlzclN4UWFKRU9kZlc3c3lSMXBUNG9SR19BVDNmdW41TWxpcHk5RjJad3VpVGlFSnU1YXpXd2Z3VlUtVzZNNGtGbGVLeXE2a09WZjVlZEgyMC1JalJxcFVJQURjQlZxVnh6SEpyWko3aXVlOWtNN2xOeG1TUnlqSjJGTG5OV3dYcnlGUDZwWnlZaURTdUhwdWhXRUlGbA?oc=5,Google News,Semglee biosimilar approval,drug_fda,2025-06-27T05:41:08.121153,0.4,0.0,0.2,0.0,0.0,0.17,0.28944129686004916,0.5337739120483399,0.28944129686004916,0.0,0.7105587031399508,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5683238905801478
2024-12-01,2024-12-01 08:00:00,Biocon Biologics gets US nod to launch Stelara biosimilar - The Economic Times,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics gets US nod to launch Stelara biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Economic Times</font>",https://news.google.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?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634157,0.0,0.5,0.2,0.0,0.0,0.15,0.016939606564301296,0.34982665644751654,0.016939606564301296,0.0,0.9830603934356987,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.550818819692904
2024-10-30,2024-10-30 07:00:00,Biocon Biologics' Bengaluru unit classified as voluntary action indicated by USFDA - The Economic Times,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics' Bengaluru unit classified as voluntary action indicated by USFDA</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Economic Times</font>",https://news.google.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?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.420597,0.0,0.5,0.2,0.0,0.0,0.15,0.013850339293537227,0.34656190713246665,0.013850339293537227,0.0,0.9861496607064628,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5415510178806118
2025-03-01,2025-03-01 08:00:00,Biosimilars Regulatory Roundup: February 2025 - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMijwFBVV95cUxNY09aTHdaZVNMLXpSUFdac2QyYThmZjQtRFZzcXhuM0RWYVAtaFBBQXNxNmRUZmVIWVJLTDJ2N2RpQUEtNTlWc2pnS1d0QWIwTGZzSjVzUG83MEIzUzlFdFhPbnJLWE5sTTZUbnRKaXB4NENldXNLd0N0UFlDM1RodFYtekxTcEcwLTd4amd5Yw?oc=5"" target=""_blank"">Biosimilars Regulatory Roundup: February 2025</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMijwFBVV95cUxNY09aTHdaZVNMLXpSUFdac2QyYThmZjQtRFZzcXhuM0RWYVAtaFBBQXNxNmRUZmVIWVJLTDJ2N2RpQUEtNTlWc2pnS1d0QWIwTGZzSjVzUG83MEIzUzlFdFhPbnJLWE5sTTZUbnRKaXB4NENldXNLd0N0UFlDM1RodFYtekxTcEcwLTd4amd5Yw?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.586732,0.0,0.0,0.6,0.0,0.0,0.15,-0.004394021861591958,0.33715842299991183,0.0,0.004394021861591958,0.995605978138408,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.513182065584776
2018-03-08,2018-03-08 08:00:00,GC Pharma gets Korean approval for Lantus biosimilar - theinvestor.co.kr,"<a href=""https://news.google.com/rss/articles/CBMiWEFVX3lxTFBRdXhoODBsNmlZZzJlS1R0RDdRcmZQUFhQM3Jra054eUNacWRkUjlXOVVIMi1oTnB6UzhUN2pGb2Jia3VlY3cza3JuSGw5aU5JN2tWMUhmUGs?oc=5"" target=""_blank"">GC Pharma gets Korean approval for Lantus biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">theinvestor.co.kr</font>",https://news.google.com/rss/articles/CBMiWEFVX3lxTFBRdXhoODBsNmlZZzJlS1R0RDdRcmZQUFhQM3Jra054eUNacWRkUjlXOVVIMi1oTnB6UzhUN2pGb2Jia3VlY3cza3JuSGw5aU5JN2tWMUhmUGs?oc=5,Google News,insulin biosimilar competition,competitive,2025-06-27T05:41:25.461928,0.0,0.0,0.4,0.0,0.2,0.12,0.4349004242287595,0.41417297684351606,0.4349004242287595,0.0,0.5650995757712405,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5047012726862787
2024-05-21,2024-05-21 07:00:00,US FDA issues approval for two aflibercept biosimilars - Ophthalmology Times,"<a href=""https://news.google.com/rss/articles/CBMirwFBVV95cUxOU0xZYXBpQVBmZXNFLWpZS0c4Z1Y3YXNaUjl0dWpUd2NXc2pqcFlCVGVjaVV3SzFXV1NxRTVORXdad2gyX1REZXdEVVE4OWNBQkx1VzBxTjdhN3RYUThHdm93NXRMNWk0dHlmTnJkVU5YbkR6bkNpdGFqUm55TUVUNmNBdGhMZ0J4bnczMFh3UklwOFB5cHlsWTdCbVVyQTZSS2Nmb2tYeUZWblVaOU5V?oc=5"" target=""_blank"">US FDA issues approval for two aflibercept biosimilars</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Ophthalmology Times</font>",https://news.google.com/rss/articles/CBMirwFBVV95cUxOU0xZYXBpQVBmZXNFLWpZS0c4Z1Y3YXNaUjl0dWpUd2NXc2pqcFlCVGVjaVV3SzFXV1NxRTVORXdad2gyX1REZXdEVVE4OWNBQkx1VzBxTjdhN3RYUThHdm93NXRMNWk0dHlmTnJkVU5YbkR6bkNpdGFqUm55TUVUNmNBdGhMZ0J4bnczMFh3UklwOFB5cHlsWTdCbVVyQTZSS2Nmb2tYeUZWblVaOU5V?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.381252,0.0,0.0,0.6,0.0,0.0,0.15,0.33406485063644753,0.5391887323379517,0.33406485063644753,0.0,0.6659351493635525,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5021945519093425
2025-03-23,2025-03-23 10:45:06,FDA declines to approve Biocon's biosimilar insulin product - FirstWord Pharma,"<a href=""https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ya1NrTmZCUHpQX2k3TU5JcHBTcHBNbFV5d1dIVGpsc0xGc2U5RXo0X1NCb2FBYzQ1T1FNa2pNZWVydkdHWjdYUzdZclVmbW4ySEdZ?oc=5"" target=""_blank"">FDA declines to approve Biocon's biosimilar insulin product</a>&nbsp;&nbsp;<font color=""#6f6f6f"">FirstWord Pharma</font>",https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ya1NrTmZCUHpQX2k3TU5JcHBTcHBNbFV5d1dIVGpsc0xGc2U5RXo0X1NCb2FBYzQ1T1FNa2pNZWVydkdHWjdYUzdZclVmbW4ySEdZ?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.586524,0.0,0.25,0.4,0.0,0.0,0.15,0.0,0.22989422082901,0.0,0.0,1.0,0,0,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5
2025-02-25,2025-02-25 08:00:00,Biocon Biologics launches Yesintek Biosimilar to Stelara in US - Indian Pharma Post,"<a href=""https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMmduU0hqTWVqZ1hIZjhlbWxQZGdEVVAzM2Rya1poeGhMLVVJM0FKMk54dUFkdUg2OEJpeVpndXhEeVJESmtCaFR3T0p0VEVsMEc0ZW5ieXNOWVhkYTVLcUtaM0pwaWxxWmgyVE5zcWpMckVoWWprZDJ6LW5fUDR1ZTdpOGxhN1lveGtncHljRkVVV2RaUWVfdVA4cUxFQ1dkdlFudW1fa3J1Z9IBsAFBVV95cUxOMFJwZ0dTMFBoeVZrck5Lem5xSGJlY1V1S2FhTEZCLTkzdXQ3ZUpNaVRsNGNVazN5QkgyM29BYjBBRU5ZdHpGc2RuNWJIdlRCWWVSQ3pDV3lWdTFFNGh2THY5QjV5LTVwRGZVVVV5WXdtVlJRQkZyenBTdjI2d2FjU19ZTlBDMUljZExEdFBZRUFJcXBDaUgxclhwdXk2d1RmY2NaM0NMOU1POTd0UHlvVg?oc=5"" target=""_blank"">Biocon Biologics launches Yesintek Biosimilar to Stelara in US</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Indian Pharma Post</font>",https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMmduU0hqTWVqZ1hIZjhlbWxQZGdEVVAzM2Rya1poeGhMLVVJM0FKMk54dUFkdUg2OEJpeVpndXhEeVJESmtCaFR3T0p0VEVsMEc0ZW5ieXNOWVhkYTVLcUtaM0pwaWxxWmgyVE5zcWpMckVoWWprZDJ6LW5fUDR1ZTdpOGxhN1lveGtncHljRkVVV2RaUWVfdVA4cUxFQ1dkdlFudW1fa3J1Z9IBsAFBVV95cUxOMFJwZ0dTMFBoeVZrck5Lem5xSGJlY1V1S2FhTEZCLTkzdXQ3ZUpNaVRsNGNVazN5QkgyM29BYjBBRU5ZdHpGc2RuNWJIdlRCWWVSQ3pDV3lWdTFFNGh2THY5QjV5LTVwRGZVVVV5WXdtVlJRQkZyenBTdjI2d2FjU19ZTlBDMUljZExEdFBZRUFJcXBDaUgxclhwdXk2d1RmY2NaM0NMOU1POTd0UHlvVg?oc=5,Google News,Biocon Biologics FDA approval,regulatory,2025-06-27T05:41:56.634718,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3025049567222595,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5
2025-01-13,2025-01-13 08:00:00,"USFDA classifies Biocon Biologics Johor Bahru site, Malaysia as VAI - Indian Pharma Post","<a href=""https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZU9TR1JOdlczalNQd0J0T2liSklocU54aTVuMUpWZTRyU3dEbGt2dV93NlJ0QjhqM1VacmVoWkpvN1BfS2xGTEFZeTFoR1dxOFhKRklYb1kwd1FPSDVnOHdCZ2t5WkdzMWV2ZHMxT2lNOGllandNbHpsU1FtOG1PTTBKdlhSQUFVOGZPVm9JYWNuM1FEbTVmM05sX1JiSDNiSmZPYVp4MjlWU2ZVRnA4YldWTTdoVm9fMmVv0gHCAUFVX3lxTFBXMWVOdFI4YzRmTFZWT2R0cXNGcWpfZ2RORFRHelNHY2xESUh4X001cHgyM015T1dsNUZrNHdZbUJwc2o0eDQ0QURmYTNDNTdBdUVtR0RQUkM5dk81bUZwaHhTNTYyV1ZZUU9uMUNDWlZzakpaY1ZlTy1uOU16YW1pTUZjWFhrNjNMLUsxVlZCcWtpY01CSDdHbDdTemNnN2MtOW8xWUdrejFzTko0X2hHV0RiTWNVbmxGenNwdHR5bGp3?oc=5"" target=""_blank"">USFDA classifies Biocon Biologics Johor Bahru site, Malaysia as VAI</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Indian Pharma Post</font>",https://news.google.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?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.420649,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3160208463668823,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5
2025-01-13,2025-01-13 08:00:00,US FDA classifies Biocon Biologics site as VAI - Express Pharma,"<a href=""https://news.google.com/rss/articles/CBMiggFBVV95cUxPOXliSi1SaXVLQWNkZ00yRTlqLXlXUTlnRjY5V3I1XzQ1aDhDSzRJemQ4R3lZOFBjYXpOejdaS2l3aFFlSWU2WWNjeHZMRm1yckpmbEJqRkZ4MU5mSHZDVXpacDRzRmZfb1pZaUEtLVR6a3F6MzNvOUo1ckpUaFNTd3B30gGHAUFVX3lxTE1LWi1faURNMm5CTDg1dnk3UkNpeTFwQmtpU1N6dmRCRlhuZDkzRUdla3FJV0tsNHktQmE3Y2d5bUdKSDBkM2h2YkJaeC1JMEcwYkpxU2w4Mm5ObkxNVm9UQThWTk9UdWljSWZvQTQxYkFTSnRPMFlzTnkyNHd2UnhTTXNIdU12aw?oc=5"" target=""_blank"">US FDA classifies Biocon Biologics site as VAI</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Express Pharma</font>",https://news.google.com/rss/articles/CBMiggFBVV95cUxPOXliSi1SaXVLQWNkZ00yRTlqLXlXUTlnRjY5V3I1XzQ1aDhDSzRJemQ4R3lZOFBjYXpOejdaS2l3aFFlSWU2WWNjeHZMRm1yckpmbEJqRkZ4MU5mSHZDVXpacDRzRmZfb1pZaUEtLVR6a3F6MzNvOUo1ckpUaFNTd3B30gGHAUFVX3lxTE1LWi1faURNMm5CTDg1dnk3UkNpeTFwQmtpU1N6dmRCRlhuZDkzRUdla3FJV0tsNHktQmE3Y2d5bUdKSDBkM2h2YkJaeC1JMEcwYkpxU2w4Mm5ObkxNVm9UQThWTk9UdWljSWZvQTQxYkFTSnRPMFlzTnkyNHd2UnhTTXNIdU12aw?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.420693,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.315216600894928,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5
2024-09-28,2024-09-28 07:00:00,US FDA concludes inspection of Biocon Biologics’ Insulins Facility in Malaysia - CNBC TV18,"<a href=""https://news.google.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?oc=5"" target=""_blank"">US FDA concludes inspection of Biocon Biologics’ Insulins Facility in Malaysia</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.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?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.420468,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3042717973391215,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5
2024-08-08,2024-08-08 07:00:00,CNBC-TV18 accesses USFDA observations for Biocon Biologics unit. Details here - CNBC TV18,"<a href=""https://news.google.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?oc=5"" target=""_blank"">CNBC-TV18 accesses USFDA observations for Biocon Biologics unit. Details here</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.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?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.421235,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3160369594891866,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.5
2022-12-05,2022-12-05 08:00:00,Kiran Mazumdar-Shaw-founded Biocon Biologics appoints Shreehas Tambe as CEO and MD - Free Press Journal,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Kiran Mazumdar-Shaw-founded Biocon Biologics appoints Shreehas Tambe as CEO and MD</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Free Press Journal</font>",https://news.google.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?oc=5,Google News,Biocon regulatory filing,regulatory,2025-06-27T05:41:53.453128,0.0,0.75,0.0,0.0,0.0,0.15,0.3317030236897615,0.6595619818899366,0.3317030236897615,0.0,0.6682969763102384,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.4951090710692845
2021-12-23,2021-12-23 08:00:00,FDA approves second insulin glargine biosimilar - Healio,"<a href=""https://news.google.com/rss/articles/CBMinwFBVV95cUxQaVl1ZUEtZGhBWExFNVRRVmFRSnpMTVV4aFlhanA4OGFjU0RveXc2WThjdmRaenJmRXFLRkdzZDh1RGE0eGZGMkpWVU9JVHlXZm1GUHhnUHByRFhkUEVKU0JNUlZvYllWRFBqaVFWYzVSbmZ6SEhFQ3NFWl8zeUszQmpEQVh0emk4QnlNS1VxYWZiaXRKX3plRVJUMWt5VkU?oc=5"" target=""_blank"">FDA approves second insulin glargine biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Healio</font>",https://news.google.com/rss/articles/CBMinwFBVV95cUxQaVl1ZUEtZGhBWExFNVRRVmFRSnpMTVV4aFlhanA4OGFjU0RveXc2WThjdmRaenJmRXFLRkdzZDh1RGE0eGZGMkpWVU9JVHlXZm1GUHhnUHByRFhkUEVKU0JNUlZvYllWRFBqaVFWYzVSbmZ6SEhFQ3NFWl8zeUszQmpEQVh0emk4QnlNS1VxYWZiaXRKX3plRVJUMWt5VkU?oc=5,Google News,insulin glargine-yfgn FDA,drug_fda,2025-06-27T05:41:11.426906,0.2,0.0,0.4,0.0,0.0,0.16,0.2864696036847522,0.5063993810653686,0.2864696036847522,0.0,0.7135303963152477,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.4594088110542565
2021-10-20,2021-10-20 07:00:00,Preferred Status for Semglee Will Test Value Proposition of Insulin Biosimilars - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMivgFBVV95cUxNYVRQMG5keFN2UkF2LXU4Ui1GZjVpUUpYNlZycGJYeU1yZmNCaUl6SnRzQ0toclZtSDlQakFJNG9YeENDLWZnZzNxY21YdHRlTGhsZDJzSW5zUm1RTXROU2JsTkRnOUhNNkZSNzJGZ19tR0s0Y2w0Rldvem13bjRueUtqLVpqck5PS1hBM0JHcFIxRlAwcm1DX2pXRVNvYjNOeEpPcHZBUm1meUU1dlU4dXhvZ2w3a1BudFY4NnRn?oc=5"" target=""_blank"">Preferred Status for Semglee Will Test Value Proposition of Insulin Biosimilars</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMivgFBVV95cUxNYVRQMG5keFN2UkF2LXU4Ui1GZjVpUUpYNlZycGJYeU1yZmNCaUl6SnRzQ0toclZtSDlQakFJNG9YeENDLWZnZzNxY21YdHRlTGhsZDJzSW5zUm1RTXROU2JsTkRnOUhNNkZSNzJGZ19tR0s0Y2w0Rldvem13bjRueUtqLVpqck5PS1hBM0JHcFIxRlAwcm1DX2pXRVNvYjNOeEpPcHZBUm1meUU1dlU4dXhvZ2w3a1BudFY4NnRn?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413209,0.4,0.0,0.2,0.0,0.0,0.17,0.21397904301665438,0.5278310760074191,0.21397904301665438,0.0,0.7860209569833456,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.3419371290499633
2020-01-08,2020-01-08 08:00:00,"Interview: Biocon CMD Kiran Mazumdar Shaw on biosimilar business, fund-raising and True North deal - CNBC TV18","<a href=""https://news.google.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?oc=5"" target=""_blank"">Interview: Biocon CMD Kiran Mazumdar Shaw on biosimilar business, fund-raising and True North deal</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.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?oc=5,Google News,Kiran Mazumdar Shaw interview,strategic,2025-06-27T05:42:01.310367,0.0,0.5,0.2,0.0,0.0,0.15,0.27823936286808115,0.6204886314498054,0.27823936286808115,0.0,0.7217606371319188,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.3347180886042436
2018-06-26,2018-06-26 07:00:00,FDA gives Biocon biosimilars plant clean bill of health - Fierce Pharma,"<a href=""https://news.google.com/rss/articles/CBMimwFBVV95cUxQamJFdml3NUpCMXZDVTIta2ItSGlkQklqYlZYMXNSMFdjclIzd1Y0ZFRfcWowaHZQQkpOLXF6T2piN1hkTWVEMjM5NjJnV0FXTjJ1UHFDRnlvTzlKS0ZHZmF2R3ExNEcyNVZ6Mmh2WjJyRkFibjVZUzhhOThXeWtjR3o0eW5lWnZQaVpWdi1RNHdINWtKVUlTOFp0UQ?oc=5"" target=""_blank"">FDA gives Biocon biosimilars plant clean bill of health</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMimwFBVV95cUxQamJFdml3NUpCMXZDVTIta2ItSGlkQklqYlZYMXNSMFdjclIzd1Y0ZFRfcWowaHZQQkpOLXF6T2piN1hkTWVEMjM5NjJnV0FXTjJ1UHFDRnlvTzlKS0ZHZmF2R3ExNEcyNVZ6Mmh2WjJyRkFibjVZUzhhOThXeWtjR3o0eW5lWnZQaVpWdi1RNHdINWtKVUlTOFp0UQ?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.421722,0.0,0.25,0.4,0.0,0.0,0.15,0.2698755351333321,0.6113400586375484,0.2698755351333321,0.0,0.7301244648666678,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.3096266053999965
2015-12-17,2015-12-17 08:00:00,Lilly gets its Lantus copycat Basaglar approved by FDA—but not as a biosimilar - BioPharma Dive,"<a href=""https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRVRpRmFscXJZd0VUU3lXM2xDVWc4aVZCVzhJb3ZjMUhJQVZLRXlpY3FNYzVVak9NM0Nvd2VicFVpM1VBdk1NTjlib0JNelM4RTB2Y1ZtVDJiTzNaTUttTG1GY3pqUThRaXMyMDc1RHZSenBsbEVCVzc4empFc1k2X2xCQUd5NTA1S3RwWWtWNXlJWWtHdjExTGxWZWI5aHFpMVhleHdDZ1NPYy1GcG1PNmh4QW5QZHpG?oc=5"" target=""_blank"">Lilly gets its Lantus copycat Basaglar approved by FDA—but not as a biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BioPharma Dive</font>",https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRVRpRmFscXJZd0VUU3lXM2xDVWc4aVZCVzhJb3ZjMUhJQVZLRXlpY3FNYzVVak9NM0Nvd2VicFVpM1VBdk1NTjlib0JNelM4RTB2Y1ZtVDJiTzNaTUttTG1GY3pqUThRaXMyMDc1RHZSenBsbEVCVzc4empFc1k2X2xCQUd5NTA1S3RwWWtWNXlJWWtHdjExTGxWZWI5aHFpMVhleHdDZ1NPYy1GcG1PNmh4QW5QZHpG?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.588057,0.0,0.0,0.4,0.0,0.4,0.13999999999999999,0.2984116217097364,0.5177285403569539,0.2984116217097364,0.0,0.7015883782902637,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.295234865129209
2022-03-04,2022-03-04 07:08:22,Biocon Biologics to acquire Viatris’ biosimilar assets worth $3.34 billion - People Matters - HR News,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics to acquire Viatris’ biosimilar assets worth $3.34 billion</a>&nbsp;&nbsp;<font color=""#6f6f6f"">People Matters - HR News</font>",https://news.google.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?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.350327,0.0,0.5,0.2,0.0,0.0,0.15,0.2649193379261886,0.5979229926109314,0.2649193379261886,0.0,0.7350806620738114,0,0,0,0.0,3.34,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.2947580137785657
2019-10-10,2019-10-10 07:00:00,"Biocon Biologics, Just - Evotec Biologics ink licensing pact for biosimilar asset - ET HealthWorld","<a href=""https://news.google.com/rss/articles/CBMi2wFBVV95cUxNdlp0cVRxSE1XelgxSU9BY0xsNnItS3lUVS1NbVNYRjhJRHVhYlpncFVublB6MjJPYkdrRFhHcU1FcGRWeTUwOHBwVURCNkF2dmd0S1l3Rnc4MW5MZkh2ajJMV3gtQ29tdnVLX0VrM0MxR3pIWUpCOEVBQmgtRDBPN1hBYnNOeERCcHlsUXptcFF0bFEyUjhOTEpkcFBOZmoxRUF3TV9BQVlLdmNKZlhCWWlJTnlfMnZNY3lKTU9hQ0h1TzZzU0dPdDlWSFhTQ016b2RVcnJQSk9BalE?oc=5"" target=""_blank"">Biocon Biologics, Just - Evotec Biologics ink licensing pact for biosimilar asset</a>&nbsp;&nbsp;<font color=""#6f6f6f"">ET HealthWorld</font>",https://news.google.com/rss/articles/CBMi2wFBVV95cUxNdlp0cVRxSE1XelgxSU9BY0xsNnItS3lUVS1NbVNYRjhJRHVhYlpncFVublB6MjJPYkdrRFhHcU1FcGRWeTUwOHBwVURCNkF2dmd0S1l3Rnc4MW5MZkh2ajJMV3gtQ29tdnVLX0VrM0MxR3pIWUpCOEVBQmgtRDBPN1hBYnNOeERCcHlsUXptcFF0bFEyUjhOTEpkcFBOZmoxRUF3TV9BQVlLdmNKZlhCWWlJTnlfMnZNY3lKTU9hQ0h1TzZzU0dPdDlWSFhTQ016b2RVcnJQSk9BalE?oc=5,Google News,Biocon licensing deal,strategic,2025-06-27T05:42:04.501196,0.0,0.5,0.2,0.0,0.0,0.15,0.2413494863493746,0.5179677621205648,0.2413494863493746,0.0,0.7586505136506254,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.2240484590481238
2020-03-11,2020-03-11 07:00:00,"Biocon, partner Mylan win patent litigation on insulin glargine device in US - Mint","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon, partner Mylan win patent litigation on insulin glargine device in US</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Mint</font>",https://news.google.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?oc=5,Google News,Biocon insulin market share,competitive,2025-06-27T05:41:26.941922,0.2,0.25,0.0,0.0,0.0,0.11000000000000001,0.37325380428012567,0.714922835583157,0.37325380428012567,0.0,0.6267461957198743,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.219761412840377
2019-03-07,2019-03-07 08:00:00,Biocon share price falls after USFDA issues six observations on Bengaluru facility - Business Today,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon share price falls after USFDA issues six observations on Bengaluru facility</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Today</font>",https://news.google.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?oc=5,Google News,Biocon quality issues,regulatory,2025-06-27T05:41:51.800664,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,-0.3224910099983216,0.45863033666610714,0.0,0.3224910099983216,0.6775089900016784,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.2174730299949648
2017-09-01,2017-09-01 07:00:00,Insulin Degludec May Be More Cost Effective Than Insulin Glargine or Its Biosimilar - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMWpTc2l5Vmltbi1lc2lmbEtBNlZmMGhJUktwWnVaVFJfMnNxWmM4UkNqTjVhVTAzSmdqbk1Uek5PVjNBTUI1Ump1Uklxd191cm5FWkVFYVhpSGczQ1g5M3NIQjdCNi1FbnYxUmhwZjF3NXN1eHhCTUNsY1lhS3dqSjM1VkRrUWRZN3V2RW9sUjdwM3dEbXFMcmpYWWxMQlVJQ1NvenFxaXUwbzNxWlFtbmhpZHZoZDhiUWJYMF85WWtvX1U?oc=5"" target=""_blank"">Insulin Degludec May Be More Cost Effective Than Insulin Glargine or Its Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMWpTc2l5Vmltbi1lc2lmbEtBNlZmMGhJUktwWnVaVFJfMnNxWmM4UkNqTjVhVTAzSmdqbk1Uek5PVjNBTUI1Ump1Uklxd191cm5FWkVFYVhpSGczQ1g5M3NIQjdCNi1FbnYxUmhwZjF3NXN1eHhCTUNsY1lhS3dqSjM1VkRrUWRZN3V2RW9sUjdwM3dEbXFMcmpYWWxMQlVJQ1NvenFxaXUwbzNxWlFtbmhpZHZoZDhiUWJYMF85WWtvX1U?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.588126,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.36976662261690674,0.6157333313169934,0.36976662261690674,0.0,0.6302333773830933,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.2092998678507203
2018-11-14,2018-11-14 08:00:00,"UK launch for Mylan, Biocon insulin glargine biosimilar Semglee - PharmaTimes","<a href=""https://news.google.com/rss/articles/CBMiogFBVV95cUxNX1FYVk1KY01pNkhabnF6UzZ5MGd6Uy1meWo3MERsXzBIb3ZuRXhya2ItdWNrVWVLNndGOUQ3bEFxVDFhLTFfeVJFQ0xWRnc0VDFSQzNHdTltZjRja21tb0FpMVkzZ1Q2WVpYaXpwdlFpSGZ6aU1YQ1dCc2RIaWFHOHJTeFB4bDVKdjVnV0ktZ0U1eF9kUnpJenZBaExUZDRkTEE?oc=5"" target=""_blank"">UK launch for Mylan, Biocon insulin glargine biosimilar Semglee</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PharmaTimes</font>",https://news.google.com/rss/articles/CBMiogFBVV95cUxNX1FYVk1KY01pNkhabnF6UzZ5MGd6Uy1meWo3MERsXzBIb3ZuRXhya2ItdWNrVWVLNndGOUQ3bEFxVDFhLTFfeVJFQ0xWRnc0VDFSQzNHdTltZjRja21tb0FpMVkzZ1Q2WVpYaXpwdlFpSGZ6aU1YQ1dCc2RIaWFHOHJTeFB4bDVKdjVnV0ktZ0U1eF9kUnpJenZBaExUZDRkTEE?oc=5,Google News,Biocon Semglee approval,drug_fda,2025-06-27T05:41:13.020559,0.4,0.25,0.2,0.0,0.0,0.22000000000000003,0.0,0.30667473872502643,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.2
2024-06-24,2024-06-24 07:00:00,Biocon Biologics receives EMA approval for cancer drug - Fortune India,"<a href=""https://news.google.com/rss/articles/CBMinAFBVV95cUxORF8ybDV4Slo5eVdEMVlIZUZQenhpd2RObV8yUWRBV3ItRFdVLVl5WEliVDdhSTJGeTNBN0ZfdkxRRU5RaHMzVmhLdGNkM2FnR004ZlpKaWJwWGprMlJCbWtoSUFxR04tVm5sYnoxVmFsdUZZS0dlSEhRZ0NIYkNsRGNqdjhSQW8wSElNamFtc0tTT2g4eFNrZ2pHaE7SAaoBQVVfeXFMTm1uRVVJWjVUWWRzakdoWjEyd1J6eHZhc1FfZ00tZGZRYWp6d2RmWGktY0U3d3JhdU40Y3lDTmFJOURHcm9ab0dNNFVMekNjcVZnQ3l1dVBja1J0dm9jTzI1ZDVybGhTS2huRTdJNnpuZm1QVnlZNjdhVDVvLWo0X0c4cl9KM0JTbFlvNkZ4SGJsVlFWc3U2Z1F6T1lwM3hHeWpIUnh6RDZSOUE?oc=5"" target=""_blank"">Biocon Biologics receives EMA approval for cancer drug</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fortune India</font>",https://news.google.com/rss/articles/CBMinAFBVV95cUxORF8ybDV4Slo5eVdEMVlIZUZQenhpd2RObV8yUWRBV3ItRFdVLVl5WEliVDdhSTJGeTNBN0ZfdkxRRU5RaHMzVmhLdGNkM2FnR004ZlpKaWJwWGprMlJCbWtoSUFxR04tVm5sYnoxVmFsdUZZS0dlSEhRZ0NIYkNsRGNqdjhSQW8wSElNamFtc0tTT2g4eFNrZ2pHaE7SAaoBQVVfeXFMTm1uRVVJWjVUWWRzakdoWjEyd1J6eHZhc1FfZ00tZGZRYWp6d2RmWGktY0U3d3JhdU40Y3lDTmFJOURHcm9ab0dNNFVMekNjcVZnQ3l1dVBja1J0dm9jTzI1ZDVybGhTS2huRTdJNnpuZm1QVnlZNjdhVDVvLWo0X0c4cl9KM0JTbFlvNkZ4SGJsVlFWc3U2Z1F6T1lwM3hHeWpIUnh6RDZSOUE?oc=5,Google News,Biocon manufacturing compliance,regulatory,2025-06-27T05:41:50.143012,0.0,0.5,0.2,0.0,0.0,0.15,-0.21686137754972373,0.4775627692222595,0.0,0.21686137754972373,0.7831386224502763,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.150584132649171
2021-04-26,2021-04-26 07:00:00,"Biocon Biologics, Viatris gets European Commission Approval for co-developed Cancer drug - The Hans India","<a href=""https://news.google.com/rss/articles/CBMizAFBVV95cUxOUklCR1hsQUpTOVhrQm9QeDV6dkhrQm56M1lUUTJwZ3h1bU1rUjNuZFlMMTExWjh4YVR3TTRiZWJlWUtDcmgycHhDejZaaUdhY2FYZzZkeGhRRGpNdXE4bmVJaTBDWlZEM3dDVk9vbnVQVDBGV3JBUzljU2pIdjFLY0txOFRaZVNPZThZTktxbDZaZGxPdjVNZW1xZEgtend2c3d2NHpZTnhWVTZHWTNrSXJuWk1OUjBxU2VCMFFJZVJpY0NOR1g3c08zY24?oc=5"" target=""_blank"">Biocon Biologics, Viatris gets European Commission Approval for co-developed Cancer drug</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Hans India</font>",https://news.google.com/rss/articles/CBMizAFBVV95cUxOUklCR1hsQUpTOVhrQm9QeDV6dkhrQm56M1lUUTJwZ3h1bU1rUjNuZFlMMTExWjh4YVR3TTRiZWJlWUtDcmgycHhDejZaaUdhY2FYZzZkeGhRRGpNdXE4bmVJaTBDWlZEM3dDVk9vbnVQVDBGV3JBUzljU2pIdjFLY0txOFRaZVNPZThZTktxbDZaZGxPdjVNZW1xZEgtend2c3d2NHpZTnhWVTZHWTNrSXJuWk1OUjBxU2VCMFFJZVJpY0NOR1g3c08zY24?oc=5,Google News,Biocon regulatory filing,regulatory,2025-06-27T05:41:53.453018,0.0,0.5,0.2,0.0,0.0,0.15,-0.21146097093246854,0.4872368939399719,0.0,0.21146097093246854,0.7885390290675315,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.1343829127974057
2019-05-02,2019-05-02 07:00:00,Chinese Study Finds Patients Taking Reference Insulin Glargine Had Better Glycemic Control - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMizAFBVV95cUxOc1Ntc0JmV2FwSExfdXE5aEhPTUdBZXVpb041TzFMZXJUdGpXckpIVmtDTTcwQ2VXcUhfMkoyXzZQMzhpM3dZSUhYWGJZbmJxLXoxeUJMeHc1V0NCd28xdzdtY2EySzZGamdnRjJWQTVHd3BuTWxJUHhEVnZsd1A2QURoT3J3WXJhNFhsVUN0X3Z0VkdhdXpueG1HTE1XZWVZSnVHNUJ2MXhRNkdfaFpiakNvdC1qZWlib0NteFRsamswMnkyVHJwVUtocDI?oc=5"" target=""_blank"">Chinese Study Finds Patients Taking Reference Insulin Glargine Had Better Glycemic Control</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMizAFBVV95cUxOc1Ntc0JmV2FwSExfdXE5aEhPTUdBZXVpb041TzFMZXJUdGpXckpIVmtDTTcwQ2VXcUhfMkoyXzZQMzhpM3dZSUhYWGJZbmJxLXoxeUJMeHc1V0NCd28xdzdtY2EySzZGamdnRjJWQTVHd3BuTWxJUHhEVnZsd1A2QURoT3J3WXJhNFhsVUN0X3Z0VkdhdXpueG1HTE1XZWVZSnVHNUJ2MXhRNkdfaFpiakNvdC1qZWlib0NteFRsamswMnkyVHJwVUtocDI?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.587991,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.3378736374495662,0.49671559490930467,0.3378736374495662,0.0,0.6621263625504338,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.113620912348699
2024-07-17,2024-07-17 07:00:00,The Path To Producing An Insulin Biosimilar - Bioprocess Online,"<a href=""https://news.google.com/rss/articles/CBMijgFBVV95cUxPRTNQcnJuNElwUGFZQVEwVVNEYTRRcHBFcEJnWlFhUTEzT3dmTGprOFMxczVmQUxIUGhBd3pZMVRSMDRfUUJBYVQ0b2dEU2swcHFrMHNLLWZ3c1BsQU5yMFJ6RDdVZFo1MXFOYmpBMkt4T2c1TWZ3Q3hNaXd0eldrNE01LWRoRTNEUUJySUl3?oc=5"" target=""_blank"">The Path To Producing An Insulin Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Bioprocess Online</font>",https://news.google.com/rss/articles/CBMijgFBVV95cUxPRTNQcnJuNElwUGFZQVEwVVNEYTRRcHBFcEJnWlFhUTEzT3dmTGprOFMxczVmQUxIUGhBd3pZMVRSMDRfUUJBYVQ0b2dEU2swcHFrMHNLLWZ3c1BsQU5yMFJ6RDdVZFo1MXFOYmpBMkt4T2c1TWZ3Q3hNaXd0eldrNE01LWRoRTNEUUJySUl3?oc=5,Google News,insulin biosimilar competition,competitive,2025-06-27T05:41:25.460936,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.0,0.30868955453236896,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.1
2024-02-29,2024-02-29 12:35:59,FDA hits Biocon insulin biosimilar with another CRL - BioProcess International,"<a href=""https://news.google.com/rss/articles/CBMimgFBVV95cUxPQ3NaT2g3Y0RhVFl5TWRtNXJ5YW9PcmstUVpqcFpLNHVxZWlqZEZwZ25kd3RtMlpWV2JMUHBVUkZrOWVoS0tMU0lBSjBQZVZKcHozdXk1bFRFSWpwWHdRLXhRanl0RV9xYjJHZkktb1ltelI5dEY1Um9mSXVpM21YRmtHaEpTTUplbmtPQWRSU3pBZFNsUzhsMFJR?oc=5"" target=""_blank"">FDA hits Biocon insulin biosimilar with another CRL</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BioProcess International</font>",https://news.google.com/rss/articles/CBMimgFBVV95cUxPQ3NaT2g3Y0RhVFl5TWRtNXJ5YW9PcmstUVpqcFpLNHVxZWlqZEZwZ25kd3RtMlpWV2JMUHBVUkZrOWVoS0tMU0lBSjBQZVZKcHozdXk1bFRFSWpwWHdRLXhRanl0RV9xYjJHZkktb1ltelI5dEY1Um9mSXVpM21YRmtHaEpTTUplbmtPQWRSU3pBZFNsUzhsMFJR?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.588014,0.2,0.25,0.4,0.0,0.0,0.21000000000000002,0.0,0.30928359429041546,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.1
2018-10-25,2018-10-25 07:00:00,"Biocon Q2 FY19 numbers reflect green shoots of biosimilar value-unlocking, says Kiran Mazumdar-Shaw - Business Today","<a href=""https://news.google.com/rss/articles/CBMi-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?oc=5"" target=""_blank"">Biocon Q2 FY19 numbers reflect green shoots of biosimilar value-unlocking, says Kiran Mazumdar-Shaw</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Today</font>",https://news.google.com/rss/articles/CBMi-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?oc=5,Google News,Biocon US market revenue,financial,2025-06-27T05:41:41.754099,0.0,0.5,0.2,0.0,0.0,0.15,0.1998979582910402,0.5427786506758796,0.1998979582910402,0.0,0.8001020417089598,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.099693874873121
2022-02-28,2022-02-28 08:00:00,Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMi7AFBVV95cUxPMXltMm1ZNVRwMWV1Z1ZvQXJhcE1NakVTZnoyb1cxcTlGOERmWUtjTXFRc2ptemZSY0o0blJSbUFnVTd0RExWUTRfRy1GQWM5dFJBenQ0bmlvZEFEVXRGVXNGckJ6N1ZYX09DRDhRU1l1QW1rTlVlQjFOSm5XOWJSVXJkTWNTdHdFQ1RmekRFNURXNzdlaldXaGpJV29DTzFBVnJTM2R3ZXZzRU9PTW81X0w2M2k4NFkwaDE4OUg1RkVpUmdJdTRBRzZ6WVFSVk1zTG9BcXVXMDJ5TkJJdW1Ybndkd0o0TDNiQU5ILQ?oc=5"" target=""_blank"">Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi7AFBVV95cUxPMXltMm1ZNVRwMWV1Z1ZvQXJhcE1NakVTZnoyb1cxcTlGOERmWUtjTXFRc2ptemZSY0o0blJSbUFnVTd0RExWUTRfRy1GQWM5dFJBenQ0bmlvZEFEVXRGVXNGckJ6N1ZYX09DRDhRU1l1QW1rTlVlQjFOSm5XOWJSVXJkTWNTdHdFQ1RmekRFNURXNzdlaldXaGpJV29DTzFBVnJTM2R3ZXZzRU9PTW81X0w2M2k4NFkwaDE4OUg1RkVpUmdJdTRBRzZ6WVFSVk1zTG9BcXVXMDJ5TkJJdW1Ybndkd0o0TDNiQU5ILQ?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.349420,0.0,0.5,0.2,0.16666666666666666,0.0,0.175,0.09133555119568634,0.42188756545384726,0.09133555119568634,0.0,0.9086644488043136,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.024006653587059
2023-02-14,2023-02-14 08:00:00,"FDA Issues CRL for Biocon Biologics, Viatris Avastin Biosimilar - Center for Biosimilars","<a href=""https://news.google.com/rss/articles/CBMingFBVV95cUxNZzBzUGxKcmloU1A4ai1QaGpYbkxMMGFwOXFKR096d2dtWlN1alhKaW5MZG5JZWQtb3R4SXlwb3ZLbDlhWDY1NHFWT3ZtVUZCY0xzRk5lb2ZHUUo0ekhoTXpYdW1BNF9KTnl2Wjl4aXRvQzZHTG9wUWx6ckJTbnhtMzhLbzVLVzhJUUFTZy0tVDdlckktYW95QUJuZ0JHZw?oc=5"" target=""_blank"">FDA Issues CRL for Biocon Biologics, Viatris Avastin Biosimilar</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMingFBVV95cUxNZzBzUGxKcmloU1A4ai1QaGpYbkxMMGFwOXFKR096d2dtWlN1alhKaW5MZG5JZWQtb3R4SXlwb3ZLbDlhWDY1NHFWT3ZtVUZCY0xzRk5lb2ZHUUo0ekhoTXpYdW1BNF9KTnl2Wjl4aXRvQzZHTG9wUWx6ckJTbnhtMzhLbzVLVzhJUUFTZy0tVDdlckktYW95QUJuZ0JHZw?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.587901,0.0,0.5,0.4,0.0,0.0,0.2,-0.004436544322195603,0.33392689757876926,0.0,0.004436544322195603,0.9955634556778044,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.0133096329665867
2023-01-09,2023-01-09 08:00:00,Biocon Biologics gets complete response letter from USFDA for proposed biosimilar Insulin-R - Medical Dialogues,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics gets complete response letter from USFDA for proposed biosimilar Insulin-R</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Medical Dialogues</font>",https://news.google.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?oc=5,Google News,Biocon regulatory filing,regulatory,2025-06-27T05:41:53.451841,0.0,0.5,0.4,0.0,0.0,0.2,0.0016862556725083379,0.31628260294596355,0.0016862556725083379,0.0,0.9983137443274916,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,2.005058767017525
2020-08-31,2020-08-31 07:00:00,Biocon-Mylan launch insulin Glargine at lowest price in US market - Business Standard,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon-Mylan launch insulin Glargine at lowest price in US market</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon insulin sales,financial,2025-06-27T05:41:40.025514,0.2,0.25,0.0,0.0,0.0,0.11000000000000001,-0.284585618802364,0.47512544930775963,0.0,0.284585618802364,0.715414381197636,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.9537568564070922
2018-10-11,2018-10-11 07:00:00,"Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars - insights.citeline.com","<a href=""https://news.google.com/rss/articles/CBMixgFBVV95cUxPNkF4R0NiZ3ZhSkd0dm8zWEFPOHpYZktGdldRY1M5bVBNdkdBUkRmQkxNWmZaZzZtLWcxczFDZnJTRWxVekhBcGNoQ2ZaQV9FbkhXaVNvbHBQaEVkMVV2ZGszYkpjWFU1MlU2eHA1emFoYnBsRE9iYUx3Z1NtR3p3cmoxU2FpY01LQzBXRmVZYTcxaGI4MTRmZGVMajZ3Y2RZbUxLaXBaallrd0ZOZkNubHhKb0NaLXg5enlXc3poRFc5dFBaM1E?oc=5"" target=""_blank"">Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars</a>&nbsp;&nbsp;<font color=""#6f6f6f"">insights.citeline.com</font>",https://news.google.com/rss/articles/CBMixgFBVV95cUxPNkF4R0NiZ3ZhSkd0dm8zWEFPOHpYZktGdldRY1M5bVBNdkdBUkRmQkxNWmZaZzZtLWcxczFDZnJTRWxVekhBcGNoQ2ZaQV9FbkhXaVNvbHBQaEVkMVV2ZGszYkpjWFU1MlU2eHA1emFoYnBsRE9iYUx3Z1NtR3p3cmoxU2FpY01LQzBXRmVZYTcxaGI4MTRmZGVMajZ3Y2RZbUxLaXBaallrd0ZOZkNubHhKb0NaLXg5enlXc3poRFc5dFBaM1E?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.588199,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.2667281522174291,0.5257312317212423,0.2667281522174291,0.0,0.7332718477825708,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.9001844566522874
2022-11-03,2022-11-03 07:00:00,IQVIA: Semglee Experience Can Help Predict Adalimumab Biosimilar Adoption - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMitAFBVV95cUxQZm13V2syMnFBcGlVNFZVY3BVNm5WdUt6UFNyUk83UFF2VHMtMndkZUVURno2dHJia0tVNEhlMVVXV2NpQThMbG9UdTd3aWt4YjYxdUVqRlFIU0JkekQ0LWZwejVEeGRwWDdEY0NBaUM5NU1SaldvS1FEc2ZTLXU5U0FOUzdZNEVkanhwaXctVXh3dUs5OERMWkJZYXhOT3F3NXlDa1JRYm9TUUM5WFhFal81dzg?oc=5"" target=""_blank"">IQVIA: Semglee Experience Can Help Predict Adalimumab Biosimilar Adoption</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMitAFBVV95cUxQZm13V2syMnFBcGlVNFZVY3BVNm5WdUt6UFNyUk83UFF2VHMtMndkZUVURno2dHJia0tVNEhlMVVXV2NpQThMbG9UdTd3aWt4YjYxdUVqRlFIU0JkekQ0LWZwejVEeGRwWDdEY0NBaUM5NU1SaldvS1FEc2ZTLXU5U0FOUzdZNEVkanhwaXctVXh3dUs5OERMWkJZYXhOT3F3NXlDa1JRYm9TUUM5WFhFal81dzg?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413183,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.2665418011527001,0.5387018017345004,0.2665418011527001,0.0,0.7334581988472999,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.8996254034581004
2022-02-28,2022-02-28 08:00:00,Biocon Biologics to Acquire Viatris’ Biosimilars Assets - ET HealthWorld,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics to Acquire Viatris’ Biosimilars Assets</a>&nbsp;&nbsp;<font color=""#6f6f6f"">ET HealthWorld</font>",https://news.google.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?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.350001,0.0,0.5,0.2,0.0,0.0,0.15,0.09067458056538397,0.4249629068374634,0.09067458056538397,0.0,0.9093254194346161,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.772023741696152
2019-10-03,2019-10-03 07:00:00,Biocon and Mylan Launch Insulin Glargine Biosimilar in Australia - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTTdua0Zyb2FtQ19WbFBtNjgwV0F6ejlDRnBGMS1iUXRrVE0yb01EMGtsUTd6dGNoa2N2eXlGWWktM1RhWGFjYTBwRzAzU1dYdkFLTGNtVnV6cXUtTGxHaWNjTzEzOGVTNml2Nzg4WUZfalFKam9UaUQ3eUl4bkNNa2FLSHVja1ptZzFMSUJkM19nbmdXUGZFQTZidlhzYWd3LW94czdpWldkdw?oc=5"" target=""_blank"">Biocon and Mylan Launch Insulin Glargine Biosimilar in Australia</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTTdua0Zyb2FtQ19WbFBtNjgwV0F6ejlDRnBGMS1iUXRrVE0yb01EMGtsUTd6dGNoa2N2eXlGWWktM1RhWGFjYTBwRzAzU1dYdkFLTGNtVnV6cXUtTGxHaWNjTzEzOGVTNml2Nzg4WUZfalFKam9UaUQ3eUl4bkNNa2FLSHVja1ptZzFMSUJkM19nbmdXUGZFQTZidlhzYWd3LW94czdpWldkdw?oc=5,Google News,Semglee biosimilar approval,drug_fda,2025-06-27T05:41:08.121832,0.2,0.25,0.2,0.0,0.0,0.16,-0.004422329636678957,0.3350002381536696,0.0,0.004422329636678957,0.995577670363321,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.613266988910037
2021-11-16,2021-11-16 08:00:00,Biocon Launches Biosimilar Semglee - Managed Healthcare Executive,"<a href=""https://news.google.com/rss/articles/CBMiigFBVV95cUxQbFpVT2xaTlU3bGFlR0hBQTFueTlTSmpmLUpINnlYVkVxdVppTGFOZWlhaVRTZlM0RHhIc2VWU2ZVVXF1VDRCT0JSV2xTdXF6dVZBUjN1YmhnSUlwRzdMXy1yMlo2TjE2SXV2bG5mRVJZYjdmdE55YWh0MzJlY0pNYW9HRVg0NUJQMlE?oc=5"" target=""_blank"">Biocon Launches Biosimilar Semglee</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Managed Healthcare Executive</font>",https://news.google.com/rss/articles/CBMiigFBVV95cUxQbFpVT2xaTlU3bGFlR0hBQTFueTlTSmpmLUpINnlYVkVxdVppTGFOZWlhaVRTZlM0RHhIc2VWU2ZVVXF1VDRCT0JSV2xTdXF6dVZBUjN1YmhnSUlwRzdMXy1yMlo2TjE2SXV2bG5mRVJZYjdmdE55YWh0MzJlY0pNYW9HRVg0NUJQMlE?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413494,0.2,0.25,0.2,0.0,0.0,0.16,0.0,0.2954886356989543,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.6
2021-07-28,2021-07-28 07:00:00,Biocon’s Global Biosimilars Portfolio - Insulin Glargine - Biocon,"<a href=""https://news.google.com/rss/articles/CBMicEFVX3lxTE9PR0hXTzc3UkJEN3lJRlJjM1VFcy0ybjF5ckRBTnZMNjFlUEl6b2syUE8xNDhVaUZWQlBIZ1hyQzNucnZxTE51Rmx5bUJGNlZzb0pFNktYbG9Rc0p4N3poX3ZvSGhRaVY5OWtQZVprYmY?oc=5"" target=""_blank"">Biocon’s Global Biosimilars Portfolio - Insulin Glargine</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Biocon</font>",https://news.google.com/rss/articles/CBMicEFVX3lxTE9PR0hXTzc3UkJEN3lJRlJjM1VFcy0ybjF5ckRBTnZMNjFlUEl6b2syUE8xNDhVaUZWQlBIZ1hyQzNucnZxTE51Rmx5bUJGNlZzb0pFNktYbG9Rc0p4N3poX3ZvSGhRaVY5OWtQZVprYmY?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413622,0.2,0.25,0.2,0.0,0.0,0.16,0.0,0.3131052454312642,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.6
2020-08-31,2020-08-31 07:00:00,"Biocon Biologics, partner Mylan launch insulin glargine in US - Mint","<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics, partner Mylan launch insulin glargine in US</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Mint</font>",https://news.google.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?oc=5,Google News,Biocon insulin sales,financial,2025-06-27T05:41:40.025490,0.2,0.5,0.0,0.0,0.0,0.16,0.0,0.3098033865292867,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.6
2024-06-24,2024-06-24 07:00:00,Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant - The Economic Times,"<a href=""https://news.google.com/rss/articles/CBMijAJBVV95cUxNVGtvbVpYbS1FXzZhR0s3TjdTZ1RaM1B4OEZEcDhJRVZjcURFa1VFUGdPakVMNWVObUgyTjBPWTVZWG9CR2Z2ZWVrcVVGY0lPSF96eXAtTlN2bVVwWFdMamE1dWFTbG84Ni1QczJqaERBaGUxLTQzcTJyZ3BwOGo5ZzM0Umh1alRBN0M3c0lqUTVMakU0TTA1dmF0Z1JfT2drX0ljUjkxYy1xNVFSSk54b3NvM1pOalkxY21BdW1mUmtma0llLWl5ZDFuLTJ4S3dRSzNLaDFkSDNTTGVaam5XMnhtUDkzZzZNblh4TXlkYmtXWGZWZDh6SjZWNHVhQTUtNy13Z084SHJMOHNH0gGSAkFVX3lxTFB0dVF3bWNQamZ5S3lsY1NyM0NBVGN3eXB5ZVpNVXZyWnBycC1QTDh3SXcyUTZ4N0xXNmdxaHdSREhxVmNvYmJERl9mdmxKeWdzQ3FLMktBNW92SHhjRGlRbTd5OFFGWXpubEs2NkFOOFZVa1BBa0pCTmV3Qmd0UG0tU2ZzMDlCeF9fMXMyaUhEcWRseXlsSDdkb2N0QmhtUEJjVlR6U2tHNmVxMEM2SVoycVJtQk82aVd3U25jc1Fnbk44dExrc1VZVno1NEg1SkI3QnZCaUV6REtOdE1pWi1OV1hkVzVLX3VTS2FEQWRKdjhwY09BSm54eWdFak1uRmtTNGJqclhid2hWanVscTR6QUE?oc=5"" target=""_blank"">Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Economic Times</font>",https://news.google.com/rss/articles/CBMijAJBVV95cUxNVGtvbVpYbS1FXzZhR0s3TjdTZ1RaM1B4OEZEcDhJRVZjcURFa1VFUGdPakVMNWVObUgyTjBPWTVZWG9CR2Z2ZWVrcVVGY0lPSF96eXAtTlN2bVVwWFdMamE1dWFTbG84Ni1QczJqaERBaGUxLTQzcTJyZ3BwOGo5ZzM0Umh1alRBN0M3c0lqUTVMakU0TTA1dmF0Z1JfT2drX0ljUjkxYy1xNVFSSk54b3NvM1pOalkxY21BdW1mUmtma0llLWl5ZDFuLTJ4S3dRSzNLaDFkSDNTTGVaam5XMnhtUDkzZzZNblh4TXlkYmtXWGZWZDh6SjZWNHVhQTUtNy13Z084SHJMOHNH0gGSAkFVX3lxTFB0dVF3bWNQamZ5S3lsY1NyM0NBVGN3eXB5ZVpNVXZyWnBycC1QTDh3SXcyUTZ4N0xXNmdxaHdSREhxVmNvYmJERl9mdmxKeWdzQ3FLMktBNW92SHhjRGlRbTd5OFFGWXpubEs2NkFOOFZVa1BBa0pCTmV3Qmd0UG0tU2ZzMDlCeF9fMXMyaUhEcWRseXlsSDdkb2N0QmhtUEJjVlR6U2tHNmVxMEM2SVoycVJtQk82aVd3U25jc1Fnbk44dExrc1VZVno1NEg1SkI3QnZCaUV6REtOdE1pWi1OV1hkVzVLX3VTS2FEQWRKdjhwY09BSm54eWdFak1uRmtTNGJqclhid2hWanVscTR6QUE?oc=5,Google News,Biocon manufacturing compliance,regulatory,2025-06-27T05:41:50.143795,0.0,0.5,0.2,0.0,0.0,0.15,0.01738237184694179,0.3409158415264553,0.01738237184694179,0.0,0.9826176281530582,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5521471155408253
2020-04-01,2020-04-01 07:00:00,FDA Clears Biocon's Insulin Factory in Malaysia - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMijwFBVV95cUxOckdFcFlnNU81Y0FqRkJGTXRnZVd3MHhwRW85eFQ5STFJUHVDTEhsN21VbXRVV0E3MjFfN3Jzc3l4dklwV21hc0ZIV3BsM2R1aHcyTW1FWk9zemYyUGJmd3k0d3RfdW1QN3h0NGN0cjZRQVNJWGZKMVdFZV9fTXdVTUJMczNzcFpRQjRXdXh4SQ?oc=5"" target=""_blank"">FDA Clears Biocon's Insulin Factory in Malaysia</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMijwFBVV95cUxOckdFcFlnNU81Y0FqRkJGTXRnZVd3MHhwRW85eFQ5STFJUHVDTEhsN21VbXRVV0E3MjFfN3Jzc3l4dklwV21hc0ZIV3BsM2R1aHcyTW1FWk9zemYyUGJmd3k0d3RfdW1QN3h0NGN0cjZRQVNJWGZKMVdFZV9fTXdVTUJMczNzcFpRQjRXdXh4SQ?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.421914,0.0,0.25,0.4,0.0,0.0,0.15,0.016705016763488754,0.37903115821414524,0.016705016763488754,0.0,0.9832949832365112,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5501150502904664
2024-06-24,2024-06-24 07:00:00,Biocon Biologics gets EMA nod to manufacture biosimilar Bevacizumab at its new facility in Bengaluru - financialexpress.com,"<a href=""https://news.google.com/rss/articles/CBMi9AFBVV95cUxPV29uNmlhWDhxVGVncnIwY0tIWWNQVnp5VFdDelQyVWpLSEVDbTAwcldUcXFicUxGaDUwcF9TdzZmeE5XcU1tTUI5c1RnY0VjUmhEVVBBdmtPTy1WUkV5cVh5THBlQnZXSmdzZFNmYjVTSFBUMy1yZEF0V3l0akRQQW90QnlqUlU1cFpHUVhxOW1kbEJ6MnpOWkhKTUVfam9JM1JRc01mUXBCeDZOeVUtU1k3dzlYYnVvaXFqNHlHSkdCbTBhZ2Y5ZHJJUGx1TFlCYVpJUThGMF9BVHlqVGpPdFVHRlhlenBzZ0JfaVhtQ3htU0hp?oc=5"" target=""_blank"">Biocon Biologics gets EMA nod to manufacture biosimilar Bevacizumab at its new facility in Bengaluru</a>&nbsp;&nbsp;<font color=""#6f6f6f"">financialexpress.com</font>",https://news.google.com/rss/articles/CBMi9AFBVV95cUxPV29uNmlhWDhxVGVncnIwY0tIWWNQVnp5VFdDelQyVWpLSEVDbTAwcldUcXFicUxGaDUwcF9TdzZmeE5XcU1tTUI5c1RnY0VjUmhEVVBBdmtPTy1WUkV5cVh5THBlQnZXSmdzZFNmYjVTSFBUMy1yZEF0V3l0akRQQW90QnlqUlU1cFpHUVhxOW1kbEJ6MnpOWkhKTUVfam9JM1JRc01mUXBCeDZOeVUtU1k3dzlYYnVvaXFqNHlHSkdCbTBhZ2Y5ZHJJUGx1TFlCYVpJUThGMF9BVHlqVGpPdFVHRlhlenBzZ0JfaVhtQ3htU0hp?oc=5,Google News,Biocon manufacturing compliance,regulatory,2025-06-27T05:41:50.143675,0.0,0.5,0.2,0.0,0.0,0.15,0.00872519608973064,0.3157316933978688,0.00872519608973064,0.0,0.9912748039102693,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5261755882691919
2022-11-30,2022-11-30 08:00:00,Saraf And Partners Acts For Viatris In Its Sale Of Biosimilars Business To Biocon Biologics For US$ 3.335 ... - Live Law,"<a href=""https://news.google.com/rss/articles/CBMiowFBVV95cUxNbkp2ZXhsTXdnYXBrdVVPYjM5RFcyYUtsTU1WS0RCMFI4TmF6SVJMSzBtN1BpSlBZU0FsaERRN1pNX1FCUmVqRjQyME1JNEo0LWVYS1g2ek1QajhRSXFzY2J0VEVrdkdSQnNmd3ZGSmxYQ2I2V1l4Q2NTQ0R3ODg3QmtWV3ViN19GTE9YNWlnRWZCY0xHd1FmYTZSUjRaaF95bU1N0gGoAUFVX3lxTE9namdJRmlpMGVlMUdKck01MmN6bzFsY2JEU00tcF93a19zQnQ3MzZJNGdsQkdqWlRIakM3X3BZZlcwUmN6T2tyWFNoVWtJYTNvb3FCaHJFLThfX0FyZXJfTUszbEhTek96OHVtN2QxcWdzTWFiY01FUUVwVUtsMnNHSV9QbDE1ZWhyX3J4Q0JMOFF5eXpxcWVxTGRzTEdzanpUV1NKRjBQQw?oc=5"" target=""_blank"">Saraf And Partners Acts For Viatris In Its Sale Of Biosimilars Business To Biocon Biologics For US$ 3.335 ...</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Live Law</font>",https://news.google.com/rss/articles/CBMiowFBVV95cUxNbkp2ZXhsTXdnYXBrdVVPYjM5RFcyYUtsTU1WS0RCMFI4TmF6SVJMSzBtN1BpSlBZU0FsaERRN1pNX1FCUmVqRjQyME1JNEo0LWVYS1g2ek1QajhRSXFzY2J0VEVrdkdSQnNmd3ZGSmxYQ2I2V1l4Q2NTQ0R3ODg3QmtWV3ViN19GTE9YNWlnRWZCY0xHd1FmYTZSUjRaaF95bU1N0gGoAUFVX3lxTE9namdJRmlpMGVlMUdKck01MmN6bzFsY2JEU00tcF93a19zQnQ3MzZJNGdsQkdqWlRIakM3X3BZZlcwUmN6T2tyWFNoVWtJYTNvb3FCaHJFLThfX0FyZXJfTUszbEhTek96OHVtN2QxcWdzTWFiY01FUUVwVUtsMnNHSV9QbDE1ZWhyX3J4Q0JMOFF5eXpxcWVxTGRzTEdzanpUV1NKRjBQQw?oc=5,Google News,Biocon R&D investment,strategic,2025-06-27T05:42:09.480466,0.0,0.5,0.2,0.0,0.0,0.15,0.007985014941892367,0.34499884554834076,0.007985014941892367,0.0,0.9920149850581076,0,0,0,0.0,3.335,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5239550448256771
2024-03-04,2024-03-04 08:00:00,Biocon Biologics gets green light to launch Yesafili biosimilar in Canada - Business Standard,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics gets green light to launch Yesafili biosimilar in Canada</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Business Standard</font>",https://news.google.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?oc=5,Google News,Biocon insider trading,sentiment,2025-06-27T05:42:22.956142,0.0,0.5,0.2,0.0,0.0,0.15,0.00523453975464563,0.20793334756578719,0.00523453975464563,0.0,0.9947654602453544,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5157036192639368
2022-03-01,2022-03-01 08:00:00,Biocon Biologics Acquires Viatris’ Biosimilar Portfolio - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMinAFBVV95cUxNWXlidXE5elVHajM4S1V5UklBSE5WVEFKM0pFSkp2X0hScjVLSUx5dFgzQWZZbXpCMDVzVXhmWmdIU09oN3drNHVnbHhCdDBwVUVKTmYxM0ZXVXYzSTMzTlRUZXU4dGlOY3kyYVpHcHJiWklvZjhpZkFKUFlOVTZ6UE9pRlBSZmh1MTBUVzduLWRiSU02TERJX0FxNHE?oc=5"" target=""_blank"">Biocon Biologics Acquires Viatris’ Biosimilar Portfolio</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMinAFBVV95cUxNWXlidXE5elVHajM4S1V5UklBSE5WVEFKM0pFSkp2X0hScjVLSUx5dFgzQWZZbXpCMDVzVXhmWmdIU09oN3drNHVnbHhCdDBwVUVKTmYxM0ZXVXYzSTMzTlRUZXU4dGlOY3kyYVpHcHJiWklvZjhpZkFKUFlOVTZ6UE9pRlBSZmh1MTBUVzduLWRiSU02TERJX0FxNHE?oc=5,Google News,Biocon revenue guidance,financial,2025-06-27T05:41:36.734690,0.0,0.5,0.2,0.0,0.0,0.15,-0.004438285614321929,0.33379588656955295,0.0,0.004438285614321929,0.9955617143856781,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5133148568429657
2024-04-09,2024-04-09 07:00:00,"Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future - Pharma Voice","<a href=""https://news.google.com/rss/articles/CBMimwFBVV95cUxQVnV5ZXhReV9pVTMzSHpjN0ZDaUpKa0VaZHNxQzU2LUpMUnVQbnU3WG5rTkkzYzJ3ZEdfMHJIamF4aWwtcDNEN2taMXdocDRoY0duYkxTVkQwV1VKSDZ5U2NYMHEyaWNac3NYOGFEa0FrODIzRTBDV2M1ZElpSERCeng4SEhPYmxTX1ZMdHNPTnNJdlB5V3d6d3Jqbw?oc=5"" target=""_blank"">Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Pharma Voice</font>",https://news.google.com/rss/articles/CBMimwFBVV95cUxQVnV5ZXhReV9pVTMzSHpjN0ZDaUpKa0VaZHNxQzU2LUpMUnVQbnU3WG5rTkkzYzJ3ZEdfMHJIamF4aWwtcDNEN2taMXdocDRoY0duYkxTVkQwV1VKSDZ5U2NYMHEyaWNac3NYOGFEa0FrODIzRTBDV2M1ZElpSERCeng4SEhPYmxTX1ZMdHNPTnNJdlB5V3d6d3Jqbw?oc=5,Google News,Semglee biosimilar approval,drug_fda,2025-06-27T05:41:08.121864,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.2943894863128662,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2024-03-01,2024-03-01 08:00:00,Biocon Biologics Biocon Campus (Site 1) facility gets 4 USFDA observations - Medical Dialogues,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics Biocon Campus (Site 1) facility gets 4 USFDA observations</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Medical Dialogues</font>",https://news.google.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?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.421832,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.31232823928197223,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2024-02-29,2024-02-29 08:00:00,US FDA issues 4 observations for Biocon Biologics' insulin facility - Moneycontrol,"<a href=""https://news.google.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?oc=5"" target=""_blank"">US FDA issues 4 observations for Biocon Biologics' insulin facility</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Moneycontrol</font>",https://news.google.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?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.382917,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3111370801925659,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2024-02-09,2024-02-09 08:00:00,Biocon Biologics Inks Pact With Sandoz For Sale Of 2 Biosimilar Products In Australia - outlookbusiness.com,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics Inks Pact With Sandoz For Sale Of 2 Biosimilar Products In Australia</a>&nbsp;&nbsp;<font color=""#6f6f6f"">outlookbusiness.com</font>",https://news.google.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?oc=5,Google News,Biocon strategic partnership,strategic,2025-06-27T05:42:03.008959,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3092639247576396,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2024-02-08,2024-02-08 08:00:00,Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMi4AFBVV95cUxPRjd6eW8tSEtDTzEzVkIwTDNoUVphNHlYRzRlWldTOURzLWo4WlVPOS0wTkstbVhqLVNPQWx3WDFzQnNWdzk3MndhVzRMTUFWUnR1M2RZbEpkVmttd1o4NGNBVnhLQV9aZ08wTE1SdjVVNTN1V25kbzVDaFhYQ1hDd3J4TDlUN1JsaUo4OWt4dzgtcE1JcGs4UkZOWEJFRVpVYWNpTG1GTDUwTV9vTVp1OHFiXzcweHNWODdRRU5tVGItdG42VldGTVd0ek1PVk5SUjU3QmpadjUzWURvelRBbw?oc=5"" target=""_blank"">Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi4AFBVV95cUxPRjd6eW8tSEtDTzEzVkIwTDNoUVphNHlYRzRlWldTOURzLWo4WlVPOS0wTkstbVhqLVNPQWx3WDFzQnNWdzk3MndhVzRMTUFWUnR1M2RZbEpkVmttd1o4NGNBVnhLQV9aZ08wTE1SdjVVNTN1V25kbzVDaFhYQ1hDd3J4TDlUN1JsaUo4OWt4dzgtcE1JcGs4UkZOWEJFRVpVYWNpTG1GTDUwTV9vTVp1OHFiXzcweHNWODdRRU5tVGItdG42VldGTVd0ek1PVk5SUjU3QmpadjUzWURvelRBbw?oc=5,Google News,Biocon strategic partnership,strategic,2025-06-27T05:42:03.008357,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.30892135699590045,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2023-10-18,2023-10-18 07:00:00,Biocon Biologics arm gets OAI status from USFDA for Malaysia insulin facility - Medical Dialogues,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics arm gets OAI status from USFDA for Malaysia insulin facility</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Medical Dialogues</font>",https://news.google.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?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.422106,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.29718929529190063,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2023-09-07,2023-09-07 07:00:00,Biocon Biologics completes integration of Viatris biosimilars business in North America - ET HealthWorld,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics completes integration of Viatris biosimilars business in North America</a>&nbsp;&nbsp;<font color=""#6f6f6f"">ET HealthWorld</font>",https://news.google.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?oc=5,Google News,Biocon regulatory filing,regulatory,2025-06-27T05:41:53.451882,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.24203125635782877,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2023-09-07,2023-09-07 07:00:00,Biocon Biologics may reveal details of its likely IPO post integration of the acquired biosimilar business - CNBC TV18,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics may reveal details of its likely IPO post integration of the acquired biosimilar business</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.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?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.350642,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3152846296628316,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2023-09-07,2023-09-07 07:00:00,Biocon Biologics completes integration of biosimilars biz - BizzBuzz,"<a href=""https://news.google.com/rss/articles/CBMiogFBVV95cUxObURXcFZoS3VHc1ppNWtlT0dMV01FSXFnRnZ3TEo1QXZBOFRWczJVS0M5LTZmSkNuVnFYdkp1R3pIMy1oN0ZWWXBfQTM0U3J6b0tBZ1ZTdWp4UFRWUXJHVDNjMDUwTlhva0lGN2ZPRkpiV1ZfVmRWZ0lJalktVmxLVEYwUUpGMHJSSExvaFpGU0tyMUV1S253MDdfTnM2VUhPT3c?oc=5"" target=""_blank"">Biocon Biologics completes integration of biosimilars biz</a>&nbsp;&nbsp;<font color=""#6f6f6f"">BizzBuzz</font>",https://news.google.com/rss/articles/CBMiogFBVV95cUxObURXcFZoS3VHc1ppNWtlT0dMV01FSXFnRnZ3TEo1QXZBOFRWczJVS0M5LTZmSkNuVnFYdkp1R3pIMy1oN0ZWWXBfQTM0U3J6b0tBZ1ZTdWp4UFRWUXJHVDNjMDUwTlhva0lGN2ZPRkpiV1ZfVmRWZ0lJalktVmxLVEYwUUpGMHJSSExvaFpGU0tyMUV1S253MDdfTnM2VUhPT3c?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.350968,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.30091331402460736,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2023-06-03,2023-06-03 07:00:00,USFDA issues zero observations to Biocon Pharma Bengaluru facility - Medical Dialogues,"<a href=""https://news.google.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?oc=5"" target=""_blank"">USFDA issues zero observations to Biocon Pharma Bengaluru facility</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Medical Dialogues</font>",https://news.google.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?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.422069,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3069764773050944,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2022-12-12,2022-12-12 08:00:00,Biocon Biologics Completes $3 Billion Acquisition of Viatris’ Biosimilars - Managed Healthcare Executive,"<a href=""https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSzFZdWoyeWFuWGdUamppTlpYZURWcWpSSXE1YnBGSGhPY2N5eFQtbTdwb1hNdnY3d1M3SElhdDRpZG1ld0hWMkYwcGJXZl90b3R4WUpiMEJfdzg1dl81QkJLYVRoR1RGWjNCcnJOOXJRX1ZPaG4tS0M4VmhETkFjT04tWlZHZEtJdFBaWmhhLTl6cF9keWVBakIzTGFNRzRsSWtkcVc4TlFYSG1tWU9SNnZUM1FTaDJxR0tV?oc=5"" target=""_blank"">Biocon Biologics Completes $3 Billion Acquisition of Viatris’ Biosimilars</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Managed Healthcare Executive</font>",https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSzFZdWoyeWFuWGdUamppTlpYZURWcWpSSXE1YnBGSGhPY2N5eFQtbTdwb1hNdnY3d1M3SElhdDRpZG1ld0hWMkYwcGJXZl90b3R4WUpiMEJfdzg1dl81QkJLYVRoR1RGWjNCcnJOOXJRX1ZPaG4tS0M4VmhETkFjT04tWlZHZEtJdFBaWmhhLTl6cF9keWVBakIzTGFNRzRsSWtkcVc4TlFYSG1tWU9SNnZUM1FTaDJxR0tV?oc=5,Google News,Biocon FDA approval impact,financial,2025-06-27T05:41:43.381759,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.29782166083653766,0.0,0.0,1.0,0,0,0,0.0,3.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2022-11-30,2022-11-30 08:00:00,Biocon Biologics completes $3.3 billion acquisition of Viatris' biosimilars business - CNBC TV18,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics completes $3.3 billion acquisition of Viatris' biosimilars business</a>&nbsp;&nbsp;<font color=""#6f6f6f"">CNBC TV18</font>",https://news.google.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?oc=5,Google News,Biocon biologics revenue,financial,2025-06-27T05:41:38.242933,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.2927764058113098,0.0,0.0,1.0,0,0,0,0.0,3.3,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2022-11-30,2022-11-30 08:00:00,Biocon Biologics completes Acquisition of Viatris’ Global Biosimilars Business - The Financial World,"<a href=""https://news.google.com/rss/articles/CBMisgFBVV95cUxQOV9TVHdKS0FfdHVsNGpHdDZjLWNxajhLYjdwWm94VmlYMENfcTlqNDg2am0zU2VrMFBwQm1fQkw3WXJlVTVTNktNSmc3dHdBMmlFa0kxR0NRMXZieFNlMHFuYnFrVUZWN3RGSEl5dzRYZjFWT1RzclN4b3RxX1FBc1Y3S1F6Zk5zZnF6dndHak5sWE1Tbk5FSjFLS09naHdmd2RrbFFISWs0TFRUSlU2VWh3?oc=5"" target=""_blank"">Biocon Biologics completes Acquisition of Viatris’ Global Biosimilars Business</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Financial World</font>",https://news.google.com/rss/articles/CBMisgFBVV95cUxQOV9TVHdKS0FfdHVsNGpHdDZjLWNxajhLYjdwWm94VmlYMENfcTlqNDg2am0zU2VrMFBwQm1fQkw3WXJlVTVTNktNSmc3dHdBMmlFa0kxR0NRMXZieFNlMHFuYnFrVUZWN3RGSEl5dzRYZjFWT1RzclN4b3RxX1FBc1Y3S1F6Zk5zZnF6dndHak5sWE1Tbk5FSjFLS09naHdmd2RrbFFISWs0TFRUSlU2VWh3?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.350542,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3103688557942708,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2022-11-29,2022-11-29 08:00:00,Biocon Biologics Completes Acquisition of Viatris' Global Biosimilars Business - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMi0gFBVV95cUxQbkdQcDBWNE5RdHo0eV9rYzhFajFvanJRQm5obHF1cWZwRXJfTEUxTHRrZFJqUjdEZmdTUWdwR2EwWl81dmZaMHpfMEM0UENfX1FrZlF2VUZvdV9oNVdJUDR5TUVZcUpYRjJsUjVPaXF1am1NdFRyRzRyVFFBZXlVRGJkUGJoR0N6Qko3cFl1alQ4TE1BRjVXaHdpcGtCN1BsVmNxWUNydnBwWWU1UFVkUVdPdXVZTk5COTRlRzZsWW1aNlVaZXlLcmNGZ0ZGbWNNZ0E?oc=5"" target=""_blank"">Biocon Biologics Completes Acquisition of Viatris' Global Biosimilars Business</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMi0gFBVV95cUxQbkdQcDBWNE5RdHo0eV9rYzhFajFvanJRQm5obHF1cWZwRXJfTEUxTHRrZFJqUjdEZmdTUWdwR2EwWl81dmZaMHpfMEM0UENfX1FrZlF2VUZvdV9oNVdJUDR5TUVZcUpYRjJsUjVPaXF1am1NdFRyRzRyVFFBZXlVRGJkUGJoR0N6Qko3cFl1alQ4TE1BRjVXaHdpcGtCN1BsVmNxWUNydnBwWWU1UFVkUVdPdXVZTk5COTRlRzZsWW1aNlVaZXlLcmNGZ0ZGbWNNZ0E?oc=5,Google News,Biocon biologics revenue,financial,2025-06-27T05:41:38.242643,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3092961510022481,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2022-11-29,2022-11-29 08:00:00,Viatris Completes Biosimilars Transaction with Biocon Biologics - PR Newswire,"<a href=""https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcjE1TGJPaHcwSlVwUXFPaDZCOTZfYy13OXhYZzN0ajFtcDRGSjFEYjM0TEp6aFNkVERBeFpWNlk1Ym9oRkJDR1JiWlpMcVJkOUZfQ182MGxPNUd0cEdfSFhQelRGRHRSMWxHSlZSTVpMaGNwaGdHWmdBcUJUZFF2NnFUUndaLUNyTnJaYkVKdy14NUJYT0F3RHB4TXB6TlpISG9LS3NjT3VZamJUbGIxMm96czI0TXFpVHk4?oc=5"" target=""_blank"">Viatris Completes Biosimilars Transaction with Biocon Biologics</a>&nbsp;&nbsp;<font color=""#6f6f6f"">PR Newswire</font>",https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcjE1TGJPaHcwSlVwUXFPaDZCOTZfYy13OXhYZzN0ajFtcDRGSjFEYjM0TEp6aFNkVERBeFpWNlk1Ym9oRkJDR1JiWlpMcVJkOUZfQ182MGxPNUd0cEdfSFhQelRGRHRSMWxHSlZSTVpMaGNwaGdHWmdBcUJUZFF2NnFUUndaLUNyTnJaYkVKdy14NUJYT0F3RHB4TXB6TlpISG9LS3NjT3VZamJUbGIxMm96czI0TXFpVHk4?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.349637,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.30944087107976276,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2022-09-01,2022-09-01 07:00:00,"FDA slaps Biocon following inspections of biosimilar production sites in India, Malaysia - Fierce Pharma","<a href=""https://news.google.com/rss/articles/CBMirgFBVV95cUxNdzVWY0FTVzAwR3dkNkg1eVhFajNMRmpNaUlnRjM1MWh6TkhsVkt4c0JHcnZ4T29yRF9wdGFGSDMxYlR3ci1VWExnOFBlYk50a241NnhTbGtvb2FoNkQxSjZmVk05N2RQMDFOUDVZbXlHQTFjV2ZWS05fZ25EU3drTDhfMk81eWhrZlpncFFpdnlJbmdya2NQZUlNaFBmU3k0ZnVWaW9meFh0MkpDc2c?oc=5"" target=""_blank"">FDA slaps Biocon following inspections of biosimilar production sites in India, Malaysia</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Fierce Pharma</font>",https://news.google.com/rss/articles/CBMirgFBVV95cUxNdzVWY0FTVzAwR3dkNkg1eVhFajNMRmpNaUlnRjM1MWh6TkhsVkt4c0JHcnZ4T29yRF9wdGFGSDMxYlR3ci1VWExnOFBlYk50a241NnhTbGtvb2FoNkQxSjZmVk05N2RQMDFOUDVZbXlHQTFjV2ZWS05fZ25EU3drTDhfMk81eWhrZlpncFFpdnlJbmdya2NQZUlNaFBmU3k0ZnVWaW9meFh0MkpDc2c?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.421156,0.0,0.25,0.4,0.0,0.0,0.15,0.0,0.1859575112660726,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2022-09-01,2022-09-01 07:00:00,Biocon Biologics receives observations from USFDA: Biocon - ET HealthWorld,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics receives observations from USFDA: Biocon</a>&nbsp;&nbsp;<font color=""#6f6f6f"">ET HealthWorld</font>",https://news.google.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?oc=5,Google News,Biocon regulatory filing,regulatory,2025-06-27T05:41:53.452057,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.31584789355595905,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2022-02-28,2022-02-28 08:00:00,Biocon Biologics to acquire Viatris Inc’s biosimilars biz for USD 3.33 bn - Trade Brains,"<a href=""https://news.google.com/rss/articles/CBMiZEFVX3lxTE9ENzhxOVRwZUlrYnoyZDdoZHJIVHNCbkpNYXQ3NTd3VzZuYTFNeXdOWTdWczBJV1FYTUx2ODJkcVJoY05DZUk2am5oTVk3RmQzTlUtNkYwNnRDZS1rQmNTUXV0ZGc?oc=5"" target=""_blank"">Biocon Biologics to acquire Viatris Inc’s biosimilars biz for USD 3.33 bn</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Trade Brains</font>",https://news.google.com/rss/articles/CBMiZEFVX3lxTE9ENzhxOVRwZUlrYnoyZDdoZHJIVHNCbkpNYXQ3NTd3VzZuYTFNeXdOWTdWczBJV1FYTUx2ODJkcVJoY05DZUk2am5oTVk3RmQzTlUtNkYwNnRDZS1rQmNTUXV0ZGc?oc=5,Google News,Biocon acquisition,strategic,2025-06-27T05:42:06.351220,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.30593512455622357,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2021-02-05,2021-02-05 08:00:00,Biocon Biologics to offer its oncology biosimilars in 30+ countries - Indian Pharma Post,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocon Biologics to offer its oncology biosimilars in 30+ countries</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Indian Pharma Post</font>",https://news.google.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?oc=5,Google News,Biocon strategic partnership,strategic,2025-06-27T05:42:03.009272,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.30816545089085895,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2020-04-16,2020-04-16 07:00:00,Biocon Biologics gets EIR from US FDA for two manufacturing facilities - Express Pharma,"<a href=""https://news.google.com/rss/articles/CBMiogFBVV95cUxPR1g0aXdVeWMySG5EQXpza3g0MXFlY2NEM1dMNVFjSWlrclJGdEtJOFY4and1b1FBdUt6Y2hLYVFnOU5CNjBJSHl3RHhXRkRscTJhOW53ZUZuV2h3QUlqN2Y2QXBpUDFib05ZS1JpSDgza3c4amRMckFOUFZzT2I0WGJxOUstSzFBd1M3dVIzdVcxWnVWZjNlVHJYSmttaTE0alHSAacBQVVfeXFMT0xlMkI0RXJRZFBER2RpWElhVDFGTkZBWXIwTlNiSkVyR0RERXR4c25SV2RjeENYdTNyeG00WE9fZTQweU5xWHVXZi0wU2NHVXRhUTBjRWZJQUtsa1BQZjIxeVBNMHNJT2ZZQXU5Mmh1cjNSOG1uMm5Ia1ZpZnFvRWVhMWVvM1RxM1c3ejk3djVxMkp2cWRodTZBRUtDVVA0Mnh6NjhqMHM?oc=5"" target=""_blank"">Biocon Biologics gets EIR from US FDA for two manufacturing facilities</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Express Pharma</font>",https://news.google.com/rss/articles/CBMiogFBVV95cUxPR1g0aXdVeWMySG5EQXpza3g0MXFlY2NEM1dMNVFjSWlrclJGdEtJOFY4and1b1FBdUt6Y2hLYVFnOU5CNjBJSHl3RHhXRkRscTJhOW53ZUZuV2h3QUlqN2Y2QXBpUDFib05ZS1JpSDgza3c4amRMckFOUFZzT2I0WGJxOUstSzFBd1M3dVIzdVcxWnVWZjNlVHJYSmttaTE0alHSAacBQVVfeXFMT0xlMkI0RXJRZFBER2RpWElhVDFGTkZBWXIwTlNiSkVyR0RERXR4c25SV2RjeENYdTNyeG00WE9fZTQweU5xWHVXZi0wU2NHVXRhUTBjRWZJQUtsa1BQZjIxeVBNMHNJT2ZZQXU5Mmh1cjNSOG1uMm5Ia1ZpZnFvRWVhMWVvM1RxM1c3ejk3djVxMkp2cWRodTZBRUtDVVA0Mnh6NjhqMHM?oc=5,Google News,Biocon FDA inspection,regulatory,2025-06-27T05:41:48.422493,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.299730916817983,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2020-04-16,2020-04-16 07:00:00,Biocon Biologics receives EIR from USFDA for two manufacturing facilities in Bengaluru - Firstpost,"<a href=""https://news.google.com/rss/articles/CBMizwFBVV95cUxPVkNiQWY1cGZ3eG5fMmt1MUdwanE0bEpKTTdvRThpWG02U2ZScjNpT253RjdQRUs0YXhaMzBnTTc1S2ZwM3dyMkVZX1VWM1hjekVCMUlMT1kyaUNpb2FFUmkxaU9qMUlySEhFcTRqQjdCeDNvRHlyeUk4YVBLaVd3RlloM0Nid1JJM1JWNndBYkdHRDhKaHNEQWZhZFNUcVk2dEhQOEFueDA5cVNXSlVVUW1jdF95cVRyZkVsYVJpMnpNWG1pdlVMc1Vfc1E3dW_SAdQBQVVfeXFMUHo4YXY2WkF5dElJa0JZbUttb0t2alhRSXpsRzAzeW43SWhENlFCRTNza09ZLW9MVldxYVVTVndPU19Gd0cyRndRRXVkcnRmYmFCdHY2MVJfTkJVRGN4YVNSVFBia3VHaGFPSU5xdWdBcWFpcTlSZmNLWGwtcmNsdmVFX05faHExY3VIb2J2UlptNWdKVnZjcE9ONDFzT3RFc19ycU51WXZsQ2hPU3VubFgtQ2VvUERiUW5YTnVCdDNhT19DNk9WOGF5TGlocE1wNmx0X2k?oc=5"" target=""_blank"">Biocon Biologics receives EIR from USFDA for two manufacturing facilities in Bengaluru</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Firstpost</font>",https://news.google.com/rss/articles/CBMizwFBVV95cUxPVkNiQWY1cGZ3eG5fMmt1MUdwanE0bEpKTTdvRThpWG02U2ZScjNpT253RjdQRUs0YXhaMzBnTTc1S2ZwM3dyMkVZX1VWM1hjekVCMUlMT1kyaUNpb2FFUmkxaU9qMUlySEhFcTRqQjdCeDNvRHlyeUk4YVBLaVd3RlloM0Nid1JJM1JWNndBYkdHRDhKaHNEQWZhZFNUcVk2dEhQOEFueDA5cVNXSlVVUW1jdF95cVRyZkVsYVJpMnpNWG1pdlVMc1Vfc1E3dW_SAdQBQVVfeXFMUHo4YXY2WkF5dElJa0JZbUttb0t2alhRSXpsRzAzeW43SWhENlFCRTNza09ZLW9MVldxYVVTVndPU19Gd0cyRndRRXVkcnRmYmFCdHY2MVJfTkJVRGN4YVNSVFBia3VHaGFPSU5xdWdBcWFpcTlSZmNLWGwtcmNsdmVFX05faHExY3VIb2J2UlptNWdKVnZjcE9ONDFzT3RFc19ycU51WXZsQ2hPU3VubFgtQ2VvUERiUW5YTnVCdDNhT19DNk9WOGF5TGlocE1wNmx0X2k?oc=5,Google News,Biocon facility inspection,regulatory,2025-06-27T05:41:58.124456,0.0,0.5,0.2,0.0,0.0,0.15,0.0,0.3064807653427124,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.5
2023-03-02,2023-03-02 08:00:00,Lilly Plans to Launch Insulin Biosimilar at 78% Discount to Lantus - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMiqwFBVV95cUxQTXlFN2JjYVFMaW51cV8zdTFRQkZ2c0dCZTBFWUhVM1pIUE52cmxoSG9Zb0VTM2lLQ2lHT0o5OUdtNGVsWmpWMlBnajdrdDlSdW9yczVFbE85dW9GRDZveG5yTGJhMmJUMUk1SDltNWhaN2ZfZDNnRTdDT3ZIcUE1X1NyVjNQYUUtSGE0dTdxUU40bzlJRWxETWpZbjVuaG50aTB0SVU0cG8wZjA?oc=5"" target=""_blank"">Lilly Plans to Launch Insulin Biosimilar at 78% Discount to Lantus</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMiqwFBVV95cUxQTXlFN2JjYVFMaW51cV8zdTFRQkZ2c0dCZTBFWUhVM1pIUE52cmxoSG9Zb0VTM2lLQ2lHT0o5OUdtNGVsWmpWMlBnajdrdDlSdW9yczVFbE85dW9GRDZveG5yTGJhMmJUMUk1SDltNWhaN2ZfZDNnRTdDT3ZIcUE1X1NyVjNQYUUtSGE0dTdxUU40bzlJRWxETWpZbjVuaG50aTB0SVU0cG8wZjA?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.587071,0.2,0.0,0.2,0.0,0.2,0.13,-0.0045581828974386954,0.3250158045026991,0.0,0.0045581828974386954,0.9954418171025613,0,0,0,78.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.313674548692316
2023-12-01,2023-12-01 08:00:00,Biocons subsidiary completes integration of Viatris biosimilars business; stock rises - Zee Business,"<a href=""https://news.google.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?oc=5"" target=""_blank"">Biocons subsidiary completes integration of Viatris biosimilars business; stock rises</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Zee Business</font>",https://news.google.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?oc=5,Google News,Biocon regulatory filing,regulatory,2025-06-27T05:41:53.453321,0.0,0.25,0.2,0.16666666666666666,0.0,0.125,0.0,0.2661971648534139,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.25
2023-09-18,2023-09-18 07:00:00,Common Patient Questions About Insulin Biosimilars Pertain to Classification - Pharmacy Times,"<a href=""https://news.google.com/rss/articles/CBMisAFBVV95cUxOaVJNTGcxd2o4T0hkWU54cExTWGVYbURJQ0pDSU03VmI2Um9xZ2ZYQnJYUVF1V1czMkZMczVNcnR6cUh5WWRpajhmOVFYbHBOVDRqcndhVy12aVRDSVpGRDBKNHQxUGtTREhxRTlaMlgtamdORkpucF9qMFpEWHBKYVJubnM4TU9EX212Nkl3YS1WR0RBcmNTVlAzWEdSUVk0Z2ZuVDViRjhES0hEWjNmVw?oc=5"" target=""_blank"">Common Patient Questions About Insulin Biosimilars Pertain to Classification</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Pharmacy Times</font>",https://news.google.com/rss/articles/CBMisAFBVV95cUxOaVJNTGcxd2o4T0hkWU54cExTWGVYbURJQ0pDSU03VmI2Um9xZ2ZYQnJYUVF1V1czMkZMczVNcnR6cUh5WWRpajhmOVFYbHBOVDRqcndhVy12aVRDSVpGRDBKNHQxUGtTREhxRTlaMlgtamdORkpucF9qMFpEWHBKYVJubnM4TU9EX212Nkl3YS1WR0RBcmNTVlAzWEdSUVk0Z2ZuVDViRjhES0hEWjNmVw?oc=5,Google News,insulin glargine-yfgn FDA,drug_fda,2025-06-27T05:41:11.427296,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,-0.034782574803289834,0.3833337068557739,0.0,0.034782574803289834,0.9652174251967102,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.2043477244098697
2021-11-05,2021-11-05 07:00:00,Prime Therapeutics to list Semglee and Insulin Glargine - Indian Pharma Post,"<a href=""https://news.google.com/rss/articles/CBMioAFBVV95cUxPbm5mbmJrNVhOQk1LMjA0WDRYSm9YRUppc3cxOGpRVnJydTRWSTJvb0UtS3YwNmRvX0dIU2pQM1JoMm1CMGRvTk16SzNlUkhoUWFDX2IyN3VaajdYc2QxYjQzMWtYM01Tdl9VSTlqY2k1d1dHd3ZaLVk1TUxPZ2lhUlhCTXhuNFA1MVgxYjFMSVpCQkxEcDY1b3ZZTVQ3M3Jw0gGnAUFVX3lxTE9PNlROYnpHRnltX1Zad3Q1X0lZS2J0RUpxSFJpemhVWmphcnpnSjFLMTB0MmZMR0ZmU2NwTGZjalBtZG00WC02a0lnSldhcHpUTkJLbXk4TGtVQ1JCdFhLdzAxanZsMURWT0prNkJPQ2ZWR0dwUXRpdmw3YlEzZ0VYUVZUdXZjRTVsM25NaUlWT0MwaHNtcGxBNXhveXQ2T1RaZlZQbGY0?oc=5"" target=""_blank"">Prime Therapeutics to list Semglee and Insulin Glargine</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Indian Pharma Post</font>",https://news.google.com/rss/articles/CBMioAFBVV95cUxPbm5mbmJrNVhOQk1LMjA0WDRYSm9YRUppc3cxOGpRVnJydTRWSTJvb0UtS3YwNmRvX0dIU2pQM1JoMm1CMGRvTk16SzNlUkhoUWFDX2IyN3VaajdYc2QxYjQzMWtYM01Tdl9VSTlqY2k1d1dHd3ZaLVk1TUxPZ2lhUlhCTXhuNFA1MVgxYjFMSVpCQkxEcDY1b3ZZTVQ3M3Jw0gGnAUFVX3lxTE9PNlROYnpHRnltX1Zad3Q1X0lZS2J0RUpxSFJpemhVWmphcnpnSjFLMTB0MmZMR0ZmU2NwTGZjalBtZG00WC02a0lnSldhcHpUTkJLbXk4TGtVQ1JCdFhLdzAxanZsMURWT0prNkJPQ2ZWR0dwUXRpdmw3YlEzZ0VYUVZUdXZjRTVsM25NaUlWT0MwaHNtcGxBNXhveXQ2T1RaZlZQbGY0?oc=5,Google News,Semglee vs Lantus,competitive,2025-06-27T05:41:22.132339,0.4,0.0,0.0,0.0,0.0,0.12000000000000002,0.0,0.31440873940785724,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.2000000000000002
2023-09-30,2023-09-30 07:00:00,Common Patient Questions About Insulin Biosimilars Pertain to Classification - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMiugFBVV95cUxNZzBSM2lmYXJOdW04b3N4aVJtYUZFYklPTFIyTnVmeDdiOHFoc2lRM1kwZ25IblJuZlZqM1d6Z3RTZVpkWnRVS092NGZnR1lrbHZrSW8wNlJEcWVCcjd0MHdCLUxJS2FJbVVsVGNqT09LR3lHZGpFcDVjSGVZWGtNaEZDdFFYOTZXaFNjQ2NlaWlMdGZvSWczVm9hbHNEWldVd0RydUpNRmpIZ1d5QTlMNmFqTWxlN2RqLVE?oc=5"" target=""_blank"">Common Patient Questions About Insulin Biosimilars Pertain to Classification</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMiugFBVV95cUxNZzBSM2lmYXJOdW04b3N4aVJtYUZFYklPTFIyTnVmeDdiOHFoc2lRM1kwZ25IblJuZlZqM1d6Z3RTZVpkWnRVS092NGZnR1lrbHZrSW8wNlJEcWVCcjd0MHdCLUxJS2FJbVVsVGNqT09LR3lHZGpFcDVjSGVZWGtNaEZDdFFYOTZXaFNjQ2NlaWlMdGZvSWczVm9hbHNEWldVd0RydUpNRmpIZ1d5QTlMNmFqTWxlN2RqLVE?oc=5,Google News,insulin glargine-yfgn FDA,drug_fda,2025-06-27T05:41:11.427386,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,-0.02310739526014787,0.36929014444351194,0.0,0.02310739526014787,0.9768926047398522,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.1693221857804437
2022-08-05,2022-08-05 07:00:00,Eris Lifesciences enters licensing deal with Biocon for insulin glargine - The Economic Times,"<a href=""https://news.google.com/rss/articles/CBMi_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?oc=5"" target=""_blank"">Eris Lifesciences enters licensing deal with Biocon for insulin glargine</a>&nbsp;&nbsp;<font color=""#6f6f6f"">The Economic Times</font>",https://news.google.com/rss/articles/CBMi_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?oc=5,Google News,Biocon licensing deal,strategic,2025-06-27T05:42:04.501380,0.2,0.25,0.0,0.0,0.0,0.11000000000000001,0.017146593467690624,0.345603687233395,0.017146593467690624,0.0,0.9828534065323093,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.151439780403072
2022-03-07,2022-03-07 08:00:00,"Civica Initiates Project to Manufacture, Distribute Insulin Biosimilars for Uninsured Patients - Center for Biosimilars","<a href=""https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdGUzZjBfLXp5aDgyTW5LMFhlTVBNM3d1ZXBuNWpXdTZVb0RETDZSRDNiaUtvOHM2Q3piaXg3dDU0ZDZTMlhwUGhidTZoZkpQNHZpX3dVQkthMy1feVV4ZnZFeTJvZkZNOXRtSEFMNVUyblpwRUFKSnpCUUgzWDBtTVhZckJPZlRtdkZEbXAxZEEyMWxwMFBnSEVuTEZsWXZHNnlQWUtMa1NEczY4RHZtQ1M3N2NPWHZITWhYT0l3Vzgxa0JQZU13VW9hUlVyRzZ4?oc=5"" target=""_blank"">Civica Initiates Project to Manufacture, Distribute Insulin Biosimilars for Uninsured Patients</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdGUzZjBfLXp5aDgyTW5LMFhlTVBNM3d1ZXBuNWpXdTZVb0RETDZSRDNiaUtvOHM2Q3piaXg3dDU0ZDZTMlhwUGhidTZoZkpQNHZpX3dVQkthMy1feVV4ZnZFeTJvZkZNOXRtSEFMNVUyblpwRUFKSnpCUUgzWDBtTVhZckJPZlRtdkZEbXAxZEEyMWxwMFBnSEVuTEZsWXZHNnlQWUtMa1NEczY4RHZtQ1M3N2NPWHZITWhYT0l3Vzgxa0JQZU13VW9hUlVyRzZ4?oc=5,Google News,biosimilar insulin pricing,competitive,2025-06-27T05:41:30.483233,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,-0.004621367785832558,0.32057207955254446,0.0,0.004621367785832558,0.9953786322141674,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.1138641033574979
2021-12-30,2021-12-30 08:00:00,Rezvoglar Broadens Insulin Glargine Biosimilar Options - Center for Biosimilars,"<a href=""https://news.google.com/rss/articles/CBMinAFBVV95cUxPN1h1V29fVkJOTURpVzN6MVBPaHdGQS0zMU1BcjRGdHp2R041c1RncVh0aDJVeUZMNnZSV2tBNjU3bWQ2NktmY19yYUVfRVVPMTh5T3BwYkVHYzc1R1hDUFJTSEZUWHdxZVVFN1FvNFU4SXV5VDJ4dUptaTlESmJtNXFFT1dCc3ZvMUlUekZDaTRLWHNIS3ZjWUFLcVM?oc=5"" target=""_blank"">Rezvoglar Broadens Insulin Glargine Biosimilar Options</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Center for Biosimilars</font>",https://news.google.com/rss/articles/CBMinAFBVV95cUxPN1h1V29fVkJOTURpVzN6MVBPaHdGQS0zMU1BcjRGdHp2R041c1RncVh0aDJVeUZMNnZSV2tBNjU3bWQ2NktmY19yYUVfRVVPMTh5T3BwYkVHYzc1R1hDUFJTSEZUWHdxZVVFN1FvNFU4SXV5VDJ4dUptaTlESmJtNXFFT1dCc3ZvMUlUekZDaTRLWHNIS3ZjWUFLcVM?oc=5,Google News,Semglee biosimilar approval,drug_fda,2025-06-27T05:41:08.121385,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,-0.004426111533213603,0.3347139967812432,0.0,0.004426111533213603,0.9955738884667864,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.1132783345996409
2023-09-21,2023-09-21 07:00:00,Meitheal partners with Chinese company for US licencing of insulin biosimilars - Pharmaceutical Technology,"<a href=""https://news.google.com/rss/articles/CBMixAFBVV95cUxQaE9RYWg2eGo5NURycXNqT2dzX1JjR1JxRngzbnNoTGpIZjN2a3lLVWhRVFBaM1RCQ1VXS2FFRkd5dkZ6S1M2SFh6aElZNEQ3OHdSeVJ4bEpQM2E1RWNBSmRiXzFRYXgyZ0RUbkFJd3dWckdLQTdUM0VUNnpEV2JIR0g0RUlpdEwxRHZjVHZDVTg2LTZ4Ykx4bzV5TWliUllnRVBkUjM1RWs5WXJFQUJGWXZiMHJIaVF4S3ZhMUpmaC1qS05s?oc=5"" target=""_blank"">Meitheal partners with Chinese company for US licencing of insulin biosimilars</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Pharmaceutical Technology</font>",https://news.google.com/rss/articles/CBMixAFBVV95cUxQaE9RYWg2eGo5NURycXNqT2dzX1JjR1JxRngzbnNoTGpIZjN2a3lLVWhRVFBaM1RCQ1VXS2FFRkd5dkZ6S1M2SFh6aElZNEQ3OHdSeVJ4bEpQM2E1RWNBSmRiXzFRYXgyZ0RUbkFJd3dWckdLQTdUM0VUNnpEV2JIR0g0RUlpdEwxRHZjVHZDVTg2LTZ4Ykx4bzV5TWliUllnRVBkUjM1RWs5WXJFQUJGWXZiMHJIaVF4S3ZhMUpmaC1qS05s?oc=5,Google News,insulin glargine biosimilar FDA,drug_fda,2025-06-27T05:41:14.588034,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.0,0.2966880798339844,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.1
2022-02-25,2022-02-25 11:31:02,Figure 3. Utilisation of insulin glargine biosimilar (100IU/ml) as a %... - researchgate.net,"<a href=""https://news.google.com/rss/articles/CBMizgFBVV95cUxPVGNHNXhyZEpZT0k4ak1WWU9KZm9CZDY2YkY0RnFjUkQ3WE1OOVpVV0MyRkZ2MTFSZWtpSkVkUGZuRlNpWlBwVGRBc1lwWHgyaTBYVUZtaXY4OXpGTURDclRLcUhWNTRRdk5VV0ZSaW1iRXZYa2F4Yl81ZU9QVUhGMkpZZ1U2eHBZai1QRXg2emJaMmkwSE96NThrNHFCWTJfbm5MRExzZXBiVzBjX3pNcnQtMlNuUUJCZlNkLWw4Y1ZvQ3lCQ19RM281djdnQQ?oc=5"" target=""_blank"">Figure 3. Utilisation of insulin glargine biosimilar (100IU/ml) as a %...</a>&nbsp;&nbsp;<font color=""#6f6f6f"">researchgate.net</font>",https://news.google.com/rss/articles/CBMizgFBVV95cUxPVGNHNXhyZEpZT0k4ak1WWU9KZm9CZDY2YkY0RnFjUkQ3WE1OOVpVV0MyRkZ2MTFSZWtpSkVkUGZuRlNpWlBwVGRBc1lwWHgyaTBYVUZtaXY4OXpGTURDclRLcUhWNTRRdk5VV0ZSaW1iRXZYa2F4Yl81ZU9QVUhGMkpZZ1U2eHBZai1QRXg2emJaMmkwSE96NThrNHFCWTJfbm5MRExzZXBiVzBjX3pNcnQtMlNuUUJCZlNkLWw4Y1ZvQ3lCQ19RM281djdnQQ?oc=5,Google News,biosimilar insulin pricing,competitive,2025-06-27T05:41:30.484597,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.0,0.31448272864023846,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.1
2021-10-28,2021-10-28 13:27:05,Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total... - researchgate.net,"<a href=""https://news.google.com/rss/articles/CBMizgFBVV95cUxQZ29OSnpXZV9Ic0NwcWo0RURjZ2ZpY0ZLRDhhU3E0RldYRW1uejFmNkFpdF85RHQ5ck1wQUhOOTV6OURVVlZIRjNrUFo0dXhLb3N6cWpqX2hTMXJvakZsRmRTbWZxMzRMZktYWW1vandXYXcxRDBPVTJDUTdvOHJLM1hzaWhKaG5nbVlsRElzczZZczNVR2J6aWJMLWFpa3QtazFob0JlYlNXQ0J5UGxkTXBROEgtQUY0dHZLdTY3Ty1oblZwRDM1OEZkcWxidw?oc=5"" target=""_blank"">Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total...</a>&nbsp;&nbsp;<font color=""#6f6f6f"">researchgate.net</font>",https://news.google.com/rss/articles/CBMizgFBVV95cUxQZ29OSnpXZV9Ic0NwcWo0RURjZ2ZpY0ZLRDhhU3E0RldYRW1uejFmNkFpdF85RHQ5ck1wQUhOOTV6OURVVlZIRjNrUFo0dXhLb3N6cWpqX2hTMXJvakZsRmRTbWZxMzRMZktYWW1vandXYXcxRDBPVTJDUTdvOHJLM1hzaWhKaG5nbVlsRElzczZZczNVR2J6aWJMLWFpa3QtazFob0JlYlNXQ0J5UGxkTXBROEgtQUY0dHZLdTY3Ty1oblZwRDM1OEZkcWxidw?oc=5,Google News,biosimilar insulin pricing,competitive,2025-06-27T05:41:30.484722,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.0,0.3142717480659485,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.1
2021-08-02,2021-08-02 07:00:00,FDA Propels Insulin Affordability with Semglee - diaTribe,"<a href=""https://news.google.com/rss/articles/CBMiiwFBVV95cUxOdFhfaXdVUmFGT3g2dWd0M1hOUDkxUXZKcEhpbGpaaVZISUUyQUNfeFFjRnk4bkl2dTZ4Sk9UZFBZbk55eVhTMlBPWUF2MExyZGlpbllVa0x0d1prMTBzdzQxUG9pM3lpLTZuUFlmdVVUR3FYVzJjcXloVWlfZVZSUTRoa0tJQTNBWVEw?oc=5"" target=""_blank"">FDA Propels Insulin Affordability with Semglee</a>&nbsp;&nbsp;<font color=""#6f6f6f"">diaTribe</font>",https://news.google.com/rss/articles/CBMiiwFBVV95cUxOdFhfaXdVUmFGT3g2dWd0M1hOUDkxUXZKcEhpbGpaaVZISUUyQUNfeFFjRnk4bkl2dTZ4Sk9UZFBZbk55eVhTMlBPWUF2MExyZGlpbllVa0x0d1prMTBzdzQxUG9pM3lpLTZuUFlmdVVUR3FYVzJjcXloVWlfZVZSUTRoa0tJQTNBWVEw?oc=5,Google News,Semglee FDA approval,drug_fda,2025-06-27T05:41:06.413129,0.2,0.0,0.2,0.0,0.0,0.11000000000000001,0.0,0.3034883936246236,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.1
2019-08-22,2019-08-22 07:00:00,Biocon’s Malaysia Insulin glargine facility receives Certificate of GMP - Express Pharma,"<a href=""https://news.google.com/rss/articles/CBMiogFBVV95cUxNcDlJb3NGUlBpTmpDQ3A5cVc1UXg0OVgzTjBDZHluME1GMmNxYlk5Q2RYeGxwQ1JUWnd0bWJhamlFa3JMOGtlbDUyVTJ4ZnRLSU9PT01wMktXUmh2NEZkeHlwQ1pjLUFaNnVBQldMaW5qN2o3dHBRZU1mblo1VVhGcjA1VkM0TDhHM2NQcnBEeTFvQzY0VnRvRkxLRC1jTEVlQWfSAacBQVVfeXFMTWJpVXp3V1piSi1YQmRucWd1aHNEQkN1UU8yRGNRYll1RWJydldVcmo3SkpCalNRT2YzMDViekhLTzRCWEdTM1hGWmJia3BnMzMzaGxtTW9VQ084QTNFVkdDX0g5UWVFbGUxVl9fVnhhcVFmZGl1YlYzOExZRXJnN21iOXJ1SjFWOTNudThldm03Z3BWd1dzaXVLOWNiNHpXaFhPNXh2aFU?oc=5"" target=""_blank"">Biocon’s Malaysia Insulin glargine facility receives Certificate of GMP</a>&nbsp;&nbsp;<font color=""#6f6f6f"">Express Pharma</font>",https://news.google.com/rss/articles/CBMiogFBVV95cUxNcDlJb3NGUlBpTmpDQ3A5cVc1UXg0OVgzTjBDZHluME1GMmNxYlk5Q2RYeGxwQ1JUWnd0bWJhamlFa3JMOGtlbDUyVTJ4ZnRLSU9PT01wMktXUmh2NEZkeHlwQ1pjLUFaNnVBQldMaW5qN2o3dHBRZU1mblo1VVhGcjA1VkM0TDhHM2NQcnBEeTFvQzY0VnRvRkxLRC1jTEVlQWfSAacBQVVfeXFMTWJpVXp3V1piSi1YQmRucWd1aHNEQkN1UU8yRGNRYll1RWJydldVcmo3SkpCalNRT2YzMDViekhLTzRCWEdTM1hGWmJia3BnMzMzaGxtTW9VQ084QTNFVkdDX0g5UWVFbGUxVl9fVnhhcVFmZGl1YlYzOExZRXJnN21iOXJ1SjFWOTNudThldm03Z3BWd1dzaXVLOWNiNHpXaFhPNXh2aFU?oc=5,Google News,Biocon manufacturing compliance,regulatory,2025-06-27T05:41:50.144169,0.2,0.25,0.0,0.0,0.0,0.11000000000000001,0.0,0.2894076307614644,0.0,0.0,1.0,0,0,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,other,0.0,1.1
